The role of B cells in the early phase of rheumatoid arthritis by Moura, Rita Alexandra Pedra Aguiar de, 1981-
Universidade de Lisboa 
 
Faculdade de Medicina 
 
 
 
 
 
 
THE ROLE OF B CELLS IN THE EARLY PHASE OF 
RHEUMATOID ARTHRITIS 
 
 
 
 
Rita Alexandra Pedra Aguiar de Moura 
 
 
 
Doutoramento em Ciências Biomédicas 
Especialidade em Imunologia 
 
 
2011 
Universidade de Lisboa 
 
Faculdade de Medicina 
 
 
 
 
 
THE ROLE OF B CELLS IN THE EARLY PHASE OF 
RHEUMATOID ARTHRITIS 
 
 
 
 
Rita Alexandra Pedra Aguiar de Moura 
 
 
Tese orientada por: 
Professor Doutor João Eurico Fonseca  
Professor Doutor Luís Graça 
 
 
Doutoramento em Ciências Biomédicas 
Especialidade em Imunologia 
 
2011 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Todas as afirmações efectuadas no 
presente documento são da exclusiva 
responsabilidade do seu autor, não 
cabendo qualquer responsabilidade à 
Faculdade de Medicina da Universidade 
de Lisboa pelos conteúdos nele 
apresentados. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A impressão desta dissertação foi 
aprovada pela Comissão Coordenadora 
do Conselho Científico da Faculdade de 
Medicina da Universidade de Lisboa em 
reunião de 21 de Junho de 2011. 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dissertação apresentada à Faculdade de 
Medicina da Universidade de Lisboa, para 
obtenção do grau de Doutor em Ciências 
Biomédicas. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
A presente dissertação foi realizada na Unidade de Investigação em 
Reumatologia do Instituto de Medicina Molecular, Faculdade de Medicina da 
Universidade de Lisboa, Lisboa, Portugal e Centre for Rheumatology, 
Division of Medicine, University College London, London, United Kingdom. 
 
O trabalho aqui apresentado foi realizado com âmbito no projecto “O papel 
dos Linfócitos B e dos Neutrófilos na génese e na manutenção da Artrite 
Reumatóide - implicações no prognóstico e terapêutica”, financiado pela  
Sociedade Portuguesa de Reumatologia e por um unrestricted research grant 
da empresa Roche. 
 
Bolsa de Doutoramento da Fundação para a Ciência e a Tecnologia 
(referência: SFRH/BD/30247/2006). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Aos meus pais e irmão 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
To be great, be entire: of what is yours nothing 
Exaggerate or exclude. 
Be whole in each thing. Put all that you are 
Into the least you do. 
Like that on each place the whole moon  
Shines, for she lives aloft. 
 
 
 
Translated by Jonathan Griffin in “Fernando Pessoa - Selected Poems” 
 
 
                                                                                                   -- 
 
    
Para ser grande, sê inteiro: nada 
Teu exagera ou exclui. 
Sê todo em cada coisa. Põe quanto és 
No mínimo que fazes. 
Assim em cada lago a lua toda 
Brilha, porque alta vive. 
 
 
 
Ricardo Reis,  
Fernando Pessoa’s heteronym 
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UMÁRIO 
 
A Artrite Reumatóide (AR) é uma doença autoimmune crónica, sistémica e de etiologia 
desconhecida, que afecta cerca de 1% da população mundial. A AR é caracterizada por uma 
poliartrite simétrica associada a dor e tumefacção de múltiplas articulações que, se não for 
tratada, conduz à destruição das articulações, incapacidade funcional, comorbilidades e 
redução da esperança de vida. 
Existem diversas doenças autoimunes que são dependentes de células B, principalmente 
através da produção de autoanticorpos. Estudos anteriores documentaram a importância das 
células B na patologia da AR através de diversos mecanismos. As células B produzem 
autoanticorpos, como o factor reumatóide (FR) e anticorpos anti-proteínas citrulinadas 
(ACPA), que se depositam como complexos imunes nas articulações, causando inflamação. 
Além disso, as células B podem funcionar como células apresentadoras de antigénio e 
activar células T, sendo também capazes de produzir citocinas uma vez activadas e 
participar na organização de estruturas linfóides secundárias.  
A descoberta da eficácia da terapêutica de depleção de células B com rituximab (RTX) 
em doentes com AR veio reforçar a posição chave destas células nesta doença autoimune, 
tendo colocado as células B no centro da investigação nesta área. Contudo, a maioria dos 
estudos neste tema tem sido focada em doentes com AR estabelecida, sendo o 
conhecimento dos mecanismos imunológicos iniciais dependentes de células B muito 
reduzido. 
O principal objectivo deste trabalho foi o estudo do papel das células B na fase muito 
inicial da AR. Para tal, um grupo de doentes com poliartrite com menos de seis semanas de 
evolução, não tratada, foi prospectivamente seguido. Foi realizada uma caracterização 
completa das subpopulações de células B no sangue periférico, analisado o conteúdo de 
citocinas e quimiocinas no soro e feita uma análise de perfil de expressão génica 
relacionado com as células B. O acompanhamento clínico destes doentes permitiu a 
identificação de um subgrupo que evoluiu para AR, que foi classificado como very early 
rheumatoid arthritis (VERA). Os restantes doentes evoluíram para um diagnóstico de 
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artrite autolimitada, ou para outras doenças crónicas inflamatórias articulares. Os doentes 
VERA foram avaliados antes do tratamento, após terapêutica de curta duração com dose 
baixa de corticosteróides e após metotrexato (MTX), de forma a analisar as possíveis 
influências do tratamento no desenvolvimento dos processos imunológicos mediados pelas 
células B nas primeiras semanas de evolução da AR. 
Nos doentes VERA, foram observadas perturbações nas células B de memória em 
circulação, nomeadamente uma diminuição da subpopulação de células B de memória pre-
switch (IgD+CD27+); um aumento dos níveis séricos de citocinas relacionadas com o 
recrutamento e a activação de células B, em particular a interleucina (IL)-6, A proliferation-
inducing ligand (APRIL) e B cell activating factor (BAFF); e alterações na expressão de 
genes relevantes para a homeostasia, desenvolvimento e sobrevivência das células B, 
nomeadamente BAFF e seus receptores. De salientar que o tratamento com corticosteróides 
e MTX, embora clinicamente eficaz na redução das manifestações inflamatórias, não 
pareceu afectar as células B periféricas, ou o padrão de citocinas em circulação. 
Adicionalmente, foi analisado um segundo grupo de doentes com AR estabelecida sob 
terapêutica com RTX. Considerando o importante papel que a citocina BAFF apresenta na 
maturação e sobrevivência das células B, foi colocada a hipótese de que o balanço entre a 
expressão do receptor de BAFF (BAFF-R) e o BAFF solúvel poderiam influenciar a 
relação entre as subpopulações de células B reconstituintes e a recidiva clínica após 
terapêutica de depleção de células B. Para testar esta hipótese, procedeu-se à análise dos 
níveis de BAFF no soro, à caracterização fenotípica da reconstituição das subpopulações de 
células B em circulação e, foi analisada a expressão de superfície do BAFF-R nestas 
subpopulações, antes e após o tratamento com RTX. 
Durante a repopulação das células B, após o tratamento com RTX, a maioria das células 
B no sangue periférico apresentou um fenótipo naïve, verificando-se em simultâneo uma 
diminuição da frequência das células B de memória em circulação, tal como esperado. Um 
dos resultados que suscitou interesse foi a observação da redução significativa da expressão 
do BAFF-R nas células B naïve e de memória nos doentes em recidiva, embora não tenham 
sido detectadas diferenças nos doentes em remissão. Além disso, os níveis de BAFF no 
soro encontravam-se dentro dos limites normais nos doentes com AR antes do tratamento 
com RTX e aumentaram significativamente após a terapêutica com RTX. No entanto, não 
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foi observada qualquer correlação entre a redução da expressão do BAFF-R quer com os 
números de células B em circulação, quer com os níveis de BAFF no soro. O aumento da 
frequência das células B de memória post-switch (IgD-CD27+) no sangue periférico 
observado nos doentes em recidiva, em comparação com os doentes em remissão, parece 
sugerir que o restabelecimento da actividade da doença possa estar associado ao processo 
de recombinação de mudança de classe de imunoglobulina. Deste modo, os resultados 
observados em doentes com AR após terapêutica de depleção de células B sugerem que 
factores responsáveis pela redução da expressão do BAFF-R possam estar intimamente 
ligados a mecanismos associados à geração de células B autoreactivas e ao 
restabelecimento da actividade da AR.  
Em conclusão, os resultados desta tese suportam a existência de alterações nos 
mecanismos de fisiopatologia associados às células B desde as primeiras semanas de 
evolução da AR que poderão contribuir para o desenvolvimento da doença. Além disso, os 
dados obtidos parecem sugerir que uma introdução precoce de terapêuticas direccionadas às 
células B, depletoras destas células ou dirigidas aos receptores das mesmas ou aos seus 
ligandos, poderá ser particularmente eficaz na indução da remissão em doentes com AR 
desde a fase inicial da doença. 
 
Palavras-chave: Artrite Reumatóide, Células B, Autoanticorpos, Corticosteróides, 
Metotrexato, Citocinas, Genes, BAFF-R, Rituximab 
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UMMARY 
 
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease of unknown 
aetiology that affects around 1% of the world population. RA is characterized by symmetric 
polyarthritis associated with pain and swelling in multiple joints. If left untreated, RA leads 
to joint destruction, functional disability, comorbidity and reduced life expectancy.  
Many autoimmune diseases are B-cell dependent, mainly through the production of 
autoantibodies. Previous studies have documented the importance of B cells in RA 
pathogenesis through diverse mechanisms. B cells produce autoantibodies, such as 
rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA). These 
autoantibodies can form immune complexes that deposit in the joints, causing 
inflammation. Additionally, B cells can function as antigen presenting cells and activate T 
cells; release cytokines once activated and participate in ectopic lymphoid organogenesis. 
The discovery that B cell depletion therapy with rituximab (RTX) was effective in RA 
patients reinforced B cells key position in this autoimmune disease and placed them in the 
central stage of research. Nevertheless, the majority of the studies on this field have been 
focused in established RA patients, while the knowledge on B cell dependent immune 
mechanisms involved in RA onset is still very scarce.  
The main goal of this work was to study the role of B cells in the very early phase of 
RA. In order to achieve this, a cohort of untreated polyarthritis patients with less than six 
weeks of disease duration was prospectively followed up. A full characterization of 
peripheral blood B cell subpopulations, serum cytokine and chemokine environment, and 
B-cell gene expression profile analysis was performed. The follow up of these patients 
allowed the identification of a subgroup that evolved into RA. Thus, these patients were 
classified as very early RA (VERA) patients. The remaining patients either had self-limited 
forms of arthritis or evolved into other chronic inflammatory joint diseases. VERA patients 
were evaluated at baseline and after short-term therapy with corticosteroids and 
methotrexate (MTX) to analyze the possible influence of treatment in the development of 
B-cell mediated immune processes in the first weeks of RA.  
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We found that VERA patients had disturbances in circulating memory B cells, namely a 
decrease in the pre-switch memory (IgD+CD27+) subpopulation; had increased serum levels 
of cytokines related with B cell recruitment and activation, in particular interleukin (IL)-6, 
A proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF); and had 
alterations in the expression of genes relevant for B cell homeostasis, development and 
survival, namely BAFF and its receptors. Of note, treatment with corticosteroids and MTX, 
although clinically effective in reducing inflammatory manifestations, did not seem to 
affect peripheral B cells or cytokine content in circulation.  
Additionally, a second cohort of RA patients with established disease and under B cell 
depletion therapy with RTX was also analyzed. Considering the important role that BAFF 
has in B cell maturation and survival, it was hypothesized that the balance between BAFF-
receptor (BAFF-R) expression and soluble BAFF could influence the relationship between 
returning B-cell subpopulations and clinical relapse after B cell depletion therapy. 
Therefore, serum BAFF levels, a phenotypic characterization of the newly emergent 
circulating B cell subpopulations during B cell reconstitution and the surface BAFF-R 
expression were analyzed in circulating B cell subsets before and after RTX treatment.  
During B cell repopulation, after B cell depletion therapy, the majority of circulating B 
cells had a naïve phenotype and simultaneously there was a decrease in the frequency of 
memory B cells in circulation, as expected. Interestingly, we found that BAFF-R 
expression was significantly reduced on both naïve and memory B cells in patients at 
clinical relapse, however, no differences were detected in patients in remission. In addition, 
BAFF serum levels were within normal range in patients before RTX and significantly 
increased after RTX treatment. Nevertheless, the reduction in BAFF-R expression was not 
correlated with B cell numbers or serum BAFF levels. The increased frequency of post-
switch memory B cells (IgD-CD27+) observed in the blood of relapsing patients in 
comparison with patients in remission might suggest that the re-establishment of active 
disease can be associated with an increase in class-switch recombination process. 
Therefore, the results observed in RA patients after B cell depletion therapy suggest that 
factors responsible for BAFF-R downregulation might be closely linked with altered 
thresholds in autoreactive B-cell generation and disease re-establishment. 
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In conclusion, the results in this thesis support the existence of alterations in the 
mechanisms associated with B cells’ physiopathology since the first weeks of RA onset, 
which can eventually contribute to RA development. Furthermore, an earlier introduction 
of B-cell directed therapies, such as B cell depletion, or indirect B-cell targeted therapies 
affecting B cell receptors or its ligands, might be of beneficial clinical use to induce early 
remission in RA patients. 
 
Key-words: Rheumatoid Arthritis, B cells, Autoantibodies, Corticosteroids, 
Methotrexate, Cytokines, Genes, BAFF-R, Rituximab 
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NTRODUCTION 
 
1. Rheumatoid Arthritis 
 
1.1. Definition 
Rheumatoid Arthritis (RA) is a chronic inflammatory autoimmune disease that 
preferentially affects the joints. RA has a prevalence of 1% worldwide in the adult 
population [1]. Onset usually occurs between 30 and 50 years of age and it is more frequent 
in women. RA is characterized by chronic pain and progressive joint damage with high risk 
of functional disability, which consequently leads to diminished quality of life and 
premature mortality [2, 3]. If not properly treated RA leads to bone and cartilage 
destruction with complete loss of joint integrity. This can occur after a period of time that 
can vary from only a few months to many years, depending on prognostic factors.  
Although RA is clinically recognized as an inflammatory process affecting joints, the 
presence of extra-articular manifestations makes this a systemic disease characterized by 
different clinical patterns. In general, the disease can affect any joint, however, small joints 
such as those of hands, wrists and feet are predominantly targeted.  
The diagnosis of RA is established according to the 1987 American College of 
Rheumatology (ACR) criteria [4] and at least four criteria must be present for a 
classification as RA (Table 1). Common symptoms of RA include symmetrical 
inflammation of large and small articulations and morning stiffness lasting at least 45 
minutes. In most patients, symptoms emerge over a period of weeks to months and are 
often accompanied by fatigue. Furthermore, the disease progression eventually affects 
multiple organ systems, such as the heart or lungs, thus contributing to a worse prognosis. 
In 2010, the ACR and the European League Against Reumatism (EULAR) reviewed and 
updated the 1987 ACR criteria [5, 6], as summarized in Table 2. However, since this new 
revisison occurred after the completion of the experimental procedures of this thesis, the 
diagnosis criteria used for RA classification were those of the 1987 ACR criteria. 
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Table 1. The 1987 American College of Rheumatology criteria for the classification of rheumatoid arthritis. 
 
 
A patient is said to have Rheumatoid Arthritis if he/she meets at least four criteria.  
 
Patients with two clinical diagnoses are not excluded.  
 
Designation as classic, definite, or probable Rheumatoid Arthritis is not to be made. 
 
 
The economic impact of RA can be explained by the high level of functional impairment 
it causes: 20 to 30% of persons with RA become permanently work-disabled within three 
years of diagnosis and 50% after ten years [7]. 
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Table 2. The 2010 American College of Rheumatology/European League Against Rheumatism classification 
criteria for rheumatoid arthritis. 
 
 
 
* The criteria are aimed at classification of newly presenting patients.  
** Differential diagnoses vary among patients with different presentations. If it is unclear about the relevant 
differential diagnoses to consider, an expert rheumatologist should be consulted. 
‡ Although patients with a score of < 6/10 are not classifiable as having RA, their status can be reassessed and 
the criteria might be fulfilled cumulatively over time. 
§ Joint involvement refers to any swollen or tender joint on examination, which may be confirmed by imaging 
evidence of synovitis.  
# “Large joints” refers to shoulders, elbows, hips, knees, and ankles. 
## “Small joints” refers to the metacarpophalangeal joints, proximal interphalangeal joints, second through 
fifth metatarsophalangeal joints, thumb interphalangeal joints, and wrists. 
†† Negative refers to international unit (IU) values that are less than or equal to the upper limit of normal 
(ULN) for the laboratory and assay; low-positive refers to IU values that are higher than the ULN but ≤ 3 
times the ULN for the laboratory and assay; high-positive refers to IU values that are > 3 times the ULN for 
the laboratory and assay. Where rheumatoid factor (RF) information is only available as positive or negative, 
a positive result should be scored as low-positive for RF. ACPA = anti-citrullinated protein antibody. 
‡‡ Normal/abnormal is determined by local laboratory standards. CRP = C-reactive protein; ESR = 
erythrocyte sedimentation rate. 
§§ Duration of symptoms refers to patient self-report of the duration of signs or symptoms of synovitis (e.g., 
pain, swelling, tenderness) of joints that are clinically involved at the time of assessment, regardless of 
treatment status. 
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1.2. Etiology and pathophysiology 
The etiology of RA is not yet fully understood. Different effector pathways and cells are 
involved in the cascade of events leading to the initiation, progression and persistence of 
this disease [8, 9] (Figure 1).  
A joint consists of two bones covered with cartilage and aligned by a capsule. The inner 
surface of the capsule corresponds to the synovial membrane. The area between the bones 
is filled with synovial fluid (SF), which is secreted by fibroblast-like synoviocytes from the 
synovial membrane. In normal conditions, SF helps to lubricate and support bones during 
movements. Early changes in rheumatoid synovial tissue are manifested by hyperplasia of 
synovial cells, edema, vascular proliferation and lymphocyte infiltration, leading to swollen 
and tender joints. The inflamed synovial membrane begins to grow irregularly, forming 
invasive pannus tissue that, consequently, invades and destroys cartilage and bone. 
Importantly, the inflammatory process that occurs is mediated by the activation of 
intracellular signaling pathways that stimulate the production and release of multiple 
cytokines, chemokines, growth factors, proteinases and adhesion molecules, which further 
cause joint destruction and the development of systemic complications.  
The inflammatory process that occurs in RA synovium is initiated when an unknown 
antigenic trigger induces the development of an inflammatory autoreactive response. 
Antigen-presenting cells (APCs) present antigenic processed peptides to T cells, 
communicating with them through the major histocompatibility complex (MHC)-T-cell 
receptor (TCR) interaction and costimulatory signals via CD28-B7 family receptor 
(CD80/86), thus activating T cells.  
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Figure 1. Representative scheme illustrating the differences between healthy and rheumatoid joints.  
In RA, the inflammatory process leads to a cellular infiltration not only of the synovial membrane, but also of 
the synovial fluid, with simultaneous angiogenesis, pannus formation, cartilage and bone erosion, swelling 
and pain. B cells mainly infiltrate synovial membrane and, once differentiated as plasma cells, are able to 
produce and release autoantibodies that form immune complexes, further increasing the inflammatory 
response. 
 
 
B cells can function both as efficient APCs and antibody producing cells. Autoreactive 
B cells in RA produce autoantibodies such as rheumatoid factor (RF), that are able to form 
immune complexes and deposit in joints. These immune complexes activate macrophages 
through the low-affinity IgG receptor FcγRIIIa [10], leading to the production of several 
proinflammatory cytokines such as tumor necrosis factor (TNF), interleukin (IL)-1β and 
IL-6. This cytokine environment induces the expression of cell-adhesion molecules, such as 
VCAM1, by synovial fibroblasts [11, 12], which contributes to an increase of cellular 
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infiltration towards the joints. Additionally, the local production of metalloproteinases [13], 
such as MMP3 or MMP9, as well as the production of receptor activator for nuclear factor 
κB ligand (RANKL) [14] increases cartilage and bone destruction. Thus, a highly regulated 
immune network seems to contribute to RA development and progression, where 
autoantibody production and immune complexes deposition seem to be essential for disease 
initiation. 
 
1.3. Environmental risk factors and genetic predisposition 
Evidence points to a complex interaction between environmental and genetic risk factors 
that contribute to RA onset [15]. The female gender, a positive family history and older age 
are associated with an increased risk for developing RA. Smoking is the best established 
environmental risk factor for RA [16-18]: in a study that included 13 monozygotic twin 
pairs discordant for RA and smoking, the smoker was the one who developed disease in 12 
out of 13 pairs [19]. Moreover, smoking was shown in several studies to be a risk factor for 
the presence of autoantibodies: RF or anti-citrullinated protein antibodies (ACPAs) [20]. 
Interestingly, the observation that RA associated autoantibodies, RF and ACPAs, may be 
present for more than 10 years before the onset of clinical disease, suggests that risk factors 
are active several years prior to the development of the disease. Furthermore, potential 
candidates implicated in an infectious aetiology have also been considered and included 
Epstein-Barr virus (EBV) [21], Mycobacterium tuberculosis [22, 23], Escherichia coli [24], 
Proteus mirabilis [25], retroviruses [26] and parvovirus B19 [27]. These associations have 
been supported by increased antibody titres against the infectious organism present in RA 
or the possibility of molecular mimicry. However, there has been no consistent evidence 
that a single infectious agent or other environmental factor explains per se the onset of RA.  
Genetic predisposition is also significant and is a fundamental determinant in RA 
susceptibility. In fact, findings based on twin studies have estimated the relative 
contribution of genetic factors to be approximately 50%, leaving the remaining part to 
environmental and stochastic factors. Genetic research of complex diseases such as RA has 
had a major contribution from new technologies that allowed for genome-wide association 
studies of risk alleles [28].  
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The most important genetic association in RA is with the human leukocyte antigen 
(HLA)-DR genes, which reside in the MHC and participate in antigen presentation [29-32]. 
The risk for developing RA is related to the presence of specific alleles of the class II gene 
HLA-DRB1, that encode a conserved sequence of aminoacids, named the shared epitope 
(SE), in the third hypervariable region (HVR3) of the class II DRβ1 chain [29]. In fact, this 
sequence is found in multiple RA-associated DR genes, including DR1, DR4 and DR14 
(for example, DRB*0101, DRB*0401, DRB*0404 and DRB*1402, respectively). The 
location of SE on the MHC molecule suggests that it might have a role in the ability of 
HLA-DR to bind and present specific arthritogenic peptides, which might cause RA. 
Indeed, the reported association between HLA-DR alleles with recognition of MHC class 
II-expressing antigen-presenting cells [33] and T cells [34] in inflamed joints, had led to the 
idea that MHC class II-dependent T-cell and B-cell activation were major drivers of the 
disease, thus reinforcing the notion of involvement of adaptive, B-cell and T-cell mediated 
immunity in RA pathogenesis.  
In 2005, PTPN22, a gene that encodes for a tyrosine phosphatase that has a role in T-cell 
and B-cell signaling, was identified as the second confirmed RA susceptibility gene [35], 
thus supporting the genetic argument for a T-cell and B-cell contribution to RA [36].  
Interestingly, many studies have already documented that the HLA-DRB1 SE and 
PTPN22 risk alleles are mainly associated with seropositive RA patients for RF, ACPAs or 
both [31, 32, 37, 38]. Several additional risk alleles for RA have been identified, such as 
TRAF1-C5 locus [39, 40], STAT4 [41] and OLIG3-AIP3 genes [42]. 
 
1.4. Prognosis and treatment 
Predictors of worse prognosis in early stages of RA include high functional impairment, 
early involvement of several joints, high erythrocyte sedimentation rate or C-reactive 
protein level at disease onset, positivity for autoantibodies, namely RF [43] and ACPAs 
[44], and early radiologic changes [15]. Furthermore, the presence of specific alleles that 
encode the susceptibility epitope on MHC molecules might also influence the severity of  
the disease, since the risk of extra-articular and erosive disease is greater if the patients are 
homozygous [45].  
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Although RA does not yet have a cure, establishing a diagnosis as early as possible and 
immediately starting therapy is the basis for a successful management of these patients. The 
goal of RA treatment should be the remission of symptoms, allowing the preservation of 
function and quality of life, minimizing pain and inflammation, joint protection and control 
of systemic manifestations. 
Treatment options for RA have been developed to stop or at least attenuate disease 
progression. Therapies that are used to treat RA are divided into three main classes: 
nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids and disease modifying 
anti-rheumatic drugs (DMARDs) (both synthetic and biological).  
NSAIDs are drugs that provide partial relief of pain and stiffness, but do not alter the 
disease course [46]. Corticosteroids are potent suppressors of the inflammatory response in 
RA. Previous studies have confirmed that these drugs are able to decrease the progression 
of RA and joint damage as detected radiographically [47-49].  
The administration of DMARDs to RA patients offers a sustained suppression of 
inflammation. In fact, early and aggressive treatment with conventional DMARDs, such as 
methotrexate (MTX), leflunomide, sulfasalazine and hydroxychloroquine can be highly 
beneficial to avoid inflammation and development of joint erosions. Observational trials 
have clearly identified MTX as the synthetic DMARD that is most likely to induce a long-
term response [50-52]. Nevertheless, combinations of DMARDs have also proven efficacy 
[53, 54]. When patients do not respond favourably to synthetic DMARDs, treatment with 
biological DMARDs is initiated. The first line biologics are TNF-inhibitory agents 
(infliximab, etanercept, adalimumab, certolizumab and golimumab) that act by partly 
neutralizing circulating and synovial TNF [55]. Other biological agents include abatacept, 
an anti-CTLA4 immunoglobulin (Ig) inhibitor [56]; tocilizumab, a IL-6 receptor antibody 
blocker [57]; and anakinra, an IL-1 receptor antagonist that has only a moderate therapeutic 
effect [58].  
Of note, the introduction of rituximab (RTX), a monoclonal antibody that selectively 
depletes B cells [59, 60], has brought a new interest to the role of B cells in RA 
pathogenesis. The relevance of B cells in the immune system and their intervention in RA 
progression is addressed in the following chapters. 
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2. B cells 
 
2.1. Origin and development 
The human body contains approximately 2×1012 lymphocytes, of which 5-15% are B 
cells. B lymphocytes are small white blood cells (6-10 µm) with a dense nucleus and little 
cytoplasm that express a membrane-bound Ig and originate and mature in the bone marrow. 
Discovered in the early 1960’s, these cells are important mediators of our immune system, 
more precisely of the humoral response, through the production and secretion of proteins 
classified as immunoglobulins or antibodies. 
 
2.1.1. Bone marrow 
B cells develop in the bone marrow of mammals, but in birds, where they were first 
studied, these cells develop and mature in a special organ called “Bursa of Fabricius” 
(hence, the designation “B”), which is situated in the cloaca of the animals [61, 62]. 
In humans, B cells are primarily produced in the fetal liver before birth and in the bone 
marrow afterwards. B cell development can be detected in human bone marrow from 20 
weeks of gestation and continues throughout life [63]. B cells arise from a lymphoid stem 
cell in the bone marrow and proceed through several maturation stages, during which they 
express different cell surface markers [64-67]. The earliest distinctive B-lineage cell is the 
progenitor B cell (pro-B cell) [68-71]. Pro-B cells proliferate in the bone marrow, filling the 
extravascular spaces between large sinusoids in the shaft of the bone, and further 
differentiate into precursor B cells (pre-B cells) [72, 73]. Generally, human pre-B cells can 
be subdivided into large proliferating cells (designated pre-BI) and small postmitotic cells 
(designated pre-BII) on the basis of cell-cycle analysis [74-76]. The bone marrow phase of 
B cell development culminates in the production of an immature B cell [77] that is not fully 
functional.  
All B cell differentiation stages in the bone marrow do not require antigen, thus 
corresponding to the antigen-independent phase of B cell development. 
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2.1.2. Periphery 
B cells leave the bone marrow when full maturation is achieved, as signalled by the co-
expression of IgM and IgD on the membrane. These naïve B cells, which have never 
encountered an antigen, circulate in the blood and lymphatic systems and are carried to 
secondary lymphoid organs (lymph nodes, spleen, Peyer’s Patches), where they reside 
(Figure 2).  
In the follicles of the secondary lymphoid organ, after encountering an antigen, mature B 
cells transform into large B-blasts and may follow two different pathways. Some proliferate 
and differentiate into short-living IgM producing plasma cells that are responsible for the 
early production of antibodies and first-line defence against antigens. A minority of the B-
blasts differentiate to form the follicle centre or germinal center (GC) [78, 79]. The non-
antigen-triggered naïve B cells form the follicle mantle or mantle zone. The follicle, 
containing a GC and a mantle zone, is known as a secondary follicle. The inner part of the 
mantle zone of the B cell follicle is designated the lymphocytic corona and is mainly 
composed of mature, naïve B cells [80]. The outer part of the mantle zone, called the 
marginal zone, is populated by different types of cells: macrophages, some T cells, 
granulocytes, plasma cells and marginal zone B cells [81]. GC are the specialized sites for 
memory B-cell generation, plasma cells differentiation and where affinity maturation of 
serum antibodies takes place [82, 83]. GC first appear at day 4-5 post-immunization, 
achieve their maximum cell number by day 10-11 and decline after three weeks [78]. 
B cells that form the GC are divided into centroblasts (large noncleaved cells) and 
centrocytes (small or large cleaved cells). Centroblasts are large, proliferating cells that lack 
surface immunoglobulin expression and accumulate at one pole of the GC, forming the 
dark zone. These cells can differentiate themselves into non-proliferating centrocytes that 
re-express surface immunoglobulin and accumulate at the opposite pole of the GC, known 
as the light zone [84].  
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Figure 2. B cell development.  
B cells arise from a lymphoid stem cell in bone marrow and proceed through several maturation stages, 
during which V(D)J recombination process occurs. When full maturation is achieved, B cells leave bone 
marrow into circulation and are carried to secondary lymphoid organs (lymph nodes, spleen, Peyer’s Patches), 
where they reside and further differentiate into memory B cells or plasma cells in germinal centers. FDC: 
follicular dendritic cell, SHM: somatic hypermutation, B: B cell, T: T cell, M: macrophage. 
 
 
Activation of GC B cells is made by follicular dendritic cells (FDC), which have a 
pivotal role in promoting B-cell proliferation and differentiation in GC [85, 86]. FDC are 
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not only very efficient in trapping and retaining antigen-antibody complexes for long 
periods of time and present them to B cells, but also are involved in B cell recruitment to 
secondary lymphoid organs with consequent follicle formation and organization through 
the secretion of the chemokine (C-X-C motif) ligand 13 (CXCL13), a B-lymphocyte 
chemoattractant [79, 87, 88]. Positive selection of B cells in GC occurs through high-
affinity binding to antigens trapped by FDC. These high-affinity B cells receive survival 
signals from both FDC [86] and T cells [89] located in the light zone, whereas low-affinity 
B cells non-triggered by antigens die by apoptosis. More than 90% of the GC B cells die as 
a result of apoptosis [90] and are then phagocytosed and digested by the so-called tingible 
body macrophages [91-93]. Only GC B cells that are stimulated and able to synthesize 
high-affinity antibodies survive and may differentiate into long-lived plasma cells or 
memory B cells.  
Long-lived plasma cells are thought to reside mainly in the bone marrow and organs that 
are directly exposed to foreign antigens (gastrointestinal tract, lungs…) [94], whereas 
memory cells reside in the follicle mantle or re-circulate freely to survey for secondary 
antigen exposure. Memory B cells are long-lived and are responsible for the ability of the 
immune system to learn. During a second encounter with an antigen, memory B cells are 
able to recognize the antigen to which the organism was previously exposed and induce a 
more rapid and effective immune response [95].  
Since B cell activation and differentiation in the periphery require antigen, this stage 
comprises the antigen-dependent phase of B cell development. In the absence of antigen-
induced activation, naϊve B cells in the periphery have a short life span, dying within a few 
weeks by apoptosis. 
 
2.2. Antibody production 
Antibodies, also called immunoglobulins, are the antigen-binding proteins present on the 
B cell membrane and secreted by plasma cells. The main function of an antibody is to 
recognize a foreign antigen exhibited by an invading pathogen or present at the surface of 
an altered cell, like a tumour cell, and facilitate the clearance and elimination of that 
antigen. Antibodies can eliminate pathogens by several mechanisms including 
 15 
 
 
 
opsonization, complement activation and direct lysis of bacteria and neutralization of 
viruses and toxins to prevent their entry into host cells.  
An antibody molecule has a common structure of four peptide chains that consist of two 
identical light (L) chains and two identical heavy (H) chains, which are linked by disulfide 
bonds. The first 100-110 amino acids of the amino-terminal region of a light or heavy chain 
vary greatly among antibodies. These segments of highly variable sequence are called 
variable (V) regions: VL in light chains and VH in heavy chains. The carboxyl-terminal 
region of both light and heavy chains consists of relatively constant sequences, designated 
as constant (C) regions: CL on the light chain and CH on the heavy chain. Most of the 
differences among antibodies fall within areas of the V regions called Complementary-
Determining Regions (CDRs) and these CDRs, on both light and heavy chains, constitute 
the antigen-binding site of the antibody molecule.  
There are two light chain types, kappa (k) and lambda (λ). In humans, 60% of the light 
chains are kappa and 40% are lambda [96]. A single antibody molecule contains only one 
light chain type, either k or λ, but never both. The heavy chain of a given antibody 
molecule determines the class of that antibody or isotype. There are five different heavy-
chain constant region sequences: µ, δ, γ, ε and α; hence in humans, the five major classes of 
antibodies are: IgM (µ), IgG (γ), IgA (α), IgD (δ) and IgE (ε), each with different structural 
and functional properties. 
 
2.2.1. Mechanisms of antibody diversity 
One of the most remarkable features of our immune system is its ability to respond to an 
apparently limitless array of foreign antigens. The major mechanisms that are responsible 
for the enormous diversity of antibodies (>1010 possibilities) produced by our immune 
system are random rearrangements of the genes that codify the variable region (antigen 
binding domain) of immunoglobulins.  
Antibody diversity is achieved by V(D)J recombination, somatic hypermutation (SHM) 
and class switching. Three separate multigene families, situated on different chromosomes, 
encode immunoglobulin light and heavy chains. In germ-line DNA, each of these multigene 
families contains several coding sequences, called gene segments that are separated by 
noncoding regions. During B cell maturation, these gene segments are rearranged and 
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brought together to form functional immunoglobulin genes [97, 98]. The k and λ light-
chain families contain V (for variable), J (for joining) and C (for constant) gene segments 
and the rearranged VJ segments encode the variable region of the light chains. The heavy-
chain family contains V, D (for diversity), J and C gene segments and the rearranged VDJ 
gene segments encode the variable region of the heavy chain. In each gene family, C gene 
segments encode the constant region. The V(D)J recombination is an ordered site-specific 
DNA rearrangement process [99] that occurs in developing lymphocytes in the bone 
marrow and is initiated by two lymphocyte-restricted specific proteins recombination-
activating gene (RAG)-1 and RAG-2 [100-103], which together form an endonuclease 
responsible for DNA double-stranded breaks at recombination signal sequences (RSS) 
[104, 105] (Figure 3). RAG proteins are expressed at high levels during ontogeny, but their 
expression diminishes in immature B cells and is usually absent in recirculating mature 
naïve B cells [106, 107]. In certain pathologies, however, like in autoimmune diseases, 
RAG expression may be upregulated [108, 109]. The importance of RAG for V(D)J 
recombination is supported by the fact that mutations in RAG genes abolish recombination 
activity and block differentiation of both B and T cells, leading to different forms of 
immune deficiency [110-112]. RSS, which are recognized by RAG in the initial event of 
the recombination process, are comprised of a highly conserved heptamer and nonamer 
sequences, separated by a relatively nonconserved spacer region of either 12 or 23 base 
pairs (bp) [105, 113]. A gene segment with 12-bp spacer can only join with a segment 
flanked by 23-bp spacer (12-23 bp rule) [104, 114].  
During variable-region gene rearrangements the heavy-chain genes rearrange first, 
followed by light-chain rearrangements. The generation of a functional immunoglobulin 
heavy-chain gene requires two separate rearrangement events within the variable region. 
The first step of recombination is a D to J association. The resulting D-J segment then 
moves next to and joins a V segment to generate a VDJ unit that encodes the entire variable 
region. Light-chain DNA rearrangements occur by the joining of a functional V segment to 
a functional J-C segment. The combinatorial diversity generated by V(D)J recombination is 
further augmented by another enzyme, terminal deoxynucleotidyl transferase (TdT) [115-
117], that randomly adds up to 20 nucleotides, called N additions, to D-J and V-DJ 
junctions.  
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Figure 3. V(D)J recombination process in light and heavy chains.  
During VDJ recombination, the gene segment rearrangements that occur in both light and heavy chains are 
possible due to specific enzymes, such as RAG proteins, that initiate the process. Further diversity is 
increased by nucleotide additions by Terminal deoxynucleotidyl transferase (TdT). Adapted from [118]. 
 
 
SHM is also a major mechanism for producing antibody diversity and increasing 
antibody affinity, which occurs in GC of secondary lymphoid organs [119-121]. SHM is a 
process that introduces point mutations, mainly nucleotide substitutions, as well as 
occasional deletions and duplications at a very high rate into the DNA of heavy and light-
chain variable-region genes, which may alter the specificity of the encoded antibodies [122-
124]. SHM introduces mutations at a rate of ~10-3 mutations per base pair per cell division, 
which is 106-fold higher than the spontaneous mutation rate in somatic cells. As a result, 
following exposure to antigen, these B cells with higher-affinity receptors will be 
preferentially selected for survival. This differential selection is due to an increase in 
antibody affinity for an antigen, a process known as affinity maturation. Thus, only B cells 
with the best fitting receptors are selected for rapid proliferation and further maturation. 
SHM appears early in the phylogeny of vertebrate immune system and operates in all 
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studied vertebrates [125]. Although the mechanism of SHM remains unknown, excitement 
in this field was triggered by the discovery of a requirement for activation-induced cytidine 
deaminase (AID), which has homology with the RNA-editing cytidine deaminase 
APOBEC-1 [126, 127].  
Class or isotype switching is a deletional DNA recombination process that occurs in 
mature B cells and consists of the replacement of an expressed heavy-chain constant-region 
gene (usually Cµ for IgM) with another one of a different biological function, thus allowing 
the expression of IgG, IgA or IgE [128]. The deleted sequence is excised in a form of 
circular DNA [129]. In this way, the antigen binding specificity of the antibody remains 
unaltered; meanwhile its effector functions are changed. This process is mediated by a 
recombination event that deletes the DNA between repeated sequences, “switch regions”, 
located upstream of the constant-region genes involved. AID catalyzes the hydrolytic 
deamination of cytidine to uridine, either as a free nucleotide or in the context of RNA and 
thus participates in class-switch recombination (CSR) [130, 131]. In fact, AID-deficient 
mice that are generated by gene-targeted mutation, lack completely the ability to undergo 
CSR and only form antibodies belonging to IgM isotype [126]. Moreover, in a group of 
immunodeficient patients with hyper-IgM syndrome, who had impaired CSR, the human 
gene encoding AID was mutated [127], so that their B cells only produced IgM molecules. 
AID is expressed specifically in GC-centroblasts [130], however, its exact role remains 
unknown. Importantly, it was demonstrated that AID deficiency also affects SHM in mice 
and humans, which supports the idea that AID is involved in both mechanisms, CSR and 
SHM [126, 132]. 
 
2.3. Antigen presentation and T cell stimulation 
Antigen presentation results from the ability of cells to process and display small 
antigenic peptides (epitopes) associated with class I or class II MHC molecules and to 
deliver a costimulatory signal to T cells. Essentially, the T cell subset activated and the 
immune response consequently initiated depends on the context in which the antigen was 
first encountered by the APC [133, 134]. Endogenous antigens, processed within the 
cytoplasm of a cell, such as peptides derived from viruses or bacteria infecting a host cell, 
or proteins derived from a cancer cell, are associated with class I MHC molecules and 
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presented to CD8+ T cells. Contrarily, exogenous antigens, internalized by phagocytosis or 
endocytosis are processed and coupled to class II MHC molecules and presented to CD4+ T 
cells.  
Three cell types are classified as professional APC: dendritic cells (DCs), macrophages 
and B cells. DCs are considered the most effective of APCs, since they constitutively 
express a high level of class II MHC molecules and present costimulatory activity [135-
137]. In fact, DCs have a central role in the immune system as they regulate both innate and 
adaptive immunity, central tolerance to self-antigens and peripheral tolerance to 
environmental antigens and allergens [137-139]. Of interest, DCs activation and maturation 
may stimulate not only T-cell proinflammatory cytokine production, but also B-cell 
antibody production. Indeed, it has been demonstrated that DCs can also promote the 
differentiation and maturation of antibody-producing B cells [140-142].  
B cells can also act as major APCs and prior to DCs [143, 144]. Binding of antigen to B 
cell receptor (BCR) leads to antigen internalization and presentation to T cells, a critical 
process in the initiation of the humoral immune response [145, 146]. B cells can internalize 
and present antigen that has been encountered either in soluble or particulate form, as well 
as when tightly bound to a non-internalizable surface [147]. The dependence of the 
efficiency of presentation differs for these three forms of antigen and it relies on antigen-
BCR affinity [148].  
After encountering an antigen, APCs can internalize it by three means: phagocytosis, 
fluid-phase pinocytosis and receptor-mediated endocytosis. B cells have the ability to 
present antigen efficiently, since they can find T cells in secondary lymphoid organs shortly 
after antigen entrance and BCR-mediated endocytosis allows them to concentrate small 
amounts of specific antigen [149-151]. BCR affinity is directly proportional to the capacity 
of B cells to present antigen to CD4+ T cells. It has been demonstrated that cells with a 
BCR of low affinity required ten times more antigen to induce CD4+ T cell proliferation 
than cells with a BCR of very high affinity, while presentation after uptake by fluid phase 
pinocytosis needed concentrations about 5000 times higher [147]. Consequently, the high 
affinity of the BCR for its specific antigen allows its efficient internalization even in the 
presence of small amounts of antigen [150]. Moreover, BCR signaling up-regulates MHC-
II expression and consequently the generation of peptide-MHC II complexes [152, 153], 
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which enhances the efficiency of antigen presentation. Given the complexity of immune 
responses and the diversity of antigens relevant to human disease, B cells probably 
participate as APC in many situations. 
 
2.4. B-T cell interaction 
For an efficient activation of B cells by soluble protein antigens, an involvement of T 
cells is required. Binding of an antigen to the BCR does not, by itself, induce an effective 
competent signal without additional interactions between numerous receptor-ligand pairs 
on the two cell types.  
Antigen capture by membrane immunoglobulin on B cells initiates signaling through the 
BCR (signal 1) that leads to an upregulation of the expression of class II MHC molecules 
[154, 155] and costimulatory B7 molecules [156-158]. Antigen is internalized, processed 
and degraded to peptides that are then presented to the cell surface as MHC-peptide 
complexes [152, 159]. T cells can recognize these MHC-peptide complexes on B cell 
membrane. Both T and B cells interact to form a T-B conjugate that ultimately leads to T 
cell-dependent B cell activation [158, 160, 161]. This interaction stimulates the expression 
of CD40-L (CD154) on T cells, which is the ligand for CD40, expressed on B cells [162, 
163]. CD40, expressed on B-lineage cells (pro-B through plasma cells), belongs to the TNF 
family of cell-surface proteins and soluble cytokines that regulate cell proliferation. 
CD40L, expressed on T cells, belongs to the TNF receptor (TNFR) family. Interaction of 
CD40-L with CD40 on B cells delivers a signal (signal 2) [164-166] to the B cell that, in 
concert with the signal generated by the BCR crosslinkage, induces the expression of 
costimulatory molecules of the B7 family [167, 168].  
The B7 costimulatory family has two ligands, B7-1 (CD80) and B7-2 (CD86) that can 
activate or inhibit a T-cell response, depending on the membrane molecule on T cell with 
which they interact, CD28 or CTLA-4 [169, 170]. CD28 is expressed by both resting and 
activated T cells and is the predominant receptor for B7 on resting T cells. CTLA-4 is 
expressed only on activated T cells, but has higher affinity for B7-1 and B7-2 than CD28, 
and can therefore limit the extent of the response. Upon binding of a B7-costimulatory 
molecule with CD28, a positive costimulatory signal is generated and the T cell is 
activated, while signaling through CTLA-4 inhibits the response of the T cell [171]. 
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Therefore, for an efficient T-cell-dependent B-cell activation a B7-CD28 interaction has to 
occur.  
The Inducible Costimulator Molecule (ICOS), a member of the CD28 family of 
costimulatory molecules expressed by T cells [172], is also a key regulator of humoral 
immunity and B cell homeostasis and functions. ICOS binds to a B7-like molecule, B7RP-1 
[173, 174], expressed constitutively on B cells [175]. A major role for the ICOS/B7RP-1 
pathway in the T cell-dependent B cell responses is supported by studies with both ICOS-/- 
and B7RP-1-/- mice that have decreased levels of serum antibodies and defective GC 
formation [176-179].  
Once activated, B cells begin to express membrane receptors for various cytokines 
produced by the interacting T cell. The signals produced by these cytokine-receptor 
interactions induce a number of intracellular signaling pathways that ultimately result in 
changes in gene expression that support B cell proliferation and can induce differentiation 
into plasma and memory cells, class switching and affinity maturation. Moreover, it has 
been demonstrated that activated B cells by sequential BCR and CD40 stimulation 
proliferate and secrete TNF, lymphotoxin and IL-6, cytokines that can act not only as 
autocrine growth and differentiation factors, but also serve to amplify the ongoing immune 
response [180].  
 
3. B cells and rheumatoid arthritis 
 
3.1. The immunopathogenic role of T and B cells in 
rheumatoid arthritis 
RA was classicaly considered mainly as a T-cell driven disease. The accumulation of 
CD4+ T cells in rheumatoid synovium [181-183] suggested that macrophages could be 
activated by T cells, especially T helper (Th)1, to produce the proinflammatory cytokines 
TNF and IL-1β [184-186]. In addiction, it has been demonstrated that Th1 cells 
predominate in the joints of patients with RA [183, 187], while the Th2 subset seems to 
have a modest contribution for RA pathogenesis as can be appreciated by the low 
expression level of Th2 cytokines, such as IL-4 and IL-13, in the synovial tissue [181, 188-
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190]. Similarly, studies in collagen-induced arthritis (CIA) mice have demonstrated that 
there is an expansion of CD4+ T-cells bearing the Th1 phenotype [191], mainly tipifyed by 
IL-12 and IFN-γ [192]. Furthermore, research developed in the SKG mice model, that have 
a point mutation in the gene encoding ZAP-70, a tyrosine kinase crucial to signal 
transduction from the T cell receptor (TCR) [193], supported the participation of CD4+ T 
cells in arthritis onset and progression [194].  
Th17 cells [195, 196] have also been associated with RA pathogenesis. In humans, 
increased levels of IL-17 have been found in RA patients and a positive correlation has 
been demonstrated with the severity of joint damage [197, 198]. Moreover, the percentage 
of Th17 cells is significantly increased in RA synovial fluid in comparison with RA or 
normal peripheral blood [199]. In animal models of arthritis, it has been demonstrated that 
local expression of IL-17 in mouse joints results in acute inflammation [200], while the 
incidence and severity of arthritis is markedly attenuated in IL-17–deficient mice [201-
203]. Furthermore, it has been shown that transferring Th17 cells to T-cell deficient mice 
induced arthritis [202]. 
Interestingly, another subset of T cells classified as CD4+CD25+, regulatory T cells 
(Tregs), contrarily to Th1, Th2 and Th17 subpopulations, may possibly hold promise for 
the treatment of RA and other autoimmune diseases, due to their self-tolerance maintenance 
and suppressive functions [204, 205]. Indeed, alterations have been found in the phenotype 
and suppressive effects of Tregs in blood and synovial fluid from RA patients [206-209]. In 
animal models of arthritis, depletion of Tregs exacerbates the disease and amplifies the cell-
mediated and humoral responses [210], whereas adoptive transfer of regulatory T cells is 
effective in treating arthritis [211].  
Despite all the observations that support a role for T cells in RA development, the 
disappointing results obtained with anti-CD4 therapy in humans [212-214] reinforced the 
notion that perhaps other parts of the inflammatory puzzle of RA should be studied more 
carefully to better understand disease pathogenesis [215-217]. Indeed, a crucial point 
remains unresolved in RA pathogenesis: do T cells activated by one or more autoantigens 
initiate the disease process, or is the influence of T cells secondary to a synovial-driven 
inflammatory response originating within the joints?  
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Although the cause that triggers RA autoimmune process remains unknown, it has been 
demonstrated that several types of cells from both innate and adaptive immune system 
actively participate and form complex networks of cell-cell interactions that contribute to 
the development and chronicity of rheumatoid synovitis and systemic inflammation [9, 11, 
141, 218]. Notably, it has been proposed that both synovial and systemic inflammation 
characteristic of RA are due to the engagement of macrophages expressing Fcgamma- 
receptors (Fcγ-R), namely FcγRIII, by immune complexes formed by RF of the IgG class in 
particular [217, 219]. IgG-RF self-associating dimers are small immune complexes that fix 
complement very poorly [220, 221] and thus are expected to gain significant access to the 
extravascular space and allow interaction with tissue macrophages, leading not only to 
synovial, but also to systemic inflammation [219, 222].  
The concept that autoantibodies such as RF could have an important role in RA 
triggering prior to T cell activation [223, 224] set the basis for the acknowledgement of B 
cell intervention in RA development. In fact, B cells play critical roles in the pathogenesis 
of RA and several lines of evidence have pointed to B cell function as the critical factor in 
the development of this disease (Figure 4).  
B cells are responsible for the production of autoantibodies such as RF and ACPAs, 
which contribute to immune complex formation, complement activation and consequent 
deposition in the joints, thus leading to the inflammatory process characteristic of RA. 
Furthermore, B cells are also very efficient APC that can activate T cells through the 
expression of costimulatory molecules. B cells can also function as cytokine and 
chemokine producing cells that promote leukocyte infiltration in the joints and formation of 
ectopic lymphoid structures, consequently aggravating angiogenesis and synovial 
hyperplasia.  
The discovery of K/BxN mouse model in 1996 [225] brought new attention to the idea 
that antibodies to systemic autoantigens might be a principal effector mechanism in 
initiating the inflammatory process in the joint. Similarly to human RA, this model presents 
lymphocyte infiltration of the synovium, synoviocyte proliferation, pannus formation, 
cartilage and bone erosion, polyclonal B cell activation, hypergammaglobulinaemia and 
autoantibody production.  
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Figure 4. An overview on the roles of B cells in rheumatoid arthritis pathogenesis.  
B cells play several important roles in RA development and progression. B cells produce autoantibodies that 
form immune complexes that activate Fcgamma-receptors and induce proinflammatory cytokine production; 
they function as antigen presenting cells and activate T cells, release cytokines upon activation and participate 
in ectopic lymphoid neogenesis. FDC: follicular dendritic cell, HEV: high endothelial venule. 
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The K/BxN mouse was originally generated by crossing a TCR transgenic strain (KRN-
C57BL/6) with a non-obese diabetic (NOD) mouse. Unexpectedly, the transgenic TCR 
from F1 offspring recognized a peptide derived from a ubiquitously expressed protein, 
glucose-6-phosphate isomerase (GPI). The T cell-dependent B cell activation by GPI 
together with a costimulatory signal via CD40L-CD40 interaction led to the production of 
arthritogenic anti-GPI autoantibodies. 
Furthermore, serum transfer to wild type, B cell-deficient or lymphocyte-deficient mice 
led to rapid onset of arthritis, which is transient, unlike the persistent arthritis in the K/BxN 
mouse [226]. Importantly, K/BxN mice devoid of B cells did not develop arthritis [225]. 
The identification of the target of the pathogenic antibody as GPI demonstrated that 
antibody to a ubiquitous antigen could lead to joint-specific disease and, therefore, renewed 
attention to the role of antibodies and immune complexes as a cause of human RA. 
Consequently, there was a revived interest in B cells as important effector cells in RA, as 
has been assumed in earlier years following the discovery of RF. 
Notably, the success of B cell depletion therapy with RTX [59, 60] and the consequent 
clinical improvement achieved by patients has brought recent attention to B cells, 
confirming their unquestionable role in RA development and progression.  
 
3.2. B cells produce autoantibodies 
Autoantibodies are the serological hallmark of autoimmune diseases and serve as 
indicators of the break in self-tolerance.  
RA is characterized by the presence of several autoantibodies in serum and synovial 
fluid. The first autoantibody to be documented in RA, RF, was described by Waaler in 
1940 [227] and it was later found to be directed to the constant (Fc) region of IgG.  
There are several autoantigens recognized by the autoantibodies present in RA that 
include cartilage components (for instance, anti-type II collagen or anti-CII; anti-human 
cartilage glycoprotein 39 or anti-gp39) [228]; enzymes (anti-glucose-6 phosphate isomerase 
or anti-GPI, anti-enolase) [229]; nuclear proteins (anti-RA33) [230, 231]; stress proteins 
and anti-citrullinated protein antibodies (ACPAs)  [232, 233]. Moreover, the spectrum of 
these self-antigens and immunologically relevant epitopes probably varies during the 
disease course, and the set of autoantigens in one individual may differ from person to 
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person [234]. In fact, the composition of the antibody response varies over time, with 
limited specificities in early RA and a mature response in late disease, in which more 
epitopes are recognized and more isotypes are used [235, 236].  
The clinical significance and pathogenic role of these autoantibodies are, however, 
largely unknown, except for RF and ACPAs, whose clinical usefulness has been 
acknowledged due to their good diagnostic sensitivity, specificity, as well as prognostic 
value.  
 
3.2.1. Rheumatoid factor 
RFs are autoantibodies that directly bind to the Fc portion of normal human IgG and are 
locally produced in RA by B cells present in the lymphoid follicles and GC-like structures 
that develop in the inflamed synovium [237, 238].  
RF has been hypothesized to be a pathogenic autoantibody with a key role in the 
physiopathology of RA [217]. In fact, RFs can be detected in serum and synovial fluid 
samples from patients and its presence is associated with more aggressive articular disease, 
a higher prevalence of extra-articular manifestations and increased morbidity and mortality 
[239, 240]. RFs induce the formation of immune complexes at the sites of synovial 
inflammation, the activation of complement and leukocyte infiltration by means of the 
downstream products of complement activation [241].  
RFs are found in multiple immunoglobulin isotypes (IgM, IgG, IgA), even if IgM is the 
RF usually measured in clinical assays, being detected in 60-80% of RA patients [233]. RF 
has been observed in many other autoimmune diseases, including systemic lupus 
erythematous (SLE) and Sjögren’s syndrome (SS), as well as in non-autoimmune 
conditions, such as chronic infections and also in healthy individuals. Nevertheless, RFs in 
RA patients are different from RFs found in healthy individuals. RFs from healthy subjects 
are of the IgM class, polyreactive and with low affinity [242], whereas RFs from RA 
patients belong to all classes and exhibit affinity maturation [243]. Indeed, RFs from RA 
patients derive from a wide range of immunoglobulin germ line genes and show a high 
frequency of substitution mutations, indicating affinity maturation. Contrarily, although 
RFs from healthy individuals show evidence of immunoglobulin gene mutation, these tend 
to be silent [244]. These observations support the concept that RFs are under strict control 
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in healthy subjects to prevent the emergence of high affinity RF. Furthermore, transient 
production of low-affinity IgM-RF is regularly induced by immune complexes [245] and 
polyclonal B-cell activators, such as bacterial lipopolysaccharides and EBV [246, 247].  
Interestingly, RF specificity to RA is strongly correlated to high titers of IgM and IgA-
RF isotypes [239, 248]. A high titer of IgA-RF is also associated with radiologic erosion, 
extra-articular manifestations and, consequently, worse outcomes [239, 240, 249]. In 
addition, high concentrations of IgG RFs within the confines of the joint are associated with 
the formation of larger, complement-fixing complexes which, together with IgM RF-based 
complexes, are likely to amplify the inflammatory process [221]. Indeed, the association 
between high titers of RF and worse prognosis indicate that RF may have an important role 
in the pathogenesis of RA. However, there are RA patients seronegative for RF who 
manifest the same disease symptoms as seropositive patients. It is possible that B cells can 
have other pathogenic functions in RF-negative patients that justify the development of the 
disease despite the absence of autoantibody production, such as antigen presentation. 
Another hypothesis is that those patients have a slightly different pathogenesis, which 
together with different prognosis and different response to treatment should classify them 
into a different condition. 
RF has proven to be, together with ACPAs, the most useful diagnostic marker of RA, 
having been included in the 1987 ACR classification criteria for RA [4] and in the new 
ACR/EULAR classification criteria [5, 6]. Furthermore, it is thought that B cells with RF 
specificity migrate into the synovium of RA patients, therefore presenting a variety of 
antigens to T cells. This leads to the perpetuation of local inflammatory responses and 
amplification of RF production in the synovium. Thus, RFs may prolong B-cell survival 
and hence maintain their own production. 
 
3.2.2. Anti-citrullinated protein antibodies  
ACPAs are a group of recently described autoantibodies which are found in 70-90% of 
RA patients and have high disease specificity (90-95%) [250, 251]. They are rarely present 
in other diseases or in healthy individuals. 
ACPAs were first detected in RA in 1998 [232], a result later confirmed by other groups 
[252, 253]. These autoantibodies recognize peptides or proteins containing citrulline, a non-
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standard aminoacid generated by the post-translational modification of arginine by 
peptidylarginine deiminase (PAD) enzymes [254], in a process known as citrullination. Of 
interest, citrullination occurs during a variety of biologic processes, including 
inflammation, apoptosis or keratinization.  
ACPAs are locally produced in RA joints, where proteins are citrullinated during the 
inflammatory process [253]. In fact, several citrullinated proteins can be found in RA 
synovium such as filaggrin, fibrin, vimentin, nuclear and stress proteins [255]. However, 
the major citrullinated protein in RA joint was found to be fibrin [256].  
Immune complex formation between ACPAs and citrullinated proteins with subsequent 
complement fixation and joint deposition occurs in RA synovium, which is thought to 
perpetuate RA synovial inflammation, causing a vicious cycle [257]. In 2000, the first 
ELISA test to detect ACPA was developed by Schellekens and co-workers [250], with the 
objective of creating a highly specific diagnostic tool for RA.  
An ACPAs-positive disease is associated with an increased joint damage and low 
remission rates [258]. Evidence from animal models and in vivo data suggest that ACPAs 
are pathogenic on the basis of induction of arthritis in rodents and additionally due to the 
presence of immunological responses in ACPAs-positive patients in a citrulline-specific 
manner [259, 260]. Interestingly, the majority of ACPAs positive patients is also positive 
for RF [261].  
Findings of clinical studies show that patients with RA who are simultaneously positive 
for RF and ACPAs (autoantibody-positive disease) differ from individuals with so-called 
autoantibody-negative disease. Indeed, histologically, ACPAs positive patients have more 
infiltrating lymphocytes in the synovial tissue, whereas those with ACPAs negative RA 
have more fibrosis and increased thickness of the synovial lining layer [262].  
Importantly, ACPAs autoantibodies not only have a better diagnostic value than RF in 
terms of sensitivity and specificity, but also seem to be better predictors of poor prognostic 
features such as progressive joint destruction [261]. Moreover, they also help to predict the 
disease outcome in patients with undifferentiated arthritis [263-265].  
In 2007, ACPAs were formally included in the EULAR published guidelines for the 
diagnosis of early RA [6]. 
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3.3. B cells participate in ectopic lymphoid organogenesis 
The rheumatoid synovium is a highly vascularized tissue infiltrated by cells from both 
the innate (macrophages and neutrophils) and adaptive (B and T cells) immune systems [9, 
218, 266, 267].  
It is possible to distinguish at least three different patterns of synovial infiltration in RA 
patients: a diffuse rearrangement of B and T cells; aggregates of B and T cells without a 
follicular microstructure; or synovial lymphocytes arranged in B-cell follicular-like 
structures with B and T cells arranged around a network of FDC that resemble functional 
ectopic GCs [266-268]. Interestingly, the patterns of lymphoid infiltrates correlate with 
clinical disease activity [269, 270] and severity [271].  
Furthermore, some chemokines have been identified to contribute to the formation of 
these ectopic lymphoid structures, namely CXCL13 [272] and CXCL12 [273], which play 
a key role in the generation of GC as the responsible factors for the recruitment of B and T 
cells, respectively. Additionally, another cytokine, lymphotoxin (LT)-β, produced by 
activated T and B cells, also appears to be essential for the formation of primary B cell 
follicles in rheumatoid synovium [274, 275]. 
The TNF-family member B cell activating factor (BAFF), an important B cell survival 
cytokine has also been detected at high levels in rheumatoid synovial fluid [276], 
suggesting that the local production of BAFF in RA joints might favour the activation of 
autoreactive B cells with simultaneous ectopic lymphoid tissue formation [277].  
Other cytokines are known to have an important role in the recruitment of B cells 
towards RA synovium and hence contribute to the development and organization of 
lymphoid structures. In fact, previous studies have documented an increase in RA joints of 
IL-6 [278], a major B cell chemoattractant [279] and IL-21, a cytokine that directly affects 
plasma cell differentiation and supports autoantibody production [280]. 
 
3.4. B cells can function as antigen presenting cells 
Autoimmune conditions are the result of disorders in the immune system that 
erroneously recognizes self-antigens. Indeed, the APC function of B cells can have a 
central role in autoimmunity.  
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A B cell is classified as autoreactive when its BCR targets a self-antigen. This contrasts 
with other APC, whose activation depends on the recognition of molecular patterns from 
the antigen as foreign. Furthermore, in many cases, autoimmunity arises when antigens that 
are sequestered from the immune system become accessible and the capacity of B cells to 
concentrate small amounts of antigen would allow them to initiate a response.  
In the case of RA, autoreactive B cells can function as APC and present processed self-
antigens to T cells, thus allowing the development of an autoreactive immune response 
[281, 282]. The presence of B cells in synovial tissue from RA patients implanted in severe 
combined immunodeficiency (SCID) mice was shown to be necessary for activation of 
CD4 T cell clones isolated from the same or other HLA-matched patients [283]. 
Furthermore, in animal models of RA, genetic manipulation to generate mice with B cells 
unable to secrete antibodies demonstrated that antigen presentation by B cells is critical for 
disease development, as targeting of the autoantigen to specific B cells resulted in T cell 
activation and joint inflammation in the absence of autoantibodies [284].  
The role of B cells as APC in autoimmunity has also been observed in several other 
autoimmune conditions such as SLE [285, 286], type 1 diabetes [287, 288] or multiple 
sclerosis (MS) [289]. Importantly, B cells seem to have a relevant role as APC in the 
pathogenesis of autoimmunity even in cases where the autoantibody secreting function of B 
cells is not a major contributor. Therefore, the importance of antigen presentation by B cells 
can vary in different situations and at different stages of each disease. 
 
3.5. T cell activation is B-cell dependent 
The activity of B cells as efficient APCs induces the stimulation of T cells within 
rheumatoid ectopic lymphoid structures [284]. The establishment of B-T cell contacts 
allows an optimal development of memory CD4+ and CD8+ T cells [290, 291]. Importantly, 
RF+ B cells are believed to play an important role in antigen presentation. In fact, it has 
been demonstrated that they can take up antigen-antibody immune complexes through their 
membrane Ig receptors, which have RF specificity [281]. These autoreactive B cells then 
process and present peptides from the antigen to T cells, inducing T cell activation and 
help. Furthermore, previous studies by Takemura and colleagues have demonstrated that T 
cell response in RA synovitis and ectopic lymphoid organization is B cell dependent [283]. 
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When CD4+ T cells were transferred into SCID mice, the animals developed arthritis but 
only in the presence of B cells and when B cells where depleted, the disease ceased to 
occur. Moreover, the production of proinflammatory cytokines by T cells could be 
disrupted by B cell depletion.  
Most of the studies that concern B-T cell interactions in RA involve CD4+ T helper 
cells. The recent discovery in mice of a new lineage of CD4+ effector T helper cells that 
selectively produce IL-17, termed Th17 cells, has provided new insights into the immune 
regulation and pathogenesis of some autoimmune diseases [195].  
The role of Th17 cells in the inflammatory process that occurs in collagen-induced 
arthritis (CIA) mice served as a trigger to investigate the possible involvement of this T cell 
subset in human RA progression [292]. Of interest, Th17 cells have indeed proven to be 
associated with RA pathogenesis [197]. In fact, it has been demonstrated that IL-17 induces 
the secretion of proinflammatory cytokines, the upregulation of RANKL and stimulates the 
activity of matrix metalloproteases, leading to cartilage destruction and bone resorption 
[293-295]. In humans, differentiation of Th17 cells is driven by the simultaneous presence 
of IL-1β and IL-6 [296], also known to affect B cell biology in RA. Recent findings state 
that signaling pathways regulated by IL-17 contribute to the development of spontaneous 
GCs in autoimmune BXD2 mice [297] through the activation of autoreactive B cells by 
NF-κB signaling [298]. Furthermore, it has been demonstrated in SLE patients that IL-17 
alone or in combination with BAFF controls the survival and proliferation of human B cells 
and their differentiation into Ig-secreting cells [299]. Moreover, studies performed in CIA 
mice model have shown that local BAFF gene targeting inhibited proinflammatory 
cytokine expression, suppressed the generation of plasma cells and Th17 cells expansion, 
thus improving joint pathology [300]. Importantly, recent in vitro studies have shown that 
Th17 cells are also effective B-cell helpers due to their ability to stimulate B-cell 
differentiation and class switch recombination [301]. Indeed, Th17 cells express B cell 
chemoattractant CXCL13, which can have important consequences not only in 
autoimmunity, but also in protective immunity against pathogens [302]. Therefore, these 
observations reinforce the notion that perhaps the interaction between B and Th17 cells in 
RA are worthy of further investigations. 
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4. Targeting B cells: present and future 
 
4.1. B cell depletion therapy: the case of rituximab 
Autoimmune conditions such as RA when not properly diagnosed and treated can have 
life-threatening consequences. The majority of autoimmune diseases are B-cell dependent 
particularly due to autoantibody production. These autoreactive B cells can arise in the 
bone marrow or in the periphery, if the self-tolerance mechanisms fail. Thus, research areas 
that concern B cell targeted therapies are of great importance to stop or at least to attenuate 
the effects of diseases with a B cell origin such as autoimmune disorders, or B cell 
lymphomas.  
RA has traditionally been treated with analgesics and NSAIDs to control symptoms and 
with DMARDs to slow the processes involved in joint destruction. Advances in research 
into the pathogenic mechanisms underlying RA have led to the development of agents able 
to tackle the inflammatory process such as anti-cytokine therapies, namely against TNF. 
Although this approach has been effective, not all patients respond to treatments [303, 304]. 
Therefore, the contributions made by other cells, particularly B cells, to the 
immunopathogenesis of RA have become the focus of intense research.  
The identification of a surface antigen that is both exclusively and highly expressed on B 
cells is essential if B cells are to be targeted effectively. CD20 expression is limited to B 
cells, begins in humans at the early pre-B cell stage and persists until the B cells undergo 
terminal plasma cell differentiation [305, 306]. Indeed, CD20 is not found on stem cells, 
pro-B cells, DCs or plasma cells [307, 308]. This specificity is vital when selecting a viable 
therapeutic target, thus making CD20 an attractive, if not ideal, target.  
Rituximab (RTX) is a genetically engineered mouse-human chimeric monoclonal 
antibody specifically targeting CD20. RTX depletes B cells by inducing cell lysis, which 
can be mediated by complement-dependent cytotoxicity, antibody-dependent cell-mediated 
cytotoxicity or apoptosis [309, 310]. RTX was first approved as a treatment of relapsed or 
refractory CD20+ B-cell non-Hodgkin’s lymphoma (NHL) in 1997 [311, 312]. In this 
context, RTX has been shown to diminish the number of B cells in the blood and bone 
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marrow of NHL patients for 9-12 months after just one treatment [313]. Importantly, RTX 
was generally well tolerated, with a very low incidence of use-associated infections.  
In 1998, Edwards and Cambridge published a seminal paper proposing, for the first 
time, the use of RTX treatment in RA patients [217], which was highly controversial and 
revolutionary at the time. However, to their credit and facing considerable scepticism, the 
results observed in a small open-label study conducted by these authors provided the first 
indication of the therapeutic potential of RTX in RA [59]. In fact, in this study, patients 
who were non-responsive to DMARD therapy had a clearcut improvement in disease 
symptoms that was evident even beyond six months after a single RTX treatment. Indeed, 
circulating B cells were depleted to near undetectable levels and no major adverse events 
attributable to the treatment were observed. Notably, the work developed by Edwards and 
Cambridge [59] together with further studies [60, 314] provided robust evidence that B 
cells play a key role in RA and that selective B-cell depletion using RTX could be 
beneficial. Importantly, the first randomized, double-blind, placebo-controlled trial using 
RTX in any autoimmune disease was the phase IIa trial in RA reported by Edwards et al in 
2004 in the New England Journal of Medicine [60]. These results were also reinforced by a 
phase IIb clinical trial in 2006 [315].  
Despite the overall clinical efficacy of TNF antagonists in RA, a substantial fraction of 
RA patients do not respond to anti-TNF therapies [316-318]. Of note, the clinical efficacy 
of RTX was also confirmed in a large study of RA patients refractory to TNF-antagonist 
therapy [319]. Furthermore, RTX therapy has proven to be successful in other autoimmune 
conditions, such as SLE [320-322], SS [323-325], or idiopathic thrombocytopenic purpura 
(ITP) [326, 327].  
Despite some controversy, there is evidence supporting a higher efficacy of RTX in 
patients with ACPA and/or RF in the serum [315, 319, 328-333]. Although RTX treatment 
has proven to be efficient in RA patients, clinical relapses have been reported to occur 
[334], which means that re-treatment is routinely necessary. B cell return into circulation 
antedates clinical relapse by variable periods of time among RTX-treated RA patients. In 
some patients, relapse is virtually coincident with B cell return, whereas in others relapse 
occurs months or even years after B cell repopulation. Importantly, disease reappearance is 
temporally more closely associated with a rise in titers of circulating autoantibodies (RF, 
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for instance) related to putative pathogenic autoreactive B cells than with global B cell 
return per se [334].  
The reasons that might account for clinical relapse can include: a) incomplete B cell 
depletion in secondary lymphoid organs or bone marrow with rescuing and the survival of 
some pathogenic B cells that could restore the disease [335-337]; b) activity of long-lived 
plasma cells residing in the bone marrow or in the synovial tissue, which are not targeted 
by RTX [60]; c) persistence of autoreactive T cells in RTX-treated patients that could lead 
to the activation of newly generated pathogenic B cell clones; d) increased BAFF 
circulating levels observed during B cell depletion therapy with RTX, which could promote 
a support for surviving or re-emerging pathogenic B cells [338]. Therefore, the continuous 
research for new B cell targeting agents that directly act on other B cell antigens (for 
instance, CD19 or CD22) may possibly reveal even more promising results.  
The failure of B cell depletion therapy observed in some patients, particularly in RF-
negative patients, raises the issue of the existence of two different patterns of RA 
physiopathology with potential implications for prognosis and treatment [336, 339]. This 
concept is still in debate due to conflicting results that have been obtained in studies of 
repeated cycles of RTX treatment [340-342]. Apparently, in nonresponder patients, RTX is 
not able to break the self-reactive pathogenic B cell clones causing RA. The reasons that 
may account for this phenomenon are unknown, but suboptimal depletion of B cells, 
survival of plasma cells or higher numbers of memory B cells before treatment may explain 
refractoriness to the first RTX course [336, 339].  
According to a consensus statement on the use of RTX, treatment with RTX should be 
repeated (six months after the first infusion) if patients experience a clinical response to the 
first treatment course and significant disease activity remains or recurs [343]. Some studies 
have demonstrated that re-treatment is not effective in patients who do not exhibit clinical 
improvement after the first RTX infusion, which reinforces the hypothesis that such 
patients represent a different pathogenic subset of RA [341]. Nevertheless, recent studies 
contradict this hypothesis [340, 342]. Indeed, it has been shown that RA patients who 
initially fail to exhibit a response to RTX may respond to a second cycle [342]. 
Importantly, it was demonstrated that re-treating nonresponders prior to full B cell 
repopulation is a possible strategy to enhance depletion in these patients. Furthermore, the 
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use of a different B-cell depleting agent or a different initial dose of RTX can present an 
alternative strategy. Therefore, these observations seem to indicate that the full potential of 
B cell depletion therapy has not been achieved by current approaches and further studies 
are required. 
 
4.2. The importance of BAFF and BAFF-receptors in B cell 
survival 
BAFF, also known as BLyS, THANK, TALL-1, zTNF-4 or TNFSF13b, is a protein 
member of the TNF family that has an important role in B cell maturation, homeostasis and 
survival [344]. BAFF binds to three receptors: B-cell maturation antigen (BCMA), 
transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) 
and BAFF-receptor (BAFF-R or BR3) [345]. The precise mechanisms that control 
expression of all three BAFF receptors are currently unclear, but studies indicate that the 
developmental stage, cytokine milieu and the microenvironment play a key role in the 
regulation of the receptor expression [346]. Nevertheless, BAFF-R is the receptor to which 
BAFF binds with higher affinity [347].  
Studies of BAFF-R-deficient mice demonstrated that BAFF was essential for B cell 
survival, primarily through the alternative NF-κB pathway [348], and for B cell maturation 
and immunoglobulin class switching through the classical NF-κB pathway [349]. 
Moreover, the essential requirement for BAFF in B cell development was shown by the 
phenotype of BAFF knockout mice, which not only had a severe deficit of mature B cells, 
but also reduced levels of immunoglobulins [350].  
Importantly, evidence supports that BAFF is implicated in the development of 
autoimmunity. Indeed, BAFF transgenic mice have B cell hyperplasia, increased levels of 
immunoglobulins and prolonged BAFF overexpression induces autoantibody production 
[344, 351]. BAFF also plays a key role in promotion and/ or progression of malignant B 
cells [352], which suggests that BAFF may represent a link between autoimmunity and the 
increased frequency of B cell neoplasms observed in autoimmune conditions. Conversely, 
BAFF may also play a role in the autoimmune manifestations observed in such B cell 
malignancies. It is suggested that excess BAFF may lower the threshold for BCR signaling 
and maintain survival of pathogenic autoreactive B cells, thus breaking B cell tolerance. 
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Several autoimmune diseases might be partially triggered by deficient B-cell tolerance 
associated with the over-production of BAFF that might lead to inappropriate survival of 
autoreactive B cells.  
In humans, BAFF levels are elevated in patients with SLE, RA, SS and other systemic 
autoimmune diseases [276]. In RA patients, BAFF levels were found to be higher in the 
synovium than in the corresponding serum, thus suggesting that local production of BAFF 
in the synovium drives the maturation of autoreactive B cells that exacerbate the 
inflammatory process [353]. In fact, generalized inflammation and high levels of BAFF 
may drive continued production of plasma cells producing pathogenic autoantibodies [299, 
354]. These observations seem to implicate BAFF in the etiology and progression of 
autoimmune disease. Furthermore, BAFF receptor system displays an intriguing biological 
complexity in the sense that two of the receptors, TACI and BCMA, also interact with a 
related TNF family ligand, known as A proliferation-inducing ligand (APRIL). APRIL not 
only affects class-switch recombination process [355-357], but also plasma cell 
differentiation and survival [358-360]. BAFF binds to BAFF-R and TACI with high avidity 
and to BCMA with lower (humans) or no (mouse) avidity, whereas APRIL binds only to 
TACI and BCMA [361]. Also, high levels of both BAFF and APRIL, along with their 
receptors, are observed in the rheumatoid synovium [362], with APRIL being produced by 
synovial DCs and BAFF by tissue macrophages [363] and synovial fibroblasts. Indeed, this 
observation could thus explain the maintenance of autoreactive B cells in joints [360]. 
Interestingly, both cytokines are also produced by the synovial B cells [364, 365].  
Additionally, BAFF up-regulates Toll-like receptors (TLRs) expression and, together 
with IL-6, promotes Ig class-switching and plasma cell differentiation [366]. In fact, plasma 
cells express TACI and/ or BCMA and their survival can be supported by either BAFF or 
APRIL that are secreted by multiple cell types within the lymph node or bone marrow 
microenvironment [367]. Therefore, targeting BAFF, APRIL or their receptors may provide 
a novel therapeutic approach to autoimmunity.  
In animal models of autoimmune disease, BAFF and/ or its receptors’ antagonists reduce 
the disease severity and delay its progression [347, 368, 369]. Clinical trials of a selective 
antibody to BAFF (belimumab) and with the BAFF/ APRIL inhibitor TACI-Ig (atacicept) 
are also currently in progress with promising results, at least in SLE [370-372]. The results 
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observed in clinical trials will shed a light over the perspectives of using BAFF, APRIL or 
its receptors as potential future B cell targets in RA, either alone or eventually in 
combination therapy with B cell depleting agents, such as RTX [373, 374]. Therefore, 
continuous research on B cell biology in RA is fundamental to better understand the 
mechanisms underlying B cell intervention in RA autoimmunity and how the pathogenic 
effects of these cells can be abrogated to stop the development of autoimmune conditions. 
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IMS  
 
The main goal of the present work was to analyze the pathogenic role of B cells in the 
early phase of RA and in relapsing RA patients after B cell depletion therapy.  
 
The specific aims of this study were: 
 
i. To characterize B cell subpopulations in the peripheral blood from very 
early arthritis patients. 
ii. To quantify cytokine, chemokine and autoantibody production in patients’ 
serum. 
iii. To study the influence of immunosuppressive treatments (corticosteroids 
and MTX) on B cells activity and function in very early rheumatoid arthritis 
patients. 
iv. To analyze the expression of a group of B-cell related activation, maturation 
and survival genes in the initial phase of RA. 
v. To characterize B cell subpopulations, BAFF-R expression and serum BAFF 
levels before and after B cell depletion therapy. 
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Abstract 
 
Objectives: To characterize circulating B cell subpopulations of arthritis patients with 
less than 6 weeks of disease duration. Methods: Peripheral blood samples were collected 
from very early untreated polyarthritis patients, with less than 6 weeks of disease duration, 
for flow cytometric evaluation of B cell subpopulations. Samples from patients that were 
later diagnosed as rheumatoid arthritis (very early rheumatoid arthritis, VERA) were also 
collected 4-6 weeks after starting a low dose of prednisone (5-10 mg) and 4 months after 
reaching the minimum effective dose of methotrexate (MTX). A matched healthy group 
was used as a control. Results: VERA patients have a lower percentage of total peripheral 
blood memory B cells (CD19+CD27+) and a significant decrease in the frequency of 
circulating pre-switch memory B cells (CD19+IgD+CD27+) as compared to controls. 
Therapy with corticosteroids or MTX was unable to restore the normal frequencies of these 
B cell subpopulations. A significant decrease in peripheral pre-switch memory B cells is 
equally observed in other early arthritis patients. Furthermore, no significant differences are 
found in the frequencies of CD4+ and CD8+ T cells in all patient groups. Conclusions: In 
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very early polyarthritis patients there is a reduction in circulating pre-switch memory B 
cells. The reasons that may account for this effect are still unknown. Short-term 
corticosteroids and MTX do not seem to have a direct effect on circulating B cell 
subpopulations in VERA patients. 
 
1. Introduction 
 
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease of unknown 
aetiology affecting about 1% of the population. RA is characterized by symmetric 
polyarthritis associated with pain and swelling in multiple joints that, if left untreated, 
ultimately leads to joint destruction [1].  
The very early inflammatory reaction that occurs in the rheumatoid synovium is mainly 
constituted by neutrophils [2, 3]. However, this first inflammatory infiltrate quickly leads to 
increased expression of inflammatory cytokines, chemokines and adhesion molecules, 
inducing the recruitment of B, T cells and macrophages [4-6]. In fact, it is this secondary 
cell infiltrate that supports the persistence of the inflammatory response and mediates 
cartilage and bone destruction. Although RA has long been considered as a T cell centred 
disorder, recent evidence suggests that B cells do play an important role in the onset and 
perpetuation of this disease [7]. B cells function both as interleukin producing cells and 
antigen presenting cells that activate T cells [8, 9] and are also responsible for the 
production of autoantibodies [10-12], such as rheumatoid factor (RF). RF can interact with 
FcγRIIIa (CD16) receptors on monocytes and macrophages inducing the production of 
tumour necrosis factor (TNF) [13]. Moreover, B cell depletion therapy with Rituximab, a 
monoclonal antibody directed to CD20, have confirmed the importance of these cells in 
established RA [14]. Several studies have shown that following B cell depletion in patients 
with RA, there is clinical and serological improvement which parallels with a decrease in 
RF levels [15]. Despite the evidence for a critical role of B cells in established RA, the 
knowledge on the participation of these cells in the early phase of the disease is still very 
scarce. In addition, the effect of commonly used Disease Modifying Anti-Rheumatic Drugs 
(DMARDs), such as MTX, on B cells is also largely unknown.   
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The major goal of this study is to characterize circulating B cell subpopulations in very 
early RA (VERA) and in other very early arthritis (VEA) patients when compared to 
healthy donors, and to evaluate whether corticosteroids and MTX therapies have an impact 
on the frequencies of these cell subsets. 
 
2. Materials and Methods 
 
2.1. Patients 
Blood samples were obtained from 46 untreated polyarthritis patients (Rheumatology 
Department, Hospital de Santa Maria, Lisbon) with less than 6 weeks of disease duration. 
22 of these patients later on fulfilled the American College of Rheumatology (ACR) criteria 
for RA [16]. These patients were classified as VERA patients and further samples were 
collected 4-6 weeks after starting a low dose of oral prednisone (5-10mg) (time 1) and 4 
months after reaching the minimum effective dose of MTX, up to a maximum of 
20mg/week, that was needed to reduce the 28 joints disease activity score (DAS28) to less 
than 3.2 (time 2) [17]. The baseline blood samples from VERA patients were compared 
with other 24 very early arthritis (VEA) patients and 29 healthy donors used controls. The 
health assessment questionnaire (HAQ) [18] was applied to all patients and the DAS28 was 
calculated in all patients that fulfilled the ACR criteria for RA. The local ethics committee 
approved the study and all patients signed an informed consent. Patient’s management was 
done in accordance with the standard practice and the study was conducted in accordance 
with the Declaration of Helsinki as amended in Edinburgh (2000). 
 
2.2. Antibodies 
Immunophenotyping of B and T cells in peripheral blood and peripheral blood 
mononuclear cells (PBMC) samples was performed using matched combinations of anti-
human murine monoclonal antibodies conjugated to fluorescein isothiocyanate (FITC), 
phycoerythrin (PE), peridinin chlorophyll protein (PerCP), or allophycocyanin (APC). Isotype 
control antibodies were used for each fluorophore. For B cell analysis, combinations of anti-
CD19 conjugated to PerCP (clone 4G7, BD Biosciences, USA) or APC (HIB19, eBioscience, 
USA), anti-IgD conjugated to FITC or PE (IA6-2, BD Biosciences) and anti-CD27 conjugated 
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to PE or APC (O323, eBioscience) were used. T cells were identified with anti-CD3 PerCP 
(SK7, BD Biosciences), anti-CD4 FITC (MEM-241, Immunotools, Germany) and anti-CD8 
APC (MEM-31, Immunotools).  
 
2.3. Whole blood staining 
Approximately 5 ml of whole blood were collected by venipuncture into tubes 
containing EDTA. Erythrocytes were lysed with FACSTM Lysing Solution (BD 
Biosciences, USA) and cells were stained, incubated for 20 minutes at 4ºC, washed and 
stored in the dark at 4ºC until analyzed by flow cytometry. Frozen PBMC samples of 
patients were also used for staining protocol in order to establish the reproducibility of flow 
cytometry data from fresh and frozen samples. A total of 200.000 cells/ sample were 
acquired with a FACSCalibur (BD). Data were analyzed with FlowJo (TreeStar, Stanford 
University, CA). Absolute cell counts were calculated from differential leukocyte count 
determined at each time point for all patients.  
 
2.4. Peripheral blood mononuclear cells isolation 
PBMC were isolated from 20 ml heparinized whole blood following density gradient 
centrifugation with PercollTM (Amersham, Sweden). Cellular viability was estimated with 
Trypan Blue (Sigma, USA). Cells were frozen in 1 ml/ 107 cells RPMI-1640 (GIBCO, UK), 
40% fetal calf serum (FCS) (Invitrogen, UK), 10% dimethyl-sulfoxide (DMSO) (Sigma, 
USA) and stored at -80ºC until further use.  
 
2.5. Measurement of autoantibodies 
Rheumatoid factors (IgM, IgG and IgA) and anti-cyclic citrullinated peptide (anti-CCP) 
were determined at baseline in all patients and also at times 1 and 2 for VERA patients. 
IgM-RF, IgG-RF and IgA-RF were measured in the serum by DRG Rheumatoid Factor 
ELISA test system kits (DRG International, Inc., USA) according to the manufacturer 
instructions and samples were processed using a ChemWell® 2910 automated analyzer. 
Serum levels of anti-CCP were measured by ELIATM CCP test system (Phadia GmbH, 
Germany) and samples were analyzed using an ImmunoCAP® 100 instrument. 
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2.6. Statistical analysis 
Statistical differences were determined using one-way ANOVA and Bonferroni’s 
multiple comparison tests using GraphPad Prism (GraphPad, San Diego, CA). For 
populations that did not follow Gaussian distribution, the Kruskal-Wallis nonparametric 
test was used. Differences were considered statistically significant for p < 0.05. 
 
3. Results 
 
3.1. Disease assessment and autoantibody production 
A total of 46 polyarthritis patients with less than 6 weeks of disease duration were 
evaluated. 22 patients, 18 female and 4 male, with a mean age of 46.9±16.3 years (range 
23-77 years) fulfilled the ACR criteria for RA later on and were classified as VERA 
patients. At baseline, 10 of the VERA patients were RF positive, 6 of whom had anti-CCP 
antibodies (analysis performed up to 6 weeks after onset). All the RF negative patients 
simultaneously lacked anti-CCP antibodies. A quantitative analysis of the production of RF 
and anti-CCP was also performed (Table 1). Patients with detectable levels for RF were 
positive for both IgM and IgG RF. Only two of the patients were positive for IgA RF (data 
not shown). Interestingly, although not statistically significant, the mean levels of RF (IgG) 
and anti-CCP decreased with therapy (Table 1). After therapy with corticosteroids and 
MTX, a clinical response associated with the decrease in DAS28 score (p=0.0019 and 
p=0.0068, respectively) could be observed. In the remaining group of 24 other very early 
arthritis (VEA) subjects, 16 female and 8 male, with a mean age of 44.8±18.5 years (range 
19-87 years), patients were later classified as having systemic lupus erythematosus (4 
cases), crystal induced arthritis (3 cases), psoriatic arthritis (2 cases), colon adenocarcinoma 
(1 case), multiple myeloma (1 case), polymyalgia rheumatica (1 case), arthritis associated 
to HIV infection (1 case), arthritis associated with Crohn’s disease (1 case), unremitting 
undifferentiated arthritis (2 cases), unremitting reactive arthritis (2 cases), and 6 patients 
entered spontaneously into remission before 3 months of follow-up, remaining without a 
specific diagnosis and were thus classified as a self-limited form of arthritis. For this study, 
29 healthy controls, 22 female and 7 male, with a mean age of 39.8±13.6 years (range 22-
63 years) were also analyzed.  
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Table 1. Characteristics of very early rheumatoid arthritis patients and other very early arthritis patients. 
 
 
 
Baseline - Before any treatment; Visit 1 - After 4-6 weeks with 5-10 mg prednisone; Visit 2 - Four months 
after reaching the minimum effective dose of methotrexate; NA – not applicable; 
 
*Differences considered statistically significant for p values < 0.05. All values indicated represent the 
mean ± standard deviation (SD). 
 
 
 
3.2. Very early rheumatoid arthritis patients have a reduced memory B 
cell subpopulation irrespective of therapy 
The main B cell memory subsets were analyzed, depending on their IgD and CD27 
expression, being classified as pre-switch memory B cells (IgD+CD27+) and post-switch 
memory B cells (IgD-CD27+). The frequencies of total peripheral blood B cells (CD19+), 
naïve B cells (CD19+IgD+CD27-), pre-switch memory B cells (CD19+IgD+CD27+), post-
switch memory B cells (CD19+IgD-CD27+), total memory B cells (CD19+CD27+) and 
plasma cells (CD19+CD27high) from VERA patients were compared to the same populations 
of healthy donors (Figure 1).  
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Figure 1. B cell analysis by flow cytometry.  
A region (gate) was defined around total lymphocytes in peripheral blood, depending upon cell size (FSC – 
forward scatter) and granularity (SSC – side scatter). Total B cells were identified based on the expression of 
the cell surface marker CD19 and its subpopulations were classified according to IgD and CD27 expression in 
healthy controls (A) and patients (B). Thus, naïve B cells (I) were classified as CD19+IgD+CD27- ; pre-switch 
memory B cells (II) as CD19+IgD+CD27+; post-switch memory B cells (III) as CD19+IgD-CD27+ and plasma 
cells (IV) as CD19+IgD-CD27high. 
 
 
The frequency of total B cells at baseline was similar between VERA patients and 
healthy controls, being the average of circulating B cells gated in total lymphocytes of 
11.69±6.85 % and 11.37±5.69 %, respectively (Figure 2A). Furthermore, corticosteroids 
and MTX did not affect the frequency of total B cells. Also, the analysis of absolute cell 
numbers of total B cells confirmed this result (Figure 2A).  Naïve B cells were significantly 
higher in VERA patients without treatment when compared to controls (Figure 2B) and 
their percentages tended to return to normal values after corticosteroid and MTX treatment, 
although this effect was not statistically significant. In addition, the analysis of absolute cell 
counts of this B cell subpopulation did not show any statistically significant difference 
between groups (Figure 2B). Both controls and VERA patients had comparable very low 
levels (less than 3%) of circulating plasma cells (Figure 2C). VERA patients had 
significantly lower frequencies of pre-switch memory B cells when compared to controls 
(Figure 3A), irrespective of therapy. Importantly, this observation was also confirmed by a 
decrease in the absolute numbers of this B cell subpopulation (Figure 3B). In contrast, no 
statistically significant differences were observed in post-switch memory B cells between 
VERA patients and controls (Figure 3C). A lower percentage of total memory B cells was 
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observed in untreated VERA patients as compared to controls (Figure 3D) and no effect 
after MTX treatment was observed. Furthermore, no correlation was found between the age 
of the patients and the percentages or absolute cell numbers of pre-switch and total memory 
B cells (data not shown). No correlation was found between DAS28 and the percentages or 
absolute cell numbers of pre-switch and total memory B cells at all time points (data not 
shown). Moreover, in order to verify whether an association existed between peripheral B 
cell abnormalities, particularly in the memory B cell pool, with the presence or absence of 
autoantibodies in the serum, circulating B cell subsets were analyzed at baseline comparing 
seronegative and seropositive VERA patients both for RF (IgM and IgG) and anti-CCP, but 
no statistically significant differences were observed (data not shown). 
We also investigated differences between VERA patients and controls in circulating T 
cells, namely total T (CD3+), CD4+ and CD8+ T cells and whether corticosteroids and MTX 
could have some effect on these populations. In VERA patients, no significant differences 
were found in the frequencies of CD4+ and CD8+ T cells as compared to controls, or after 
treatment (data not shown).  
Although 22 VERA patients were selected for this study, 5 patients were lost for follow-
up, technical problems occurred with the processing of the samples in 4 patients and 3 
patients missed one of the appointments. Thus, the number of patients considered at each 
time point (n) is indicated together with the appropriate data in all figures. 
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Figure 2. Therapy with corticosteroids and methotrexate does not affect circulating total B cells, naïve B 
cells and plasma cells of very early rheumatoid arthritis patients.  
Data from flow cytometry analysis of peripheral blood B cells from VERA patients without treatment and 
after therapy with corticosteroids and MTX. Total B cells (CD19+) (A) were gated on total lymphocytes and 
represented are the frequencies and absolute cell numbers. Naïve B cells (CD19+IgD+CD27-) (B) and Plasma 
cells (CD19+CD27high) (C) were gated in CD19+ B cells. Differences are considered statistically significant 
for p < 0.05. 
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Figure 3. Very early rheumatoid arthritis patients have reduced frequencies and absolute numbers of pre-
switch memory B cells.  
Data from flow cytometry analysis of memory B cells from VERA patients without treatment and after 
therapy with corticosteroids and MTX. All subpopulations were gated in CD19+ B cells. Representation of 
Pre-switch memory B cells (CD19+IgD+CD27+) frequencies (A) and absolute numbers (B). Post-switch 
memory B cells (CD19+IgD-CD27+) (C) and Total memory B cells (CD19+CD27+) (D) frequencies are 
represented. Differences are considered statistically significant for p < 0.05. 
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3.3. Very early arthritis patients have a diminished pre-switch memory 
B cell subset at baseline 
Other very early polyarthritis patients evaluated with less than 6 weeks of disease 
duration who later were diagnosed as different types of arthritis other than RA were 
followed in this study for comparison with VERA patients. VEA patients did not show any 
statistically significant difference in both frequencies and absolute numbers of total B cells 
(Figure 4A), naïve B cells (Figure 4B) or plasma cells (Figure 4C) when compared to 
controls. However, similarly to what was observed in VERA patients, VEA patients had a 
significantly (p<0.05) lower frequency of pre-switch and total memory B cells as compared 
to controls (Figure 5). Interestingly, the frequency of pre-switch memory B cells was 
similar in both VEA and VERA patients without treatment, being the average of 
6.94±4.64% and 5.33±3.82%, respectively (Figure 5A). The analysis of absolute numbers 
of pre-switch memory B cells in the peripheral blood of VEA patients confirmed a 
statistically significant reduction in this B cell subpopulation (Figure 5B). No other 
statistically significant results were obtained with post-switch memory B cells (Figure 5C), 
or with CD4+ and CD8+ T cells (data not shown).  
The sub analysis of the 6 patients that entered spontaneously into remission depicted the 
same pattern. As noted for VERA patients, no correlation was found between the age of 
VEA patients and the percentages or absolute cell numbers of pre-switch and total memory 
B cells (data not shown). 
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Figure 4. Early arthritis patients do not have any significant difference in circulating total B cells, naïve B 
cells and plasma cells when compared to healthy controls.  
Data from flow cytometry analysis of peripheral blood B cells from other early arthritis patients at baseline. 
Total B cells (CD19+) (A) were gated on total lymphocytes and represented are the frequencies and absolute 
cell numbers. Naïve B cells (CD19+IgD+CD27-) (B) and Plasma cells (CD19+CD27high) (C) were gated in 
CD19+ B cells. Differences are considered statistically significant for p < 0.05. 
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Figure 5. Early arthritis patients have reduced frequencies and absolute numbers of pre-switch memory B 
cells.  
Data from flow cytometry analysis of memory B cells from other early arthritis patients at baseline. All 
subpopulations were gated in CD19+ B cells. Representation of Pre-switch memory B cells 
(CD19+IgD+CD27+) frequencies (A) and absolute numbers (B). Post-switch memory B cells (CD19+IgD-
CD27+) (C) and Total memory B cells (CD19+CD27+) (D) frequencies are represented. Differences are 
considered statistically significant for p < 0.05. 
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4. Discussion  
 
Several studies have documented the presence of B cells in the rheumatoid synovium [5, 
19-23] and reinforced the importance of these cells in RA progression. However, little is 
known about peripheral blood B cell subpopulations and their functions in the very early 
phase of the disease. 
Our results demonstrate, for the first time, that VERA patients have a lower pre-switch 
memory (CD19+IgD+CD27+) B cell subset as compared to controls and that treatment with 
corticosteroids and MTX does not affect this B cell subpopulation. However, this difference 
does not appear to be specific of VERA patients, since other early arthritis patients with the 
same disease duration show a similar pattern. As a consequence, the reduction of pre-
switch memory B cells seems to be an early manifestation of polyarthritis. 
It has been demonstrated that adult circulating B cells can be separated into three 
subpopulations on the basis of CD27 and IgD expression: IgD+CD27- naïve B cells, 
IgD+CD27+ and IgD-CD27+ memory B cells [24-26]. Klein et al [27] have also described 
that IgM+IgD+CD27+ B cells carried somatically hypermutated antibodies, which 
indicates that this population is in fact a memory B cell subset. However, the functional 
differences and characteristics between the two memory B cell subpopulations remain to be 
clearly elucidated. In a study performed by Shi et al [28], data were obtained that helped to 
clarify the differences between memory B cell subsets. In fact, it was demonstrated that 
IgD+CD27+ are unclass-switched memory B cells that play a crucial role in secondary 
immune response by producing high-affinity IgM in the early phase of infections and IgD-
CD27+ are class-switched memory B cells that mainly express surface IgG and IgA 
isotypes. These findings were reinforced by the discovery that activation-induced cytidine 
deaminase (AID), which is essential for class-switch recombination process [29, 30], was 
spontaneously expressed in IgD-CD27+ B cells, but was not found in IgD+CD27+ memory 
B cells [28].  
CD27 is now an important marker for analysis of B cell differentiation in diseases 
characterized by disturbances in B cell development. In fact, distinct types of abnormal B 
cell homeostasis have been documented in some autoimmune diseases and other 
immunodeficiency disorders. Of interest, previous reports had already mentioned a 
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decrease of IgD+CD27+ memory B cell subset in patients with systemic lupus 
erythematosus (SLE) [31], primary Sjögren Syndrome (SS) [32-34] or Systemic Sclerosis 
(SSc) [35]. Also, a reduction in circulating memory B cells was demonstrated in patients 
with X-linked Hyper-IgM Syndrome [36], Chronic Granulomatosus Disease [37] and HIV 
infection [38]. Hence, lower levels of circulating memory B cells seem to be a hallmark 
linked with chronic inflammation rather than an exclusive feature of autoimmune 
conditions. Furthermore, in a study performed by Hansen et al [39], it was shown that the 
generation of the peripheral B cell memory subset in SS patients seems to be particularly 
affected by abnormalities in postrecombinational events. Our observations suggest that 
changes in the B cell memory subset also occur in very early stages of RA and other 
polyarthritis. In VERA patients, despite the clinical response induced by corticosteroids and 
MTX, no effect of these treatments was reflected in changes of IgD+CD27+ memory B cell 
levels.  
Since B cells differentiate into memory or plasma cells [26], the reduced frequency of 
circulating memory B cells in both VERA patients and other early arthritis patients could 
be explained by a skewing towards plasma cell differentiation, or by an increase in naïve B 
cell population, thus resulting in less memory B cells. However, in our study we did not 
find any statistically significant difference in the frequencies of circulating plasma cells 
when comparing both VERA and VEA patients with controls, although we might not 
exclude the possibility of this B cell subpopulation being increased in the bone marrow, 
where it mainly resides [40], or in the rheumatoid synovium. Disturbances in the naïve B 
cell subpopulation have been observed in other autoimmune conditions associated 
simultaneously with a decrease of circulating memory B cells. In fact, SS [34, 41] and SSc 
[35] patients have a predominance of CD27- naïve B cells and a reduced frequency of 
CD27+ memory B cells in circulation. In our study, VERA patients had an increased naïve 
B cell subpopulation observed at baseline as compared to controls, returning this B cell 
subset to normal values upon corticosteroids and MTX therapy. Nevertheless, this effect 
was not statistically significant. Moreover, there was not a statistically significant 
difference between absolute cell counts of this B cell subpopulation in VERA patients as 
compared to controls. Also, similar results were observed in VEA patients when analyzing 
naïve B cells. Considering our results, we hypothesize that during the initial phase of 
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arthritis, circulating pre-switch memory B cells are recruited to the synovial membrane, 
where the production of high-affinity IgM is induced, which can react with antigens (self 
and non-self, depending if it is an autoimmune condition or not) and lead to inflammation. 
Importantly, it has been demonstrated that in established RA patients there is an 
accumulation of both pre-switch IgD+CD27+ and post-switch IgD-CD27+ memory B cells 
in the synovial membrane, which supports our hypothesis [42]. Furthermore, there is also 
the possibility that in the initial phase of arthritis pre-switch memory B cells are recruited 
towards secondary lymphoid organs, where consequently become activated, thus leading to 
a decrease in the circulating pool. 
In addition, corticosteroids and MTX did not affect the levels of the other B cell 
subpopulations in circulation, or CD4+ or CD8+ T cell frequencies. Corticosteroids are 
frequently administered to RA patients and their use can cause redistribution of lymphocyte 
populations [43], since long-term low-dose corticosteroids therapy induces a decrease in B 
cell counts [44]. However, our results indicate that short-term low doses of corticosteroids 
do not appear to affect B cell counts. On the other hand, the effect of MTX on circulating 
blood cells in autoimmune conditions is controversial [45-47]. In a study performed by 
Bohm et al [48] it was observed that SLE patients treated with short-term MTX had slightly 
increased levels of total CD3+, CD4+ and CD8+ T cells, while monocytes and B cells 
remained stable. However, long-term MTX treatment decreased absolute numbers of both 
B and T cells. Moreover, a decrease of autoantibody levels accompanied the B cell 
response to long-term MTX. Nevertheless, several studies by Lacki et al [49-52] state that 
there are no significant differences in the percentage of CD3+, CD4+ and CD8+ T cells in 
RA patients treated with long term MTX, although a decrease of B cell levels is observed. 
Our results seem to indicate that T and B cell subsets are not affected by short term 
treatment with MTX in VERA patients. 
 
5. Conclusions 
 
In summary, in the first few weeks of arthritis onset there seems to be an alteration in the 
frequency of circulating memory B cells, particularly pre-switch memory B cells, as 
compared to controls. In addition, the short term use of corticosteroids and MTX do not 
 79 
 
 
seem to affect circulating B cell subpopulations in VERA patients. However, since other 
early arthritis patients, who did not fulfil the ACR criteria for RA, also had a decrease of 
pre-switch memory B cells before any treatment was started, it seems that this effect is not 
unique and specific to the initial phase of RA. Further studies are required for a better 
understanding of the biological meaning of the reduction in the memory B cell pool in an 
early arthritis condition. 
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Abstract 
 
Objectives: B cells play an important role in the perpetuation of rheumatoid arthritis 
(RA), particularly as autoantibody producing cells. The immune complexes that further 
develop deposit in the joints and aggravate the inflammatory process. However, B cells 
contribution in the very early stage of the disease remains unknown. The main goal of this 
work was to determine the concentration of cytokines potentially relevant for B cell 
activation in serum from very early polyarthritis patients, with less than 6 weeks of disease 
duration, who latter on evolved into RA (VERA). Methods: APRIL, BAFF and IL-21 
levels were measured by ELISA in the serum of VERA, other very early arthritis (VEA), 
established RA patients and controls. Synovial fluid (SF) samples of established RA were 
also analyzed. Results: VERA patients have higher levels of APRIL and BAFF as 
compared to VEA, established RA and controls. Furthermore, APRIL and BAFF levels are 
also significantly elevated in RA-SF when compared to serum. Conclusions: The increased 
levels of APRIL and BAFF in VERA patients suggests that B cell activation and the 
development of autoreactive B cell responses might be crucial in early phases of RA. 
Therefore, APRIL and BAFF could be promising targets for therapy in the early phase of 
RA. 
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1. Introduction 
 
B cells play critical roles in rheumatoid arthritis (RA) pathogenesis. They are the source 
of rheumatoid factors (RF) and anti-cyclic citrullinated peptide (CCP) autoantibodies, 
which contribute to immune complex formation in the joints. These cells are also efficient 
antigen presenting cells and contribute to T cell activation through expression of 
costimulatory molecules. B cells simultaneously respond and produce chemokines and 
cytokines that promote leukocyte infiltration into the joints, formation of ectopic lymphoid 
structures, angiogenesis and synovial hyperplasia. Moreover, B cell depletion therapy with 
rituximab, as well as the promising results obtained with atacicept in a phase Ib trial [1], 
confirmed the importance of these cells in established RA [2, 3]. However, B cells 
participation in the early phase of the disease is not yet completely understood. 
Interestingly, our previous studies showed a significant decrease of pre-switch memory B 
cells (IgD+CD27+) in peripheral blood of very early RA (VERA) patients, with less than 6 
weeks of disease duration, when compared to controls [4]. In accordance with the results of 
another group it is highly likely that this B cell subset migrates towards the synovial 
membrane, contributing for the onset of the synovitis process [5]. Our hypothesis is that the 
cytokine environment in early RA favors the recruitment, activation and survival of B cells 
and herein we tested this concept in a cohort of very early polyarthritis patients.   
 
2. Materials and Methods 
 
2.1. Patients 
Blood samples were collected from 19 untreated very early polyarthritis patients with 
less than 6 weeks of disease duration, who after a minimum follow-up of 3-4 months 
fulfilled the 1987 American College of Rheumatology (ACR) criteria for RA [6]. These 
patients were classified as VERA patients. Further samples were collected 4-6 weeks after 
starting a low dose of oral corticosteroids (5-10 mg of prednisone) (Time 1) and 4 months 
after reaching the minimum effective dose of methotrexate (MTX) (Time 2) up to a 
maximum of 20 mg/week required to reduce the 28 joints disease activity score (DAS28) to 
 85 
 
 
less than 3.2 [7]. Also, baseline blood samples from VERA patients were compared with 19 
other very early arthritis (VEA) patients who, after the same follow-up, did not evolve into 
RA and with 24 controls. Additionally, 12 blood and 15 synovial fluid (SF) samples were 
obtained from MTX treated established RA patients. Of note, SF samples were only 
collected from established RA, since most VERA patients did not have joint effusions in 
easily accessible joints (Table 1). The health assessment questionnaire (HAQ) [8] and the 
DAS28 were applied to all patients. The study was approved by the local ethics committee 
and all patients signed an informed consent. Patient care was conducted in accordance with 
the standard clinical practice in the Rheumatology Department, Hospital de Santa Maria, 
Lisbon and the study was performed in accordance with the Declaration of Helsinki as 
amended in Edinburgh (2000). 
 
2.2. Cytokine quantification 
A proliferation-inducing ligand (APRIL), B cell activating factor (BAFF) and 
interleukin (IL)-21 levels were determined by enzyme linked immunosorbent assay 
(ELISA) (Bender MedSystems GmbH, Vienna, Austria) according to the provider's 
instructions. Samples were analyzed using plate reader Infinite® M200 (Tecan, Männedorf, 
Switzerland). 
 
2.3. Measurement of autoantibodies 
RF-immunoglobulin M (RF-IgM) was determined in all patients by IMTEC 
Autoimmune Diagnostics ELISA kit (Human GmbH, Wiesbaden, Germany) according to 
the manufacturer instructions and samples were processed using a ChemWell® 2910 
automated analyzer. Serum levels of anti-CCP were measured by ELIATM CCP test system 
(Phadia GmbH, Freiburg, Germany) and samples were analyzed using an ImmunoCAP® 
100 instrument. 
 
2.4. Statistical analysis 
Statistical differences were determined with non-parametric Kruskal-Wallis and Mann-
Whitney tests using GraphPad Prism (GraphPad, San Diego, CA). Correlation analysis was 
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performed using Spearman’s test. Differences were considered statistically significant for p 
< 0.05. 
 
3. Results 
 
3.1. Characterization of patients and disease evaluation 
A total of 38 polyarthritis patients with less than 6 weeks of disease duration were 
consecutively included. VERA patients had a mean age of 59±17 years, 84.2% were 
female, 42% were RF positive and 32% anti-CCP positive. The baseline DAS28 and HAQ 
were 6.1±1.8 and 1.4±0.8, respectively. After treatment with corticosteroids and MTX there 
was a significant reduction of both DAS28 and HAQ values (Table I). VEA patients were 
classified as having spondyloarthritis (5 cases), systemic lupus erythematosus (4 cases), 
crystal induced arthritis (2 cases), Sjögren’s syndrome (1 case), paraneoplastic polyarthritis 
related to multiple myeloma (1 case), arthritis associated to HIV infection (1 case), and 5 
patients entered spontaneous remission before 3 months of follow-up, remaining without a 
specific diagnosis and were thus classified as presenting a self-limited polyarthritis. These 
early polyarthritis patients represent a subset of a larger cohort previously described by our 
group [4]. Furthermore, unpaired blood and SF samples were collected from established 
RA patients who had similar DAS28 and HAQ values to those of VERA patients at 
baseline (Table 1).  
 
3.2. APRIL and BAFF levels are increased in very early rheumatoid 
arthritis patients at baseline 
At baseline, APRIL and BAFF levels were significantly higher in VERA patients as 
compared to both VEA and controls (Figure 1A). No differences were observed between 
treated or untreated VERA patients, or between VEA and controls (Table 1). Moreover, no 
significant differences in IL-21 levels could be observed in VERA when compared with 
both VEA patients and controls, or after therapy with corticosteroids and MTX (data not 
shown). Furthermore, there was no correlation between DAS28, anti-CCP or RF 
autoantibodies and APRIL and BAFF serum concentrations (data not shown). 
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Table 1. Clinical information and cytokine levels in healthy controls, very early rheumatoid arthritis, very 
early arthritis and rheumatoid arthritis patients. 
 
 
 
All values indicated in table represent mean ± standard deviation. NA - not applicable; ND - not 
determined; SF – synovial fluid. 
 
 
a
 The indicated DAS28 value corresponds to the baseline DAS28 3V score due to the unavailability of 
Visual Analogue Scale (VAS) parameter at baseline in established RA group of patients. 
 
* DAS28 and HAQ values were compared between VERA and VEA patients with reference to VERA 
baseline values.  
 
Differences are considered statistically significant for p < 0.05.   
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Figure 1A. Very early rheumatoid arthritis patients have higher APRIL and BAFF levels than controls and 
those with very early arthritis at baseline.  
Serum samples from VEA patients with no therapy and healthy controls were analyzed by ELISA technique. 
Dotted lines represent the limit of detection for the assay. Differences were considered to be statistically 
significant at p < 0.05.  
 
 
 
3.3. Very early rheumatoid arthritis patients have higher APRIL and 
BAFF levels in comparison to established rheumatoid arthritis patients 
In order to compare early RA with the chronic phase, we also analyzed established RA 
serum samples. Importantly, VERA patients, in baseline and even after MTX treatment, 
had higher circulating levels of both APRIL (p<0.05) and BAFF (p<0.001) in comparison 
with established RA. However, regarding IL-21, no differences could be found in VERA 
when compared with established RA (data not shown). Furthermore, no significant 
differences could be observed in established RA in comparison with controls (data not 
shown). 
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3.4. Established rheumatoid arthritis synovial fluid has increased levels 
of APRIL, BAFF and IL-21 
To verify if in established RA patients a B cell activation environment could be present 
in the joint fluid despite lower APRIL and BAFF serum levels, we tested the same cytokine 
panel in established RA-SF. APRIL, BAFF and IL-21 levels were in fact increased locally 
in the joints of established RA patients in comparison with RA serum (Figure 1B).  
 
 
 
 
 
Figure 1B. Established rheumatoid arthritis patients have increased levels of APRIL, BAFF and IL-21 locally 
in the joints.  
Serum and synovial fluid (SF) samples from established RA patients were analyzed by ELISA technique. 
Dotted lines represent the limit of detection for the assay. Differences were considered statistically significant 
at p < 0.05. 
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4. Discussion 
 
In the present work, a cytokine pattern favoring B cell activation is observed in RA 
patients with less than 6 weeks of disease duration, when compared with other causes of 
very early arthritis (VEA) and established RA. Our previous results demonstrated a 
significant decrease of pre-switch memory B cells (IgD+CD27+) in peripheral blood of 
VERA patients [4]. This is in agreement with the report from other group referring a 
migration of this B cell subset towards the synovial membrane [5]. In fact, in established 
RA, ectopic germinal center-like structures develop in the inflamed synovial tissue that 
support survival of B cells and autoantibody production [9]. Therefore, we also analyzed 
established RA-SF samples and depicted the presence of a cytokine-based B cell survival 
environment that could explain the maintenance of potentially autoreactive B cells in the 
synovium. Our results demonstrated that VERA patients have increased APRIL and BAFF 
levels when compared to VEA and controls. Interestingly, APRIL was also increased in 
VERA patients’ serum as compared to established RA and its levels were even higher in 
RA-SF suggesting a local upregulation in the synovium. APRIL affects not only class-
switch recombination process [10-12], but also plasma cell differentiation and survival [13, 
14], which could thus explain the maintenance of autoreactive B cells in the joints [15]. 
Actually, a highly positive association between the infiltration of plasma cells and synovial 
fluid levels of APRIL has been demonstrated in RA patients [15, 16]. BAFF, similarly to 
APRIL, is a fundamental B cell survival factor and we have also detected increased serum 
levels in VERA patients when compared with established RA. Moreover, BAFF was also 
significantly elevated in RA-SF in comparison with RA serum. Previous studies have 
demonstrated that BAFF increases the chemokine (C-X-C motif) ligand 13 (CXCL13)-
dependent chemotaxis of memory B cells through BAFF receptor (BAFF-R) triggering 
[17]. Therefore, increased BAFF levels in RA could support the migration of pre-switch 
memory B cells towards RA synovium, thus justifying the decrease of this B cell 
subpopulation in circulation. Furthermore, IL-21 increased levels in RA-SF support local 
plasma cell differentiation and autoantibody production [18]. Additionally, therapy with 
neither corticosteroids nor MTX affected cytokine production in VERA patients. However, 
the patients with established RA that we have studied were on chronic treatment with MTX 
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and low dose corticosteroids and this might have influenced the serum levels of APRIL and 
BAFF. The effect of low dose corticosteroids and MTX on cytokine production in RA 
patients is still controversial [19, 20]. So, an absence of effect of short-term therapy with 
corticosteroids and MTX on the cytokines analyzed was not entirely unexpected in VERA, 
but an effect on chronic-treated patients might in fact occur.   
 
5. Conclusions 
 
In conclusion, we have shown increased APRIL and BAFF levels in very early RA and 
in RA-SF, which could hypothetically support the maintenance, expansion, activation and 
survival of autoreactive B cells since the first weeks of disease onset. Therefore, we suggest 
that APRIL and BAFF may be potential promising treatment targets in the very early phase 
of RA.  
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Abstract 
 
Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease 
characterized by sustained synovitis. Recently, several studies have proposed neutrophils 
and Th17 cells as key players in the onset and perpetuation of this disease. The main goal 
of this work was to determine whether cytokines driving neutrophil and Th17 activation are 
dysregulated in very early rheumatoid arthritis patients with less than 6 weeks of disease 
duration and before treatment (VERA). Methods: Cytokines related to neutrophil and Th17 
activation were quantified in the serum of VERA and established RA patients and 
compared with other very early arthritis (VEA) and healthy controls. Synovial fluid (SF) 
from RA and osteoarthritis (OA) patients was also analyzed. Results: VERA patients had 
increased serum levels of cytokines promoting Th17 polarization (IL-1β and IL-6), as well 
as IL-8 and Th17-derived cytokines (IL-17A and IL-22) known to induce neutrophil-
mediated inflammation. In established RA this pattern is more evident within the SF. Early 
treatment with MTX or corticosteroids led to clinical improvement but without an impact 
on the cytokine pattern. Conclusions: VERA patients already display increased levels of 
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cytokines related with Th17 polarization and neutrophil recruitment and activation, a 
dysregulation also found in SF of established RA. Thus, our data suggest that a cytokine-
milieu favoring Th17 and neutrophil activity is an early event in RA pathogenesis. 
 
1. Introduction 
 
Rheumatoid arthritis (RA) is the most common chronic autoimmune disease, affecting 
approximately 1% of the population worldwide. This disease comprises a syndrome of 
pain, stiffness and symmetrical synovitis which leads to joint destruction, functional 
disability and substantial comorbidity due to involvement of multiple organs and systems. 
The migration of leukocytes towards the synovium is crucial for the establishment of a 
chronic inflammatory process in RA [1-3]. This multi-regulated mechanism involves 
interactions with endothelial cells through cell adhesion molecules and complex cytokine 
and chemokine pathways.  
Neutrophils specifically play an important role in the onset and perpetuation of RA, not 
only as interleukin producing cells, but also for being responsible for the release of high 
amounts of reactive oxygen species (ROS) and destructive enzymes, such as 
metalloproteases, contributing to joint erosions [4]. Neutrophils are among the first 
leukocytes to arrive at sites of inflammation. In fact, these cells are the most abundant in 
the synovial fluid of patients with active RA and previous results from our group showed 
that the synovial tissue is heavily infiltrated by neutrophils in the first weeks of RA onset 
[5]. Interestingly, in animal models of arthritis, neutrophil depletion prevented joint 
inflammation if neutrophil depleting antibodies were given before the induction of arthritis. 
Moreover,  when the depleting antibody was given very early after the induction of arthritis 
complete abrogation of the inflammatory symptoms was also achieved [6].   
T helper (Th)-17 cells have also been proposed to have a relevant role in the early phase 
of RA through the production of interleukin (IL)-17 [7, 8]. This cytokine promotes the 
recruitment and survival of neutrophils, induces the secretion of proinflammatory 
cytokines, the upregulation of RANK ligand (RANKL) and stimulates the activity of matrix 
metalloproteases, leading to cartilage catabolism and bone resorption [9, 10]. The 
recruitment, activation and effector function of Th17 cells and neutrophils are driven by a 
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network of cytokines and chemokines, secreted by multiple cellular sources. In established 
RA, it has been reported that IL-1β, IL-6, IL-8, IL-17 and tumor necrosis factor (TNF) are 
elevated in the serum and this correlates with a higher disease activity [11-13]. 
Nevertheless, our knowledge on the influence of the cytokine network on RA onset remains 
scarce. The characterization of the cytokine profile at this stage, where the transition from 
an acute to a chronic inflammatory phase occurs, may lead to the identification of early key 
players, with potential implications for early treatment strategies.  
Thus, the main goal of our work was to determine whether cytokines driving neutrophil 
and Th17 cell activation and proinflammatory function were already present in very early 
RA (with less than 6 weeks of disease duration) and how this early cytokine environment 
differs from established RA. We also evaluated whether the introduction of low dose 
corticosteroids and methotrexate (MTX) therapy had any influence on the cytokine profile 
observed at that early stage of the disease.  
We found that cytokines related with Th17 polarization and neutrophil recruitment and 
activation were elevated in early RA and that the conventional therapeutic options, 
although able to control clinical manifestations of the disease, were ineffective in reversing 
this underlying proinflammatory drive. 
 
2. Materials and Methods 
 
2.1. Patients 
Blood samples were obtained from 38 consecutive untreated polyarthritis patients with 
less than 6 weeks of disease duration. Some of these patients (19) after a minimum follow 
up of 3 months fulfilled the 1987 American College of Rheumatology (ACR) criteria for 
RA [14]. These patients were classified as Very Early Rheumatoid Arthritis (VERA) 
patients and further samples were collected 4-6 weeks after starting a low dose of oral 
corticosteroids (5-10 mg of prednisone) (Time 1) and 4 months after reaching the minimum 
effective dose of MTX (Time 2), up to a maximum of 20 mg/week, that was required to 
reduce the 28 joints disease activity score (DAS28) to less than 3.2 [15]. The remaining 
early arthritis patients (19), who did not evolve into RA, were classified as very early 
polyarthritis (VEA). Baseline blood samples from VERA and VEA patients were compared 
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with 27 healthy donors used as controls. Additionally, 12 blood and 15 SF samples were 
obtained from established RA patients. SF samples were also collected from 10 OA 
patients (Rheumatology Department, Hospital de Santa Maria, Lisbon) (Table 1). Due to 
the clinical characteristics of the very early arthritis patients, SF in easily accessible joints 
was not available in VERA and VEA patients and thus SF was not analyzed in these groups 
of patients. The health assessment questionnaire (HAQ) [16] and DAS28 were applied to 
all patients. The study was approved by the local ethics committee and all patients signed 
an informed consent. Patient care was conducted in accordance with the standard clinical 
practice and the study was performed in accordance with the Declaration of Helsinki as 
amended in Edinburgh (2000).  
 
2.2. Cytokine quantification 
IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12(p70), IL-17A, IL-22, IL-23 and interferon-
gamma (IFN-γ) levels were measured in the serum and SF by FlowCytomix assay kit (FC) 
(Bender MedSystems, Vienna, Austria) according to the manufacturer instructions. 
Standard curves for each cytokine were generated by using reference cytokine 
concentrations supplied by the manufacturer. Samples were acquired with a FACS Calibur 
(BD Biosciences, San Jose, CA, USA). Raw data of the FC bead assay were analyzed by 
FlowCytomixPro2.2 software (Bender MedSystems). 
 
2.3. Measurement of autoantibodies 
Rheumatoid factor (RF)-IgM was determined in all patients by IMTEC Autoimmune 
Diagnostics ELISA kit (Human GmbH, Wiesbaden, Germany) according to the 
manufacturer instructions and samples were processed using a ChemWell® 2910 automated 
analyzer (GMI, Ramsey, Minnesota, USA). Serum levels of anti-cyclic citrullinated peptide 
(anti-CCP) were measured by ELIATM CCP test system (Phadia GmbH, Freiburg, 
Germany) and samples were analyzed using an ImmunoCAP® 100 instrument (Phadia 
GmbH). 
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2.4. Statistical analysis 
Statistical differences were determined with non-parametric Kruskal-Wallis, Mann-
Whitney and Wilcoxon Signed-Rank tests using GraphPad Prism (GraphPad, San Diego, 
CA). Correlation analysis was performed using Spearman’s test. Differences were 
considered statistically significant for p < 0.05. 
 
3. Results 
 
3.1. Characterization of patients and disease evaluation 
A total of 38 polyarthritis patients with less than 6 weeks of disease duration were 
evaluated. Nineteen patients fulfilled the 1987 ACR criteria for RA after a minimum 
follow-up of 3 months and were classified as VERA patients. The mean age of the VERA 
patients was 59±17 years-old, 84% were female, 42% were RF positive and 32% anti-CCP 
positive, the initial DAS28 was of 6.1±1.8 and the initial HAQ was of 1.4±0.8.  After 
treatment with a low dose of prednisone and MTX there was a significant reduction of both 
DAS28 and HAQ values (Table 1). 
The group of VEA patients included 19 patients, who evolved into several different 
diagnosis: spondyloarthritis (5 cases), systemic lupus erythematosus (4 cases), crystal 
induced arthritis (2 cases), Sjögren’s syndrome (1 case), paraneoplastic polyarthritis related 
to multiple myeloma (1 case), arthritis associated to HIV infection (1 case). Five patients 
entered spontaneously into remission before 3 months of follow-up, remaining without a 
specific diagnosis and were thus classified as presenting a self-limited form of polyarthritis. 
The mean age of the VEA patients was 40±13 years-old, 79% were female, all patients 
were RF and anti-CCP negative, the initial DAS28 was of 4.5±1.6 and the initial HAQ was 
of 0.8±0.6.  Both DAS28 and HAQ values were significantly lower than those of VERA 
patients at baseline (Table 1). These early polyarthritis patients represent a subset of a 
larger cohort previously described by our group [17].  
Furthermore, blood samples were collected from 12 established RA patients, with a 
mean age of 60±10 years old, 92% were female, 67% were RF positive and 45% anti-CCP 
positive (Table 1). Additionally, SF samples were also collected from 12 established RA 
patients, with a mean age of 57±10 years old and 73% were female (Table 1). The 
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established RA group of patients had a DAS28 and a HAQ mean scores similar to VERA 
baseline values.  
 
Table 1. Clinical information about healthy controls and patients with very early rheumatoid arthritis, very 
early arthritis, rheumatoid arthritis, or osteoarthritis. 
 
 
 
NA – not applicable; ND – not determined.  
SF – synovial fluid 
 
*DAS28 and HAQ values were compared between VERA and VEA patients with reference to VERA 
baseline values.  
 
Differences were considered statistically significant for p values < 0.05.  
 
 
 
3.2. IL-8 is increased in very early rheumatoid arthritis patients and 
locally in the joints of established rheumatoid arthritis patients 
Given the proposed role of neutrophils in the pathogenesis of RA [18, 19], we quantified 
the major neutrophil chemoattractant, IL-8, in the serum of VERA patients. At baseline, 
VERA patients had significantly higher levels of IL-8 when compared to both VEA and 
healthy controls (Figure 1A). After 2-4 weeks of low-dose corticosteroids and after 4 
months of MTX therapy there were no significant changes in the levels of circulating IL-8 
(data not shown). Interestingly, VERA patients also had significantly higher circulating 
levels of IL-8 in comparison with serum from established RA (Figure 1A). Neutrophils 
accumulate locally in the joints of RA patients [20]. Thus, we quantified the concentration 
of IL-8 in the SF of RA patients and compared to SF from OA patients. We found 
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significant higher levels of IL-8 in the SF of RA patients in comparison to OA SF (Figure 
1B).  
 
 
 
Figure 1. IL-8 is increased in the serum of very early rheumatoid arthritis patients and in the synovial fluid of 
established rheumatoid arthritis.  
(A) The serum concentration of IL-8 was measured in VERA and VEA patients as well as healthy controls 
and patients with established RA. Serum concentration of IL-8 was increased in VERA patients, compared 
with any other group. Dotted line represents the limit of detection for the assay. (B) The concentration of IL-8 
was measured in the synovial fluid (SF) collected from patients with established RA and from a control group 
with OA. We found a significant increase of IL-8 in RA-SF. Differences were considered statistically 
significant for p values < 0.05 according to the Mann-Whitney test. 
 
 
3.3. IL-17 levels are dysregulated in both very early rheumatoid 
arthritis and established rheumatoid arthritis patients 
Previous studies from our group showed that there is a delay in the apoptosis of 
circulating neutrophils in VERA patients [21]. Therefore, we analyzed IL-17A levels in 
these patients, since it has already been described that this cytokine is important for the 
survival of neutrophils [22]. Moreover, IL-17A is a signature cytokine of Th17 cells, a 
subset proposed to have a key role in RA pathogenesis [9, 23]. We found that VERA 
patients had significantly higher levels of IL-17A when compared to healthy controls, but 
not with VEA patients (Figure 2A). Furthermore, in our previous work we found no 
difference in the frequency and absolute numbers of CD4+ and CD8+ T cell subpopulations 
in the peripheral blood of these patients, when analyzed by flow cytometry [17]. 
Regarding the effects of early therapy, we found that neither corticosteroids nor MTX 
affected the level of IL-17A (data not shown). Moreover, IL-17A was also significantly 
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increased locally within the joints of established RA patients in comparison with control SF 
from OA patients (Figure 2B).  
 
 
 
Figure 2. Very early rheumatoid arthritis patients and synovial fluid of established rheumatoid arthritis 
display increased levels of IL-17A.  
(A) The serum concentration of IL-17A was measured in VERA and VEA patients as well as healthy controls 
and patients with established RA. The serum concentration of IL-17A was increased in VERA patients 
compared with healthy controls. (B) The concentration of IL-17A was measured in the synovial fluid (SF) 
collected from patients with established RA and from a control group with OA. In the SF of RA patients, we 
observed a significant increase of IL-17A. Dotted lines represent the limit of detection for the assay. 
Differences were considered statistically significant for p values < 0.05 according to the Mann-Whitney test. 
 
 
3.4. Rheumatoid arthritis has a Th17- cytokine pattern since the very 
first weeks of onset 
Having found that IL-17A was elevated in VERA patients, we decided to quantify a 
panel of cytokines known to be associated with Th17 polarization. At baseline, VERA 
patients had significantly higher levels of IL-1β and IL-22 in comparison with both VEA 
and healthy controls. In addition, we also found that VERA patients have significantly 
higher IL-6 levels than healthy controls (Figure 3). Furthermore, the significantly higher 
circulating levels of IL-6 and IL-22 were maintained in established RA (Figure 3).  
Locally, within the joints of RA patients, the synovial fluid displayed elevated levels of 
IL-1β and IL-6 in comparison with OA SF (Figure 4 and Table 2). Moreover, no significant 
differences could be observed for IL-23 in circulation or locally in the joints (data not 
shown). 
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We have also studied cytokines associated with the function of Th2 (IL-4, IL-10) and 
Th1 (IL-2, IL-12 (p70) and INFγ) cells. However, no statistically significant differences 
could be observed for any of these cytokines (data not shown).  
 
 
 
 
 
 
Figure 3. Cytokines related to Th17 polarization are increased in the serum of very early rheumatoid arthritis 
patients.  
The serum concentrations of IL-1β, IL-6 and IL-22 were measured in VERA and VEA patients as well as 
healthy controls and patients with established RA. All three cytokines were increased in VERA patients 
compared with healthy controls. IL-6 was equally elevated in all groups of patients with an inflammatory 
disease, while the other two cytokines were increased only in VERA (IL-1β), or in VERA and RA patients 
(IL-22).  Dotted lines represent the limit of detection for the assays. Differences were considered statistically 
significant for p values < 0.05 according to the Mann-Whitney test. 
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Figure 4. Cytokines related to Th17 polarization are increased in the synovial fluid of established rheumatoid 
arthritis.  
The concentrations of IL-1β and IL-6 were markedly increased in the synovial fluid (SF) collected from 
patients with established RA, when compared with OA. Dotted lines represent the limit of detection for the 
assays. Differences were considered statistically significant for p values < 0.05 according to the Mann-
Whitney test. 
 
 
 
Table 2. Cytokine levels in healthy controls, very early rheumatoid arthritis, very early arthritis, established 
rheumatoid arthritis and osteoarthritis patients. 
 
 
 
Values are represented as median (range). 
SF – synovial fluid 
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4. Discussion 
 
Several studies have previously demonstrated that neutrophils play an important role in 
the onset of RA [21]. This hypothesis is supported by data from animal models [24]. In 
fact, neutrophils are the most abundant leukocytes in the synovial fluid of patients with 
active RA and, in early RA, these cells show significantly lower levels of apoptosis when 
compared to patients with other persistent forms of arthritis or with arthritis that have a self 
limited disease course [25]. Additionally, previous results from our group demonstrated 
that there is also a delay in the apoptosis of circulating neutrophils in VERA patients [21] 
and that these cells heavily infiltrate the synovial tissue during RA onset [5].  
In the present study, we demonstrate that a neutrophil- and Th17-driving cytokine 
pattern is present in untreated VERA patients with less than 6 weeks of disease duration. 
We consider this observation of interest because the knowledge concerning the immune 
mechanisms associated with the onset of RA is still elusive. In fact, the majority of early 
RA studies include patients with 3 to 12 months of disease duration or even more. In 
accordance with an early participation of neutrophils in RA, our results revealed that VERA 
patients have increased levels of IL-8 when compared to both VEA and healthy controls, 
which could explain the pre-activated state of circulating neutrophils [18] and their 
recruitment towards the synovial fluid since the very first weeks of RA onset.  
In addition, Th17 cells are known to be important for the promotion of neutrophil-
mediated inflammation by producing IL-17A, a cytokine known to indirectly activate 
neutrophil chemotaxis and extend their survival [10, 22]. We found a high serum 
concentration of IL-17A in VERA patients, as well as locally within the joints of patients 
with established RA. This might indicate that there is an activation of Th17 cells from a 
very early phase of the disease, that can promote neutrophil participation in RA 
pathogenesis [22]. However, we found no evidence for changes in the frequency of T cell 
subsets in the peripheral blood of VERA patients [17]. This observation is not unexpected, 
given the relatively small representation of antigen-specific T cells in the circulating pool, 
being the activated T cells driving the pathology more likely found within the tissues [26]. 
In a study performed by Kokkonen and colleagues [27] the levels of several cytokines and 
chemokines were analyzed in blood samples from a group of individuals 3.3 years before 
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RA onset (“pre-patients”) and compared with healthy donors and RA patients with 7.7±3.6 
months of disease duration. An interesting finding was that IL-17 was present at its highest 
concentration in pre-patients and the level of this cytokine was lower in RA patients. This is 
in accordance with our own results, since we observed an increased level of IL-17 in RA 
patients with less than 6 weeks of disease duration, while in established RA patients the 
levels were not significantly different to healthy controls. Remarkably, the IL-17 median 
concentration observed in our established RA cohort (2.6 pg/ml) was even lower than that 
of RA patients from the work of Kokkonen and colleagues (6.0 pg/ml). Thus, this 
observation reinforces the role of IL-17 in the initial phase of RA and, as the pathogenesis 
progresses to a chronic stage, other factors are subsequently brought into action in the 
peripheral blood. Unlike Kokkonen and colleagues, we have not detected differences in 
Th1 and Th2-related cytokines between both VERA and established RA patients in 
comparison with controls. These discrepancies might be related with the different 
methodologies used. 
Additionally, the elevated levels of IL-1β observed in VERA patients can stimulate 
endothelial cells, T and B cells and fibroblasts in the joints to produce IL-6 and IL-8.  But 
importantly, IL-1β together with IL-6, both found to be increased in VERA patients, are 
known to promote the differentiation of Th17 cells, which in turn secrete IL-17A and IL-22 
[28, 29], two cytokines that were elevated in VERA patients and have an essential function 
in the pathogenesis of autoimmune diseases [29].  
Currently, the treatment of choice for RA at the time of presentation is MTX. 
Interestingly, in spite of clinical improvement (DAS28 reduced from 6.1±1.8 to 3.1±1.6), 
neither therapy with low-dose corticosteroids nor combined therapy with low-dose 
corticosteroids and MTX corrected the dysregulated cytokine pattern observed in VERA 
patients. In fact, low-dose corticosteroids and MTX have unclear effects on RA cytokine 
network. For instance, corticosteroids fail to reduce serum levels of IL-1β and IL-8 [30] 
and MTX does not alter serum IL-1β concentration when compared to pre-treatment levels 
[31, 32]. Our results suggest that the conditions contributing to Th17 cells and neutrophil-
mediated inflammation, thus driving early pathogenesis, are not modified with early 
treatment with low-dose corticosteroids and MTX.  
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The elevated IL-1β, IL-6, IL-8 and IL-17A levels observed in the SF of RA patients 
confirm a local role for these cytokines in the maintenance of synovitis. Moreover, IL-6 can 
support a continuous recruitment of autoreactive B cells towards the synovium [33, 34], 
contributing to an exacerbation of the inflammatory process due to the production of 
autoantibodies and immune complexes.  
 
5. Conclusions 
 
Taken together, our data reinforce the potential relevance of therapies targeting IL-1β 
[35, 36] and IL-6 [37, 38] in early RA. In addition the data also establish IL-8 and IL-17A 
as other potential therapeutic targets at an early stage of the disease. Finally, we found that 
MTX and corticosteroids, although effective in reducing disease activity in VERA patients, 
do not appear to correct underlying cytokine dysregulation driving the Th17/neutrophil 
mediated inflammation.   
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Abstract  
 
Background: B cells play several important roles in Rheumatoid Arthritis (RA). Given 
the beneficial effect of B cell depletion therapy in RA as well as the observed alterations in 
B cell subpopulations in this disease, we evaluated whether changes in the expression of 
genes related with B cell survival and activation were already present in untreated very 
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early RA (VERA) patients  (<6 weeks of disease duration). Methodology/Principal 
Findings: The expression of a group of B-cell related activation and survival genes was 
quantified in peripheral blood mononuclear cells (PBMC) from VERA patients by real-time 
PCR and compared with untreated early RA (<1 year, ERA), established treated RA 
patients (RA) and other untreated early arthritis conditions (EA). Serum BAFF was 
quantified by ELISA. BAFF gene expression and serum levels were highest in VERA 
patients. The expression of BAFF-R increased with disease progression, while TACI was 
elevated since the first weeks of RA onset. Pax5 gene expression was also increased in all 
RA stages. CXCR5 was only elevated in established RA. No differences were observed in 
BCMA, AID, Blimp-1 and Bcl-2 expression. Conclusions: Disturbances in the expression 
of B-cell related activation and survival genes, particularly BAFF and TACI, occur since 
the onset of RA and precede changes in BAFF-R. These alterations can potentiate the 
development of autoreactive B cells since the first weeks of RA onset. 
 
1. Introduction 
 
Rheumatoid Arthritis (RA) is a chronic autoimmune disease that mainly targets the 
joints and affects approximately 1% of the population worldwide [1, 2]. B cells play several 
critical roles in RA pathogenesis. Previous studies by our group have demonstrated that 
very early RA patients have disturbances in peripheral blood memory B cells [3] and 
increased circulating B-cell related cytokines [4]. Furthermore, it has also been documented 
that genes regulating and affecting cellular processes such as proliferation, apoptosis, 
cytokine networks and autoimmunity were differently expressed in RA B-cells [5, 6]. These 
observations set the grounds for hypothesizing that B-cell biology is dysregulated since 
early RA development and consequently contributes to the induction and perpetuation of a 
pathogenic humoral immune response. Importantly, gene expression profiling of peripheral 
blood cells in different stages of RA progression may be useful not only to provide insights 
into pathogenesis, but also to identify and allow the future development of clinically useful 
biomarkers [7-10]. Therefore, the main goal of this work was to analyze a group of genes 
related with B cell survival, homeostasis and activation in very early RA patients and 
compare with different stages of RA progression. 
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2. Materials and Methods 
 
2.1. Patients 
Blood samples were collected from 8 consecutive untreated polyarthritis patients 
(Rheumatology Department, Hospital de Santa Maria, Lisbon) with less than 6 weeks of 
disease duration who, after a minimum follow-up of 3 months, fulfilled the 1987 American 
College of Rheumatology (ACR) criteria for RA and were classified as Very Early 
Rheumatoid Arthritis (VERA) patients. Additionally, blood samples were also obtained 
from 7 untreated early polyarthritis patients with less than 1 year of disease duration, but 
more than 6 weeks of disease duration, who, after a minimum follow-up of 3 months, 
fulfilled the 1987 ACR criteria for RA and were classified as early RA (ERA), and 10 
untreated early polyarthritis patients with less than 1 year of disease duration who did not 
evolve into RA and were classified as early arthritis (EA) (Rheumatology Department, 
Hospital de Santa Maria, Lisbon and Hospital da Luz, Lisbon).  Furthermore, blood 
samples from 14 established RA patients treated with methotrexate (MTX) (Rheumatology 
Department, Hospital de Santa Maria, Lisbon) were also collected for comparison. Blood 
samples from VERA, ERA, RA and EA patients were compared with 16 healthy donors 
used as controls. The local ethics committee (Comissão de Ética do Hospital de Santa 
Maria, Lisbon, Portugal) approved the study and all patients signed an informed consent. 
Patient’s management was done in accordance with the standard practice and the study was 
conducted in accordance with the Declaration of Helsinki as amended in Seoul (2008).  
 
2.2. Measurement of autoantibodies and cytokine quantification 
Rheumatoid Factor (RF)-IgM was determined in all patients by IMTEC Autoimmune 
Diagnostics ELISA kit (Human GmbH, Germany) according to the manufacturer 
instructions and samples were processed using a ChemWell® 2910 automated analyzer. 
Serum levels of anti-cyclic citrullinated peptide (anti-CCP) were measured by ELIATM 
CCP test system (Phadia GmbH, Germany) and samples were analyzed using an 
ImmunoCAP® 100 instrument. B cell activating factor (BAFF) levels were quantified by 
enzyme linked immunosorbent assay (ELISA) (Bender MedSystems, Austria) according to 
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the provider's instructions and samples were analyzed using plate reader Infinite® M200 
(Tecan, Switzerland). 
 
2.3. Peripheral blood mononuclear cells isolation 
Peripheral blood mononuclear cells (PBMC) were isolated from 20 ml heparinized whole 
blood following density gradient centrifugation with Percoll (Amersham, Sweden). Cellular 
counts were estimated with Trypan Blue (Sigma-Aldrich, USA). Cells were frozen in 1 ml/ 
107 cells RPMI-1640 (GIBCO, UK), 40% fetal calf serum (FCS) (Invitrogen, UK), 10% 
dimethyl-sulfoxide (DMSO) (Sigma-Aldrich, USA) and stored at -80ºC until further use.  
 
2.4. RNA extraction and cDNA synthesis 
Total RNA from frozen PBMC was extracted using the RNeasy Mini kit (Qiagen, 
Germany) according to the manufacturer’s instructions and treatment with RNase-free 
DNase Set (Qiagen, Germany) was performed to avoid contamination of genomic DNA. 
RNA concentration and purity were determined with NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, USA). RNA integrity of samples was 
confirmed using an Agilent 2100 Bioanalyzer with an RNA 6000 Pico Assay (Agilent 
Technologies, Germany) and by observing distinct 28S and 18S ribosomal bands on an 
agarose gel. Total RNA was reverse-transcribed into cDNA using DyNAmoTM cDNA 
Synthesis Kit for qRT-PCR (Finnzymes, Finland) with random hexamers (300 ng/µl), 
according to the manufacturer’s instructions, performed on Piko Thermal Cycler 
(Finnzymes, Finland). The cDNA samples were stored at -20ºC. 
 
2.5. Quantitative Real Time PCR analysis 
The quantitative real time polymerase chain reaction (qPCR) was performed on Rotor-
GeneTM 6000 (Corbett Life Science, USA) using SensiMixTM SYBR No-ROX Kit (Bioline, 
UK). The qPCR programme consisted of an initial denaturation step at 95ºC for 10 minutes, 
followed by 40 cycles of 95ºC for 15s, 60ºC for 15s and 72ºC for 15s. Genes and primer 
sequences analyzed in this study are indicated in Table 1. Primers were designed using the 
Universal ProbeLibrary Assay Design Center from Roche (https://www.roche-applied-
science.com/sis/rtpcr/upl/index.jsp) and ProbeFinder software version 2.45. All the qPCR 
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products were analyzed by electrophoresis in 1% agarose gels. The 18S rRNA was used as 
endogenous control in relative gene quantification using the comparative cycle threshold 
(Ct) method (2-∆∆Ct) [11]. All data were analyzed with Rotor-Gene 6000 Series Software 
version 1.7.87.  
 
2.6. Statistical analysis 
Statistical differences were determined using non-parametric Mann-Whitney and 
Kruskal-Wallis tests for comparisons between two and three or more groups, respectively, 
using GraphPad Prism (GraphPad, San Diego, CA). Correlation analysis was performed 
using Spearman’s test. Differences were considered statistically significant for p < 0.05. 
 
3. Results 
 
3.1. Characterization of patients and disease evaluation 
RA patients in three different clinical stages were included in this study. Untreated 
VERA patients (n=8) with less than 6 weeks of disease duration had a mean age of 59±15 
years-old, 75% were female, 63% were RF positive and 43% anti-CCP positive. The 
baseline 28 joints disease activity score (DAS28) was of 7.0±0.7. These VERA patients 
represent a subset of a larger cohort previously described by our group [3]. The group of 
untreated ERA patients (n=7) had a mean disease duration of 0.6±0.3 years, a mean age of 
53±5 years-old, 87% were female, 83% were RF positive, 57% were anti-CCP positive and 
the mean DAS28 score was of 5.4±1.4. Established RA patients (n=14) had an average 
disease duration of 13.2±12.3 years, were mostly under MTX monotherapy (n=12) and two 
patients were receiving MTX and sulphasalazine (SLZ) simultaneously. The mean age of 
these established RA patients was 61±12 years-old, 79% were female, 71% were RF 
positive, 64% anti-CCP positive and the mean DAS28 score was of 5.1±1.2 (Table 2).  
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Table 1. Genes and sequences of primers used in quantitative real time PCR. 
 
 
 
 
The EA group included 10 patients, who evolved into several different diagnoses: 
systemic lupus erythematosus (3 cases), spondyloarthritis (2 cases), arthritis associated to 
dermatomyositis (1 case), arthritis associated to HIV infection (1 case), unremitting 
undifferentiated arthritis (2 cases) and one patient entered spontaneously into remission 
before 3 months of follow-up, remaining without a specific diagnosis and was thus 
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classified as presenting a self-limited form of polyarthritis. EA patients had mean disease 
duration of 0.4±0.6 years, a mean age of 39±15 years-old, 91% were female, all patients 
were RF and anti-CCP negative and the initial DAS28 was of 5.0±1.3 (Table 2). 
 
 
Table 2. Clinical information of early arthritis, very early rheumatoid arthritis, early rheumatoid arthritis and 
established rheumatoid arthritis patients. 
 
 
 
 
VERA - Very Early Rheumatoid Arthritis; ERA - Early Rheumatoid Arthritis; RA - Rheumatoid Arthritis; 
EA - Early Arthritis; CRP - C-reactive protein; ESR - Erythrocyte Sedimentation Rate; DAS28 – Disease 
Activity Score; RF – Rheumatoid Factor; Anti-CCP – anti-cyclic citrullinated peptide; NA – not 
applicable; ND – not determined.   
 
Values are represented as mean ± standard deviation.  
*Differences were considered statistically significant for p values < 0.05 in comparison with VERA 
patients.  
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3.2. Peripheral blood mononuclear cells from very early rheumatoid 
arthritis patients have increased expression of BAFF, TACI and β2m 
while established rheumatoid arthritis patients have a higher BAFF-R 
and CXCR5 expression 
A group of genes related with B cell homeostasis and survival (BAFF, BAFF-R, TACI, 
BCMA), class-switching (AID), chemotaxis (CXCR5), plasma cell differentiation (Pax5 
and Blimp-1), immune system activation (β2m) and apoptosis (Bcl-2) was analyzed in three 
independent groups of RA patients representing different stages of disease progression:  
less than 6 weeks (VERA), less than a year (ERA) and established RA patients with mean 
disease duration of 13 years. Results were compared with EA patients and healthy controls. 
Disturbances in gene expression levels of BAFF receptors were found in both early and 
established RA patients in comparison with healthy controls. BAFF-R expression was 
elevated in ERA and RA patients in comparison with controls, while no significant 
differences were observed in VERA and EA (Figure 1A). Importantly, established RA 
patients had higher BAFF-R levels when compared to VERA, which suggests that BAFF-R 
expression increases with disease progression. Furthermore, TACI gene expression levels 
were significantly increased in VERA, ERA and RA patients in comparison with controls, 
while no differences were detected in EA (Figure 1B). BCMA levels were similar in all 
patients when compared to controls and no significant differences were detected (data not 
shown). Interestingly, BAFF expression was highest in VERA patients in comparison with 
controls, RA and EA (Figure 1C). Importantly, this early increase in BAFF mRNA 
expression observed in VERA was not observed in EA patients, thus suggesting a possible 
specific event of RA pathogenesis. Contrarily, CXCR5 expression was higher in RA 
patients not only in comparison with controls, but also with VERA patients (Figure 1D).  
Additionally, Pax5 gene mRNA levels were raised in all RA patients in comparison with 
controls (Figure 1E). Of note, EA patients had a significant lower expression of Pax5 in 
comparison with established RA. The expression levels of β2m were significantly elevated 
in VERA, ERA and EA patients in comparison with controls and established RA (Figure 
1F). Interestingly, established RA patients had significantly reduced β2m levels when 
compared to controls. Moreover, no significant differences were observed in AID, Blimp-1 
and Bcl-2 expression (data not shown).  
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Figure 1. Very early rheumatoid arthritis patients have increased BAFF, TACI and β2m mRNA levels in 
comparison with controls and established rheumatoid arthritis have higher BAFF-R and CXCR5 expression.  
Relative gene expression from peripheral blood mononuclear cells (PBMC) was determined by real-time PCR 
in VERA, ERA, RA, EA patients and controls. The relative mRNA quantities (2-∆∆Ct) of (A) BAFF-R, (B) 
TACI, (C) BAFF, (D) CXCR5, (E) Pax5 and (F) β2m are indicated. Differences were considered statistically 
significant for p<0.05 in comparison with *Controls, **EA, #VERA, ##ERA and &RA. 
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3.3. Correlation analysis between gene expression, serum BAFF levels 
and clinical data 
Since there were alterations in BAFF-receptors relative gene expression not only in early 
RA, but also in established RA patients, BAFF serum levels were quantified in all groups 
of patients to analyze the possible existence of a correlation between the cytokine 
production and its receptors mRNA expression. VERA patients had the highest BAFF 
serum levels in comparison with controls, ERA, RA and EA patients (Figure 2), but no 
correlation could be observed with any of the BAFF-receptors expression (data not shown). 
Furthermore, no correlation was found between BAFF serum levels with age, DAS28, 
erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), swollen and tender joint 
counts, or with any of the genes analyzed for all patients (data not shown).  
 
 
 
 
Figure 2. BAFF serum levels are raised in very early rheumatoid arthritis patients when compared to early 
rheumatoid arthritis, established rheumatoid arthritis, early arthritis patients and controls.  
Serum BAFF levels were determined by ELISA in all patients’ samples and controls. Represented are the 
median values and intervals. Dashed line represents the limit of detection for the assay. Differences were 
considered statistically significant for p<0.05 in comparison with *Controls, **EA, #VERA, ##ERA and 
&RA. 
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4. Discussion 
 
Differences in expression of BAFF, BAFF-receptors and genes related with B-cell and 
immune system activation were found between early and established RA patients (Figure 
3). BAFF is a fundamental B cell survival factor essential for B cell proliferation and 
activation [12]. BAFF binds to three receptors: BAFF-R, BCMA and TACI. The precise 
mechanisms that control expression of all three BAFF receptors are currently unclear, but 
studies indicate that the developmental stage, cytokine milieu and the microenvironment 
play a key role in regulation of receptor expression [13]. Interestingly, disturbances in 
BAFF-receptors expression occur in several pathologies [14-18], including RA, where it 
has been demonstrated an increase in both BAFF and BAFF-R mRNA expression in RA 
synovial tissue [19].  
 
 
 
Figure 3. Comparison of relative gene expression between very early rheumatoid arthritis, early rheumatoid 
arthritis, established rheumatoid arthritis, early arthritis patients and controls.  
Represented are the median values of BAFF-R, TACI, CXCR5, Pax5, β2m and BAFF relative mRNA 
quantity (2-∆∆Ct) for each group analyzed. 
 
 
We have found that BAFF-R was significantly increased in later stages of RA (both 
ERA and RA patients) and TACI expression was elevated in all RA patients since the first 
weeks of RA development. These observations suggest that disturbances in TACI 
expression occur since very early RA onset and BAFF-R expression increases with RA 
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progression (Figure 3), which can contribute for the development of autoreactive B cells 
and consequent disease aggravation. Furthermore, BAFF serum levels and mRNA 
expression were highest in VERA patients. Studies with knockout mice have demonstrated 
that B-cell proliferation depends upon either BAFF-R or TACI signaling [20]. Excess 
BAFF may lower the threshold for B cell receptor (BCR) signaling and maintain survival 
of pathogenic autoreactive B cells, thus breaking B cell tolerance. Signaling through BAFF-
R can result not only in survival enhancement [21, 22], but also in B cell maturation [23], 
while TACI triggering can stimulate isotype switching and plasma cells differentiation [24]. 
It has been demonstrated that TACI provides positive signals driving T-independent B cell 
response [25] and survival of activated B cells and plasmablasts [24, 26], but also delivers 
negative signals suppressing B cell activation [27]. In fact, TACI functional activity is 
ambiguous: while TACI-/- mice predominantly develop autoimmunity and 
lymphoproliferation [28], TACI deficiency in humans primarily manifests itself as an 
antibody deficiency syndrome [29]. It is interesting to consider the hypothesis that during 
the first weeks of RA onset, the elevated BAFF serum levels could negatively regulate 
BAFF-R expression on B cells and, simultaneously, up-regulate TACI. The induction of 
TACI expression on activated B cells could serve as a danger signal, reflecting the need to 
avoid the potential harmful effects of prolonged activation of B cells through BAFF-BAFF-
R interaction [21, 30]. With disease progression, signaling through BAFF-R eventually 
surpasses TACI, thus allowing autoreactive B cells to persist. Indeed, the higher affinity of 
BAFF, present at lower concentrations at later RA stages, towards BAFF-R instead of 
TACI expressed by B cells more prone to be autoreactive supports this notion. Also, TACI 
binds A proliferation-inducing ligand (APRIL) and BAFF equally with high affinity [31] 
and serves as the only receptor for BAFF/ APRIL heterotrimers [32]. Previous results from 
our group demonstrated that APRIL levels are increased not only in serum from VERA 
patients, but also in synovial fluid from established RA [4]. Since class-switch 
recombination (CSR) process depends on APRIL signaling via TACI [33], the maintenance 
of high levels of TACI expression in VERA, ERA and RA patients could contribute for the 
development of CSR and autoantibody formation by autoreactive B cells. Nevertheless, 
TACI role is still not clear and further studies on TACI function are required. Of note, 
contrarily to untreated VERA patients, in established RA the hypothesis that MTX therapy 
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influences serum BAFF levels and inversely affects BAFF-receptors gene expression 
cannot be excluded. Pax5 gene codifies a transcription factor, also known as B-cell-specific 
activation protein (BSAP), which is essential for B cell commitment as well as for B cell 
development, and continuous expression of Pax5 is required throughout the B cell lineage 
to maintain the functional identity of B cells [34]. Therefore, it was not surprising that Pax5 
expression was increased in all RA patients. Importantly, Pax5 gene expression was higher 
in RA patients in comparison with EA. This observation, together with the absence of 
differences in BAFF, BAFF-R and TACI expression in EA patients as compared to controls 
reinforces the specific role of B cells in RA progression when compared to other forms of 
arthritis. Furthermore, the increased levels of β2m observed in VERA, ERA and EA 
patients indicate early immune system activation not only in RA diagnosis, but also in other 
forms of arthritis. Of note, increased serum and synovial fluid β2m have been found in RA 
[35, 36]. The reduced expression of β2m mRNA in established RA patients could be due to 
treatment with immunosuppressive agents, such as MTX, that downregulate immune 
responses. Moreover, no differences were observed in AID levels in our study. Since CSR 
and somatic hypermutation (SHM), both processes that require the action of AID [37], 
occur during germinal-center (GC) responses in organized lymphoid tissues, we believe 
that AID expression in early and established RA is higher in B cells infiltrating not only 
RA synovium [38], but also secondary lymphoid organs [39] than in circulating B cells. 
Additionally, CXCR5 and also its ligand, CXCL13, involved in B cell chemotaxis, are 
upregulated in RA synovium [40], suggesting a local role in B cell chemotaxis towards 
synovial membrane. Indeed, the increased CXCR5 levels observed in RA patients in 
comparison with controls and VERA reveals that this effect in circulation is stronger in 
later RA stages. Blimp-1 genetic variants have recently been associated with RA risk [41]. 
Blimp-1 is expressed in antibody-secreting cells from human and mouse, but is absent from 
earlier stages of B cell ontogeny [42]. Thus, the absence of differences in circulating 
Blimp-1 levels is due to the fact that only a minority of plasma cells is present in circulation 
and the expression of this gene initiates during terminal differentiation of plasma cells [43] 
during GC reactions. Additionally, the absence of variations in Bcl-2 expression in RA 
patients in comparison with controls suggests that this gene does not play a significant role 
in RA pathogenesis [44]. In summary, disturbances in the expression of B cell related 
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survival and activation genes occur since the very early phase of RA. Increased BAFF 
serum and mRNA levels can contribute for the persistence of autoreactive B cells and, 
together with TACI elevated expression, reinforce the importance of an earlier introduction 
of therapies targeting not only B cells directly (anti-CD20), but also BAFF-receptors, or its 
ligands [45]. 
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Abstract 
 
Objectives: To examine the expression of B-cell activating factor receptor (BAFF-R) on 
naïve CD27− and memory CD27+ B cells in normal individuals and patients with 
rheumatoid arthritis (RA) undergoing B-cell depletion therapy with rituximab. Patients 
and Methods: BAFF-R expression on B-cell subsets was determined in normal controls 
(NC, n=11), active patients with RA pre-rituximab (pre-RX, n=15), relapsing patients either 
concordant for B-cell repopulation (C-R, n=13) or discordant, with relapse more than 3 
months after repopulation (D-R, n=11) and patients in remission over 3 months post-
repopulation (discordant non-relapsing (D-NR), n=5). Serum BAFF was measured by 
ELISA and analyzed using Mann–Whitney test. Results: There was no significant 
difference between NC, pre-RX and D-NR patients in % BAFF-R-positive B cells or mean 
fluorescence intensity (MFI) in naïve and memory B cells. Relapsing patients had 
significantly lower MFI and % BAFF-R-positive cells in both naïve and memory 
compartments from NC and pre-RX (C-R and D-R, p<0.01). BAFF levels in pre-RX 
patients were within the normal range and did not correlate with BAFF-R expression in any 
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patient group. D-NR patients had relatively lower proportions of pre and post-switch 
CD27+ B cells than pre-RX patients (D-NR versus pre-RX, p<0.05 for both) and also lower 
numbers of post-switch B cells than D-R patients (D-NR versus D-R, p<0.05). Conclusion: 
BAFF-R expression was significantly reduced on both naïve and memory B cells in 
patients at relapse, regardless of the relationship with B-cell repopulation or serum BAFF 
levels. Re-establishment of active disease was also associated with an increase in class-
switch recombination. Factors responsible for lower levels of BAFF-R may relate to altered 
thresholds for autoreactive B-cell generation at relapse in patients with RA.  
 
1. Introduction 
 
B-cell-activating factor (BAFF), also known as B lymphocyte stimulator (BLyS), 
THANK, TALL-1, zTNF-4 or TNFSF13b, is a protein member of the tumour necrosis 
factor (TNF) family that plays an important role in B-cell maturation, homeostasis and 
survival [1]. BAFF binds to three receptors on B cells: TACI, BCMA and BAFF-R (or 
BR3), with BAFF-R being the only ligand that exclusively binds BAFF [2].  
Studies of BAFF-R-deficient mice demonstrated that BAFF was essential for B-cell 
survival, primarily through the alternative nuclear factor κ light-chain enhancer of activated 
B cells pathway [3], and for B-cell maturation and immunoglobulin (Ig) class switching 
through the classic nuclear factor κ B pathway [4]. B cells from these animals develop 
normally up to the IgM+ transitional stage but do not complete their maturation in the 
spleen [5]. The numbers of memory and marginal zone cells and of serum Ig are severely 
reduced (> 90%) as were responses to both T-dependent and T-independent stimuli [2]. 
Human B cells are less dependent on BAFF-R signaling for maturation than murine B 
cells. In the few reported cases of common variable immunodeficiency related to BAFF-R 
deficiency in humans, circulating BAFF levels were greatly elevated and peripheral B-cell 
numbers were reduced (fourfold lower). The condition was of late onset and was not 
associated with severe infections [6]. Although mature but not transitional B cells were 
reduced in these individuals, class-switched memory B cells were detectable. 
Correspondingly, vaccination studies showed that T-dependent responses appeared to be 
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much less dependent on BAFF-R signaling than T-independent responses. As in BAFF-
R−/− mice, IgA responses in these patients were not compromised. 
One of the suggested roles for BAFF, based largely on animal experiments, is that 
increased levels will lower thresholds for the survival of autoreactive B-cell clones, and 
decrease competition within germinal center environments [7, 8]. In humans, elevated 
levels of serum BAFF have been associated with both the presence and activity of several 
autoimmune diseases (Sjögren’s syndrome, systemic lupus erythematosus (SLE) and 
idiopathic thrombocytopenia) [9-15]. In patients with rheumatoid arthritis (RA), the 
relationship is less clear, with conflicting reports as to whether levels of circulating BAFF 
are significantly elevated and if there is a relationship with disease activity or titers of 
autoantibodies [14, 16, 17]. 
Following treatment of RA patients with rituximab, serum BAFF levels have been 
shown to rise, reflecting the loss of the majority of peripheral B cells. The correlation of 
BAFF levels with peripheral B-cell counts is not, however, perfect and it has been 
suggested that BAFF levels form a more accurate indicator of total B-cell mass [18]. 
Chronically raised BAFF levels have been suggested to exert a negative feedback on 
BAFF-R expression [19]. 
One of the key initial findings of the clinical response to rituximab was that B-cell return 
was not always associated with relapse, and that disease could remain in remission for 
months or even years following B-cell repopulation [20]. In patients with RA, rises in 
autoantibodies, particularly rheumatoid factor (RF), seem to herald relapse following 
regardless of whether clinical relapse has been concordant or discordant with B-cell return 
[21]. Serum BAFF levels rose rapidly after rituximab and then fell with rising peripheral B-
cell numbers, although the relationship was not always clear. There was also some evidence 
for an increased uptake of BAFF if relapse occurred concurrently [17, 21]. 
The re-establishment of clinical disease following B-cell depletion therapy relies on 
engaging proinflammatory pathways, which are quiescent in the absence of circulating B 
cells and, therefore, provides a unique opportunity to study the re-emergence of the disease 
process. As a result of its importance in B-cell survival, particularly for new emigrant and 
naïve B cells, we hypothesized that the balance between BAFF-R expression and soluble 
BAFF may influence the relationship between returning B-cell populations and the 
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resumption of autoimmunity. With this in mind, we measured serum BAFF levels and 
BAFF-R expression on B-cell populations to determine whether there was any relationship 
between serum BAFF levels and BAFF-R on naïve and memory B cells at different key 
time points after rituximab therapy. 
 
2. Materials and Methods 
 
2.1. Patients 
Blood samples were obtained from 11 normal controls (NC) and 44 consecutive patients 
with a diagnosis of RA who fulfilled the American College of Rheumatology criteria for 
RA [22]. The patients were all attending the Department of Rheumatology at University 
College London Hospital and were treated with rituximab, on the basis of clinical need. 
Patients received 2-weekly infusions of 1 g rituximab preceded by 100 mg intravenous 
methylprednisolone. The study was approved by the hospital ethics committee and all 
patients gave informed consent before entering the study. The normal range for cluster of 
differentiation 19+ (CD19+) B cells used by the local pathology laboratory was 0.03–
0.40×109/l. Levels less than 0.005×109/l were defined as undetectable. 
 
2.2. Detection of B cells 
Depletion of B cells in the peripheral blood was deemed to have occurred when CD19+ 
B cells were undetectable. In all patients, total peripheral blood B-cell depletion was 
achieved for at least 2 months. B-cell return (B-cell repopulation) was defined as when B 
cells were again detectable in the peripheral blood (i.e., when the CD19+ cell count was 
≥0.005×109/l). 
 
2.3. Clinical relapse 
Clinical relapse after rituximab was based on any return of symptoms of RA plus a rise 
in C-reactive protein following an original fall of at least 50% in C-reactive during the 
previous course of B-cell depletion therapy. Patients at clinical relapse were classified as 
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concordant (relapse ≤ 3 months after repopulation in peripheral blood) or discordant 
(relapse > 3 months after repopulation in peripheral blood). 
 
2.4. Peripheral blood mononuclear cells isolation and staining 
Peripheral blood mononuclear cells (PBMC) were freshly isolated from 10 ml 
heparinized whole blood following density gradient centrifugation with Ficoll-Paque Plus 
(GE Healthcare, Uppsala, Sweden) and stained on the same day of collection. Cells were 
washed and cellular viability was estimated with Trypan blue (Sigma, St. Louis, USA). 
PBMC (1×106/sample) were incubated with appropriate conjugated antibodies for 15 
minutes at room temperature in the dark and then washed. Erythrocytes were lysed with BD 
PharmLyse (BD, Biosciences, San Diego, USA) buffer according to the manufacturer’s 
instructions and cells were then fixed with paraformaldehyde 2% for 5 minutes at room 
temperature. PBMC were stored in the dark at 4°C until analyzed by flow cytometry. A 
total of 300.000 cells/sample gated in total lymphocytes were acquired with FACSCalibur 
(BD). Data were analyzed with FlowJo (TreeStar, Stanford University, California, USA). 
Absolute cell counts were calculated from the differential leukocyte count determined at 
each time point for all patients. 
 
2.5. Phenotypic analysis 
Immunophenotyping of B and T cells in PBMC samples was performed using matched 
combinations of anti-human murine monoclonal antibodies conjugated to fluorescein 
isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll protein cyanin (PerCP-
Cy5.5), or allophycocyanin (APC). For B-cell analysis, combinations of anti-CD19 
conjugated to PerCP-Cy5.5 or APC (clone HIB19), anti-IgD FITC (clone IA6-2) and anti-
CD27 PE (clone O323) were used to define naïve (CD19+IgD+CD27−), pre-switch 
memory (CD19+IgD+CD27+), post-switch memory (CD19+IgD−CD27+) and 
IgD−CD27− B cells. The expression of BAFF-R was analyzed using combinations of anti-
CD19 PerCP-Cy5.5, anti-CD27 PE and anti-BAFF-R FITC (11C1, mouse IgG1, clone 
8A7) and the mean fluorescence intensity (MFI) of BAFF-R was determined for naïve 
(CD19+CD27−) and memory B cells (CD19+CD27+). All antibodies used were purchased 
from BD Biosciences and eBioscience (San Diego, USA). 
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2.6. Measurement of BAFF 
BAFF levels were quantified in serum samples from healthy controls and from patients 
at the various time points, using the Human Quantikine BAFF/BLyS immunoassay ELISA 
kit (R&D Systems, United Kingdom). The mean ± SD for normal sera (n=36) were given 
as 1.17±0.28 ng/ml (range 0.67–2.45 ng/ml). 
 
2.7. Statistical analysis 
Statistical differences were determined using the non-parametric Mann–Whitney test 
using GraphPad Prism (GraphPad, San Diego, California, USA). Differences were 
considered statistically significant for p<0.05. Linear regression was used to correlate 
BAFF levels and BAFF-R expression. 
 
3. Results 
 
3.1. Patient cohorts 
The mean age was 42 years (range 33–81) and the mean disease duration was 15 years 
(range 2–20). All patients had erosive disease. Two patients were seronegative for both RF 
and anti-citrullinated protein antibodies before treatment. The cohorts of consecutive 
patients with RA included 15 patients with active disease who were studied pre-rituximab 
(pre-RX) and 29 patients who had already received one or more courses of rituximab. In 
consecutive patients presenting at clinic, blood for FACS analysis was taken from all 
relapsing patients. CD19 counts were subsequently examined and patients assigned to 
concordant relapsing (C-R) or discordant relapsing (D-R) groups. If the patients had 
already repopulated according to the laboratory notes, but had remained well for more than 
3 months after the date of repopulation, they were assigned to the discordant non-relapsing 
(D-NR) group. Five groups were therefore described for analyses: (1) NC (n=11); (2) 
patients with active RA pre-RX (n=15); (3) C-R (n=13); (4) D-R (n=11); (5) D-NR (n=5), 
taking into account repopulation and relapse after rituximab as described (Table 1). 
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Table 1. Serum BAFF levels and percentage of BAFF-R expression on CD19+ B cells before and after B cell 
depletion therapy. 
 
 
 
NC: normal controls; Pre-RX: pre-rituximab; C-R, concordant clinically relapsing; D-R, discordant 
clinically relapsing; D-NR, discordant clinically non-relapsing. 
 
All values indicated in table represent median (range). 
 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 compared with NC (Mann-Whitney).  
 
#p<0.01, # #p<0.001, # # #p<0.0001 compared with pre-RX. 
 
 
 
3.2. Serum BAFF levels in normal controls and in rheumatoid arthritis 
patients 
Median BAFF levels in the 16 patients with RA tested before rituximab were within the 
normal range (Table 1). As previously described, BAFF levels rose following rituximab 
[22]. Levels were found to remain raised at relapse in both patient groups (C-R and D-R, 
p<0.01, compared with both NC and patients pre-RX) and to a lesser extent in patients who 
had repopulated but not relapsed (D-NR, p<0.05) when compared with NC only (Table 1), 
but no statistically significant differences in BAFF levels were observed between C-R, D-R 
and D-NR patients. 
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3.3. Percentage of naïve and memory B cells expressing BAFF-R 
The percentages of CD19+ B cells expressing BAFF-R in CD27+ and CD27− 
subpopulations in patients and NC are represented in Table 1. Significant differences were 
seen between the percentage expression of BAFF-R on naïve and memory B cells in 
relapsing patients (C-R and D-R groups) compared with NC, and for the memory B-cell 
population, levels in relapsing patients were also significantly reduced compared with pre-
RX values. In the D-R group, decreased expression on naïve B cells was also significant 
compared with pre-RX values. In patients whose B cells had returned but had not yet 
relapsed (D-NR), no such decreases were found between the percentages of BAFF-R 
expressing naïve or memory populations compared with NC or with the pre-RX group. 
Furthermore, when the percentages of BAFF-R expressing naïve and memory B cells in 
patients who were relapsing (both C-R and D-R) were compared with D-NR patients, a 
significantly lower percentage expression was found in both naïve and memory populations 
(naïve D-NR versus C-R and D-R, p<0.05 and p<0.01, respectively; memory D-NR versus 
C-R or D-R, p<0.01 for both). The low expression of BAFF-R was not caused by 
contamination of the CD19+ gate with plasmablasts (which express low levels of BAFF-R) 
as they were gated out of the analysis. 
 
3.4. Mean fluorescence intensity of BAFF-R expression on naïve and 
memory B cells 
Figure 1 shows representative dot plots and histograms of BAFF-R expression on 
CD19+ B cells (panel A), PBMC differentiated into naïve and memory B cells on the basis 
of CD27 expression (panel B) and histograms of the MFI of BAFF-R on naïve (grey line) 
and memory (dark line) B cells (panel C). BAFF-R expression appeared to be decreased in 
patients who were discordant for relapse after B-cell return, both when remaining well or 
relapsing, in the examples shown. These individuals also had a tendency for a higher 
proportion of naïve to memory B cells (panels A and B). A left shift in MFI of BAFF-R 
expression was also observed in all naïve and memory populations following rituximab 
compared with those of NC (panel C). In order to explore these initial observations, the 
MFI of BAFF-R expression on naïve and memory CD19+ B cells pre-RX were compared 
with those of B cells from NC (Figure 2). Naïve B cells from both groups of patients at 
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relapse (C-R and D-R) expressed significantly lower levels of BAFF-R when compared 
with NC (MFI; C-R 58.8 and D-R 53.7 versus NC 85.5). Memory B cells from both cohorts 
of relapsing patients also showed significantly lower expression of BAFF-R than NC (MFI; 
C-R 56.5 and D-R 46.7 versus NC 78.0). Furthermore, C-R patients showed a tendency to 
lower MFI levels than pre-RX patients in both naïve (58.8 versus 70.4, p=0.06) and 
memory B-cell populations (56.5 versus 61.2, p=0.07). We also observed a tendency 
towards lower BAFF-R MFI in D-R patients when compared with pre-RX levels in 
memory B cells, although again this did not reach statistical significance (46.7 versus 61.2, 
p=0.07). Of interest, no significant differences were found in the MFI of BAFF-R 
expression on either naïve or memory B-cell populations in the D-NR patient group when 
compared with NC or RA patients before treatment. 
 
3.5. Relationship between BAFF levels and BAFF-R mean fluorescence 
intensity in naïve and memory B cells 
Our initial observation was that BAFF-R expression was significantly lower on B cells 
from patients undergoing relapse than on B cells from patients whose B cells had returned 
but in whom disease was not yet re-established (Figure 2). We therefore examined whether 
there was any relationship between circulating BAFF levels and expression (MFI) of 
BAFF-R (Figure 3). Although no statistically significant correlations were found, we could 
distinguish different patterns between pre-RX, C-R, D-R and D-NR patients. When patients 
were relapsing (C-R and D-R), BAFF-R MFI was consistently lower, irrespective of serum 
BAFF levels. Nevertheless, in patients who had repopulated but remained well (D-NR), 
there was a tendency for a negative correlation between circulating BAFF and BAFF-R 
MFI more evident in memory B cells (r2=0.88, p=0.06) (Figure 3). However, samples from 
only four patients were available for analysis in this group. 
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Figure 1. Characterization of BAFF-R expression in normal controls and patients with rheumatoid arthritis 
before and after B-cell depletion therapy.  
The expression of BAFF-R on CD19+ B cells in the lymphocyte gate in peripheral blood mononuclear cells is 
shown in panel A. In panel B, combinations of CD27 and CD19 were used to differentiate memory (M; 
CD19+CD27+) and naïve (N; CD19+CD27−) B cells. Numbers in each quadrant represent percentages of 
each subpopulation in individual experiments. The histograms in panel C show representative experiments in 
which the mean fluorescence intensity (MFI) of BAFF-R expression for CD27+ (dark line) and CD27− (grey 
line) are shown. Dotted lines depict the MFI of BAFF-R expression on the naïve B-cell (CD27−) population 
from normal controls (NC) to enable comparison with other histograms in each example. Pre-RX: pre-
rituximab; C-R: concordant clinically relapsing; D-R: discordant clinically relapsing; D-NR: discordant 
clinically non-relapsing. 
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Figure 2. The mean fluorescence intensity of BAFF-R expression on B cells is reduced in rheumatoid arthritis 
patients at clinical relapse. 
Peripheral blood mononuclear cells were gated on the CD19+ B-cell population and the mean fluorescence 
intensity (MFI) of BAFF-R expression determined on CD27- naïve (A) and CD27+ memory (B) B-cell 
subpopulations. Normal controls (NC) and patient groups were compared using the Mann–Whitney test and 
statistical significance indicated (*p<0.01, **p<0.001). Pre-RX: pre-rituximab; C-R: concordant clinically 
relapsing; D-R: discordant clinically relapsing; D-NR: discordant clinically non-relapsing. 
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Figure 3. Relationship between circulating BAFF levels and BAFF-R expression.  
The values for the mean fluorescence intensity (MFI) of BAFF-R expression on CD27- naïve (A) and CD27+ 
memory (B) B-cell subpopulations in individual patients were plotted against BAFF levels (ng/ml) that were 
measured in serum stored at the same time point (upper limit of normal range 2.45 ng/ml). Regression 
analysis was performed and significance values determined for each curve. Pre-RX: pre-rituximab; C-R: 
concordant clinically relapsing; D-R, discordant clinically relapsing; D-NR: discordant clinically non-
relapsing. 
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3.6. B-cell subpopulations in peripheral blood associated with different 
patterns of response to rituximab  
It has previously been suggested that patients with higher numbers of circulating 
memory/post-switch B cells, either before treatment induction or at relapse were more 
likely to have a shorter clinical response to rituximab [23, 24]. We showed here that 
memory B cells from relapsing patients in particular tended to express lower levels of 
BAFF-R (MFI) and that this was so over a wide range of circulating BAFF levels. We 
therefore examined whether there was any relationship between subpopulations of B cells 
in patients with different patterns of clinical response/relapse (Figure 4). Circulating B-cell 
(CD19+) subpopulations were defined according to IgD and CD27 expression and 
classified as naïve (IgD+CD27−), pre-switch memory (IgD+CD27+), post-switch memory 
(IgD−CD27+) and double-negative (IgD−CD27−) B cells. The median (range) of total 
numbers of CD19+ B cells in each patient group were for pre-RX: 175 (58–472)×106/l, C-
R: 42 (15–192)×106/l, D-R: 61 (13–166)×106/l, D-NR: 71 (21–328)×106/l. The median 
percentage and interquartile range of each subpopulation are shown for NC and patient 
groups in Figure 4. The distribution of naïve to memory B cells in humans is approximately 
60:40. The B-cell subpopulation distribution of B cells from patients with RA pretreatment 
was broadly similar to NC, except for a slightly increased proportion of double-negative B 
cells (7.3% versus 3.9%, p=0.04). Following rituximab, repopulation of the periphery 
begins with naïve B cells, which mature at a greater or lesser rate into pre and post-switch 
CD27+ B cells. Full restoration of memory cell populations may not be achieved for years 
after treatment. As expected, the relative ratio of naïve to memory B cells was increased at 
repopulation, mirroring ontogeny, but the relative percentage of naïve cells was only 
significantly higher in the non-relapsing patients compared with NC (p<0.05). The pre-
switch memory B-cell population was significantly decreased in all patients post-rituximab 
(C-R 4.2%, p=0.0004; D-R 4.9%, p=0.002 and D-NR 4.7%, p=0.03) when compared with 
NC (12.2%). In patients who relapsed at B-cell return, post-switch memory B cells had 
already reached levels approximating those of NC (C-R 12.4% versus NC 19.6%, p=0.28), 
but remained reduced in the D-NR group when compared with NC (6.6% versus 19.6%, 
p=0.03), pre-RX (6.6% versus 18.1%, p=0.02) and D-R (6.6% versus 17.9%, p=0.05).  
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Figure 4. Characterization of circulating B cell subpopulations in normal controls and patients with 
rheumatoid arthritis before and after B cell depletion therapy.  
Peripheral blood mononuclear cells were gated on CD19 to characterize B-cell subpopulations further on the 
basis of IgD and CD27 expression into naïve, pre and post-switch memory and double negative B cells. 
Significance levels, using the Mann–Whitney test, for comparisons between the different groups are depicted 
as: *p<0.05 versus normal controls (NC), **p<0.05 versus pre-rituximab (pre-RX), ***p<0.05 discordant 
clinically non-relapsing (D-NR) versus discordant clinically relapsing (D-R). C-R: concordant clinically 
relapsing. 
 
 
We also used regression analysis to determine whether serum BAFF levels were related 
to the percentage of particular B-cell subsets. This produced mostly negative results, 
although higher BAFF levels were statistically associated with numbers of pre-switch 
memory B cells in patients who were relapsing more than 3 months after B-cell 
repopulation (D-R, p=0.02, data not shown). 
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3.7. Relationship of BAFF-R expression and B-cell phenotypes with 
months between repopulation and relapse 
It is also possible that differences in levels of BAFF-R and B-cell phenotype distribution 
in patients discordant for repopulation and relapse (D-R and D-NR cohorts) were related at 
least partly to differences in the time of sample collection following repopulation. We 
therefore compared months between repopulation and relapse in the two cohorts and found 
them not to be significantly different (months between repopulation and sample collection 
in the D-NR cohort range 4–46, median=13; D-R cohort range 5–24, median=7; p=0.594, 
Mann–Whitney, data not shown). 
 
4. Discussion 
 
Using the 11C1 monoclonal antibody, which recognizes occupied and unoccupied 
BAFF-R on human cells [25], we found that BAFF-R levels on CD27+ and CD27− B cell 
subpopulations in RA patients before rituximab were similar to those of B cells from NC, 
although there was a tendency towards lower values especially in memory B-cell 
populations (MFI, p=0.098, Table 1 and Figure 2). We also report that BAFF-R expression 
was significantly reduced on B cells from patients with RA when they were undergoing 
relapse following rituximab. Low BAFF-R levels were not due to an increase in circulating 
plasmablasts (data not shown), which have been associated with clinical relapse [26]. 
Significantly, reduced BAFF-R expression was found in both naïve and memory 
subpopulations and on B cells from patients who relapsed when B cells returned, as well as 
in those patients who relapsed more than 3 months after B-cell return. In addition, as all 
patients in the pre-RX group had active RA and were studied before the induction of B-cell 
depletion therapy for resistant disease the results also imply that reduced BAFF-R 
expression was not necessarily a consequence of inflammation and active disease, but was 
more likely related to the re-establishment of disease. 
The bioactive trimeric form of soluble BAFF is produced by a variety of cell types, 
namely myeloid and dendritic cells, neutrophils and some stromal cells [27]. In humans, 
BAFF signaling through BAFF-R does not appear to be directly involved in B-cell 
maturation or in most T-cell-independent responses [6]. BAFF-R is expressed on human B 
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cells from the transitional stage onwards and is then lost from memory B cells as they 
differentiate into Ig-secreting plasma cells [28]. Stimulation through Toll-like receptor 
pathways (CpG, IL-2, IL-15) is more efficient than T-dependent pathways (CD40L, IL-2, 
IL-10) at downregulating BAFF-R expression on memory B-cell populations [7, 28]. It was 
also found that stimulation of naïve cells through either pathway had no effect on BAFF-R 
expression, although positive responses of naïve human cells to either stimulus are poor 
[28]. 
Investigations of BAFF-R expression on B cells from patients with rheumatic diseases 
are limited and to some extent report contrasting findings and none describe patients with 
RA or the effect of rituximab. Carter et al [25] showed that normal levels of BAFF-R were 
present on B cells in patients with SLE, but were of reduced availability due to occupancy 
by soluble BAFF. Low levels of BAFF-R expression and a negative correlation between 
BAFF-R expression and higher disease activity in patients with SLE have been described 
[19]. In patients with Sjögren’s syndrome, BAFF-R expression was decreased on both 
naïve and memory B cells, with the lowest levels found in patients with extraglandular 
involvement [19]. Analysis of BAFF-R messenger RNA from B cells from these patients 
suggested that the lower expression was due to a post-translational modification and not to 
any reduction in BAFF-R mRNA. This could be explained if decreased BAFF-R expression 
reflected the recent binding of bioactive BAFF to BAFF-R followed by internalization or 
shedding [25]. In turn, this could be due to the chronic exposure of B cells to constantly 
high circulating levels of BAFF, which are often found in these patients. Carter et al [25] 
showed that the receptor/cytokine complex was not internalized. Loss of the receptor 
following ligation by BAFF was, however, confirmed by Sellam et al [19], who showed 
that overnight, but not short-term, culture with physiologically encountered concentrations 
of BAFF reduced BAFF-R levels on B cells from normal donors. 
Our experience here and in earlier studies [17] was that BAFF levels were not 
significantly raised in patients with active RA. However, following rituximab, BAFF levels 
rise rapidly and remain raised for variable periods of time. In our serial studies [17], we 
found that in individual patients, BAFF levels fell more sharply in patients in whom relapse 
was associated with B-cell return, than in those patients who relapsed months after B-cell 
return. This may have reflected increased BAFF binding to BAFF-R or TACI following B-
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cell receptor (BCR) engagement. We could not confirm these results here as individual 
patients were not studied serially over the course of their cycle of treatment. In the present 
study, serum BAFF remained raised to similar levels in sera from patient cohorts discordant 
or concordant with respect to B-cell return and relapse. Within each group of patients, 
however, there was no correlation between BAFF levels and BAFF-R expression (Figure 3) 
suggesting that reduced expression was not solely due to chronically raised BAFF levels, 
although this possibility could not be excluded with certainty. 
When levels of expression of BAFF-R on naïve and memory populations in pre-RX 
patients and controls were compared, CD27+ memory B-cell values tended to be lower, 
although this did not reach statistical significance (p=0.07, data not shown). The main 
finding of the study was that BAFF-R levels were significantly reduced on both naïve and 
memory B cells from relapsing, compared with non-relapsing, patients and pre-RX patients. 
This suggested that the reduction in BAFF-R levels may have been initiated in naïve cells, 
which then carried the “low” BAFF-R phenotype into the mature memory B-cell stage. In-
vitro experiments by others have shown that BAFF could modulate BAFF-R expression in 
a dose-dependent manner [25]. As we found no correlation between raised BAFF levels and 
reduced BAFF-R expression and low BAFF-R expression on naïve populations as well as 
memory B cells associated with the re-establishment of disease, we suggest that another 
mechanism may be responsible. 
Patients with RA have been shown to possess a number of genetic polymorphisms 
linked to tolerance checkpoints in the bone marrow or the periphery [29]. Evidence of 
altered thresholds for BCR signaling [30] have been described in patients with RA and 
suggested to contribute to the generation of autoreactive cells. There is also accumulating 
evidence that pre-B/immature B cells from patients with RA are pre-activated before they 
exit from the bone marrow [31]. It was recently shown that B cells at the pre-B/immature 
naïve stage in the bone marrow of patients with RA had evidence of increased TLR9 
protein expression and mRNA compared with osteoarthritis patients and also expressed the 
activation marker CD86 [32]. Disease-induced changes such as the formation of germinal 
center-like structures, cytokines such as TNF, or increased levels of bacterial DNA/RNA in 
the bone marrow environment in patients with RA may disrupt the environment in which 
pre-B cells are developing [33]. Reduced ability to express receptors for the pro-survival 
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cytokine BAFF on transitional and naïve B cells after exiting the bone marrow may result 
as part of the unusual cytokine environment in which the B cells developed. 
Once in the circulation, BCR specificity becomes a crucial determinant of B-cell 
survival and function. The expression of BCR specific for citrullinated proteins and 
increased numbers of RF-specific B cells have been described by Samuels et al [31] within 
early (CD10+IgM+) populations exiting the bone marrow and also in mature naïve B cells 
(CD10−IgM+) in RA patients compared with normal individuals. The conclusion is 
therefore that alterations of tolerance checkpoints both within the bone marrow and in the 
periphery may be occurring in patients with RA. Within the polyreactive pool exiting the 
bone marrow, BCR specificities with promiscuous potential such as those possessed by the 
relatively high proportion of RF B cells that can obtain help from T cells with specificity 
for a wide range of processed peptides [34], may have a survival advantage that could 
override the disadvantages of low BAFF-R expression/signaling in a genetically 
predisposed individual. We have shown that BAFF levels do not appear to be limiting in 
relapsing patients, but lower levels of BAFF-R expression on newly generated B cells may 
reduce survival potential and favour “expanded” cohorts of B cells able more easily to 
obtain productive, but not necessarily antigen-specific, T-cell help. 
As well as being an effective treatment for many patients with RA, rituximab gives us an 
opportunity to study elements important for relapse through our ability to study the re-
establishment of disease. Following clearance of rituximab from the bone marrow, newly 
generated B cells expand into an environment that has retained a variable number of 
resistant B cells, a mature T-cell compartment and long-lived plasma cells. First, we know 
that B-cell return to the periphery is mandatory for relapse [20]. Second, the gap between 
B-cell return and relapse may reflect the relationship between the re-expansion of surviving 
memory B-cell clones under the influence of newly generated B cells. In both scenarios, 
maturation into Ig-secreting cells is often coincident with relapse, as shown by rises in 
autoantibodies [17, 35] and also by the reported association with circulating plasmablasts 
[23]. Our finding of a lower proportion of post-switched memory B cells in non-relapsing, 
repopulated patients compared with relapsing patients supports the view that B-cell class-
switch recombination is associated with relapse. The depletion of CD27high memory B cells 
has previously been associated with clinical response to rituximab [23, 36] and low 
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circulating numbers of IgD−CD27+ memory B cells associated with low clinical activity 
indices and a longer clinical response, as reported by our group and others [20, 37]. The 
parallel finding that BAFF-R levels in the non-relapsing repopulated patients were similar 
to those of pre-RX patients support our hypothesis that the signals required for BAFF-R 
downregulation are intimately linked to the re-establishment of disease. We also found that 
a population of double-negative (IgD−CD27−) B cells was significantly raised in patients 
with RA compared with controls, but their proportions did not change following rituximab. 
These cells may be similar to a previously described memory B-cell population in patients 
with SLE by Wei et al [38], although others have found that only approximately 50% of 
this double-negative B-cell population bore markers of mutation and class switch [39]. 
Although no statistically significant reduction in BAFF-R expression was present in RA 
patients before treatment, the ranges of percentage expression and MFI were wide (Table 1, 
Figure 2). It is possible that a proportion of B cells with low BAFF-R levels are being 
generated throughout the clinical course of RA, but that the numbers of detectable BAFF-
Rlow B cells may vary. 
B-cell survival and differentiation is the result of a complex interplay between survival 
factors, in particular the BAFF/APRIL system in concert with the specificity and strength 
of signal through the BCR [40]. From this study, we have shown that low levels of BAFF-
R expression are related to the re-expansion of possibly pathogenic species of B cells 
associated with relapse. The re-establishment of active disease in patients with RA after 
rituximab may therefore involve preferential survival properties of autoreactive B cells, due 
to the unusual properties of their BCR and the ability also to overcome possible 
consequences of lower levels of BAFF-R signaling [27, 31]. 
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ISCUSSION 
 
The role of B cells in the very early phase of rheumatoid 
arthritis 
 
Several studies have documented the importance of B cells in RA pathogenesis through 
diverse mechanisms. In fact, B cells produce autoantibodies such as RF and ACPAs, which 
can form immune complexes and deposit in the joints, causing inflammation; present 
antigens and activate T cells; release cytokines and participate in ectopic lymphoid 
neogenesis. The discovery that B cell depletion therapy with RTX was effective in RA 
patients reinforced the key position of these cells in this autoimmune disease and placed B 
cells in a central stage of research. Nevertheless, the majority of the research in this field 
has been focused in established RA patients, while the knowledge associated with the 
immune mechanisms involved and the role of B cells in RA onset is still very scarce. In 
fact, even the so called “early RA” studies have included patients with three to 12 months 
of disease duration that in many aspects already correspond to an established 
immunobiology. Therefore, the major novelty of the present study was the analysis of the 
first few weeks of RA onset. Indeed, a cohort of untreated polyarthritis patients with less 
than six weeks of disease duration was followed up and a full characterization of peripheral 
blood B cell subpopulations, serum cytokine and chemokine environment and B-cell gene 
expression profile analysis were performed. The follow-up of these patients allowed the 
identification of a subset that evolved into RA, which was classified as very early RA 
(VERA). The remaining patients either had self-limited forms of arthritis or evolved into 
other chronic inflammatory joint diseases. Clinical and laboratorial evaluations of VERA 
patients were done at baseline and after short-term treatment with corticosteroids and MTX.  
Interestingly, it was found that VERA patients have disturbances in circulating memory 
B cells, namely a decrease in pre-switch memory (IgD+CD27+) subpopulation; have 
increased serum levels of cytokines related with B cell recruitment and activation; and have 
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alterations in the expression of genes related with B cell homeostasis, development and 
survival. Importantly, these observations support an ongoing role of B cells in RA 
pathogenesis since the first weeks of RA onset. Furthermore, it was observed that short-
term therapy with corticosteroids and MTX, although effective in clinical improvement, did 
not seem to affect peripheral B cells or cytokine content in circulation.  
 
Characterization of peripheral blood B cell 
subpopulations 
 
An interesting and surprising finding of the present work was the observation that 
VERA patients displayed disturbances in circulating memory B cells, particularly lower 
numbers of pre-switch memory B cells (IgD+CD27+). Importantly, this constituted the first 
evidence of an early involvement of B cells in RA physiopathology. Therefore, 
understanding the role of this B cell subpopulation in RA pathogenesis might help to better 
comprehend the mechanisms involved in RA progression. 
In humans, up to 40% of peripheral blood B cells express CD27 and have hypermutated 
variable regions in their Ig receptors. These cells are usually considered to be memory B 
cells generated in GCs during immune responses to T-cell dependent antigens [1, 2]. 
During GC reactions, B cells proliferate and undergo repeated cycles of SHM, with 
antigen-selected clones eventually leaving the GC to become memory B cells [3]. In 
humans, GCs reactions and the development of both memory B cell subsets (pre-switch 
IgD+CD27+ and post-switch IgD-CD27+) begin soon after birth [4]. Indeed, blood 
IgM+IgD+CD27+ cells are present and mutated in infants with less than two years of age, 
suggesting that these cells are generated and diversified at early stages of life [5, 6]. 
Nevertheless, there is still considerable debate and controversy concerning the exact 
function and phenotype of IgD+CD27+ B cells in humans. In fact, it has not yet been clearly 
established whether the IgD+CD27+ memory subpopulation only participates in T cell-
independent immune responses, due to the fact that this population can also express heavily 
mutated Ig genes [7]. Some studies have suggested that IgD+CD27+ cells differ from 
classical memory cells and are instead splenic marginal zone (SMZ) B cells involved in T-
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cell independent responses. Contrarily to the equivalent B cell population in mice, these 
cells recirculate and diversify their Ig receptors by hypermutation in a GC-independent 
pathway [5, 8]. The presence of T-independent antigens in the mature environment of the 
SMZ is assumed to trigger the effector function of IgM+IgD+CD27+ cells, the 
differentiation into IgM-secreting plasma cells or, after isotype switch, the secretion of 
mutated antibodies [9-11]. Furthermore, the dependence of these cells on the splenic 
microenvironment is highlighted by their reduced numbers in splenectomized patients and 
the existence of a correlation between this specific subset and protective immunity against 
pneumococcal infections [12, 13].  
The knowledge concerning pre-swich memory IgD+CD27+ B cells’ ability to somatically 
hypermutate their Ig genes is also controversial. Recently, it has been shown that no 
significant AID expression is detected in the splenic IgM+IgD+CD27+ fraction in young 
infants (less than two years old) [6]. B cells displaying an IgM+IgD+CD27low phenotype are 
present in the SMZ and, despite numerous antigenic challenges provided by standard 
childhood vaccinations, the overall complexity of the heavy chain variable (VH) gene 
rearrangement repertoire of IgM+IgD+CD27+ cells in blood and spleen was similar to that in 
naïve B cells, with no sign of antigen activation or clonal expansion [6]. Nevertheless, other 
studies seem to contradict this notion [1, 14, 15]. Indeed, it has been demonstrated in a 
study of healthy adult population that IgM+IgD+CD27+ B cells resemble class-switched and 
IgM-only memory cells in terms of cell phenotype, and comprise 15% of circulating B cells 
[1]. Importantly, it was shown that in addition to IgM-only B cells, IgM+IgD+CD27+ cells 
represent a further population of IgM-bearing B cells in the peripheral blood that expresses 
somatically mutated VH genes. IgD+CD27+ B cells also comprise a small subpopulation of 
IgM-IgD+CD27+ (IgD-only cells) (less than 1%) expressing a highly mutated VH region 
genes [1, 16, 17]. Of note, it has been shown that in a transgenic mouse model, marginal 
zone B cells can also be recruited for T-cell dependent responses, forming GCs that 
subsequently undergo SHM and affinity maturation [18]. Another possible explanation for 
the generation of IgD+CD27+ cells involves an early branching point in GC differentiation, 
before the onset of isotype switching [19, 20], which accounts for the lower mutation 
frequency generally observed in these cells than for class-switched IgD-CD27+ B cells from 
the same individual [5, 21].  
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In VERA patients, the hypothesis that pre-switch memory IgD+CD27+ cells are able to 
differentiate into plasmablasts and produce RF cannot be excluded. In fact, IgD+CD27+ B 
cells present several features that suggest a role in autoimmunity [22-24]. Previous reports 
had already mentioned a decrease in IgD+CD27+ memory B cells in patients with SLE [25], 
SS [26, 27], or systemic sclerosis [28]. Interestingly, their number was associated with RA 
relapse during B cell reconstitution in RTX treated patients [29, 30]. Moreover, similarly to 
post-switch memory IgD-CD27+ B cells, they may also differentiate into plasmablasts and 
produce isotype-switched antibodies [22, 31-35].  
It has been demonstrated in a transgenic mouse model for RF that the activation of 
splenic autoreactive B cells, as well as hypermutation, occurred in the T zone-red pulp 
border rather than in the GC [36-38]. Importantly, this observation contradicted the idea 
that GCs were the only site in the immune system that supported and sustained high rates of 
SHM [39]. Notably, it has been observed that not only autoreactive B cell responses often 
occur extrafollicularly, generating short-lived plasmablasts [40], but also that T cells are not 
required for initiation of RF responses and TLR signals are essential [38].  
The decrease in circulating levels of pre-switch memory B cells (IgD+CD27+) in VERA 
patients can possibly be explained by a recruitment of this B cell subpopulation towards the 
synovial membrane, where it accumulates and contributes to the main inflammatory 
process characteristic of RA. Indeed, it is known that rheumatoid synovial membrane is 
infiltrated by B and plasma cells [41, 42]. In addition, a migration of this B cell subset to 
secondary lymphoid organs, such as spleen or lymph nodes, cannot be excluded. 
Importantly, it has been demonstrated that established RA patients have also a significant 
lower frequency and lower absolute numbers of peripheral blood pre-switch memory 
IgD+CD27+ B cells, an effect that was abrogated by anti-TNF therapy [43]. Notably, it was 
found that both pre-switch IgD+CD27+ and post-switch IgD-CD27+ memory B cells 
accumulate in the synovial membrane of RA patients [43, 44], which reinforces the 
proposed hypothesis and the pathogenic role of memory B cell subpopulations in RA 
progression.  
In the first weeks of RA onset, pre-switch memory B cells can be responsible for the 
production of high affinity IgM antibodies and, eventually, isotype-switched antibodies, 
that accumulate locally in the joints. These antibodies can contribute to immune complexes 
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formation and help to induce the triggering of an inflammatory response in the rheumatoid 
synovium, leading to the activation of both innate and adaptive immune systems.  
Furthermore, short-term therapy with corticosteroids and MTX, despite improved 
clinical symptoms in VERA patients as indicated by a decrease in DAS28, was not able to 
restore pre-switch memory IgD+CD27+ B cells to normal levels. Long-term therapy either 
with corticosteroids or MTX affects B cell numbers, suggesting that the absence of an 
effect on these cells that we have observed is justified by the short term exposure [45, 46]. 
The beneficial effects of B cell depletion therapy with RTX in RA patients have also 
brought a new attention to the role of memory B cells in RA pathogenesis and might help to 
elucidate the relevance of IgD+CD27+ B cells in RA progression. It is known that B cell 
depletion is not definitive and B cell repopulation usually occurs 6-9 months after RTX 
infusions. During B cell reconstitution, newly generated immature B cells are the first to 
predominate early in the blood, while memory B cells tend to be profoundly and 
continuously depleted [47, 48]. However, it has been demonstrated that high numbers of 
overall memory B cells (CD19+CD27+) and enhanced C-reactive protein (CRP) levels 
before the initiation of RTX treatment are predictive of an earlier relapse [30, 47-49]. 
Interestingly, patients with lower numbers of IgD+CD27+ memory B cells at the beginning 
of peripheral B cell repopulation had a much more favourable clinical response. It was 
shown that nonresponder patients had higher absolute numbers of IgD+CD27+ in 
comparison with responders, at B cell return [30]. Therefore, the extent of memory B cell 
repletion, particularly IgD+CD27+ cells, seems to be a key factor in influencing the 
pathophysiology of RA.  
Since a high number of memory B cells before therapy may be a less favourable 
biomarker for early relapse, an effective depletion of this B cell subset might be essential to 
achieve longer and persistently effective clinical results. However, the occurrence of 
clinical relapses is a concern and implies re-treatment of patients, indicating that a single 
cycle of B cell depletion seems to be insufficient to reestablish self-tolerance by eliminating 
autoreactive memory B cell clones. 
Very early arthritis (VEA) patients, who evolved into other conditions than RA, also had 
a decrease in IgD+CD27+ B cells in peripheral blood. Of interest, a reduction in circulating 
memory B cells has been shown in patients with X-linked hyper-IgM syndrome [22], 
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chronic granulomatous disease [50] and human immunodeficiency virus (HIV)  [51]. 
Hence, lower levels of circulating memory B cells seem to be linked with chronic 
inflammation rather than an exclusive feature of autoimmune conditions. Nevertheless, 
other factors such as environment or genetic predisposition, can influence and contribute to 
the development and outcome of autoimmune diseases in patients who already display 
disturbances in circulating memory B cells [52-55], such as the case of our very early 
polyarthritis patients cohort that have evolved into RA. 
 
Cytokine environment and cellular interactions 
 
Since VERA patients display disturbances in circulating B cell subpopulations, an 
extensive analysis of the cytokine enviroment that could potentially contribute to this effect 
was performed. Importantly, it was found that VERA patients have increased levels of 
cytokines related to B cell recruitment (IL-6), maturation and survival (APRIL, BAFF), 
thus reinforcing the notion of an early activation of B cells during RA onset.  
Several types of cells from both innate and adaptive immune system have an 
intervention in RA pathogenesis [41, 56-61], as illustrated in figure 1. Macrophages, 
neutrophils, fibroblasts, B and T cells, osteoclasts, are able to interact with each other and 
lead to RA progression, mainly through the production and secretion of cytokines, 
chemokines and adhesion molecules that facilitate cellular recruitment and infiltration of 
joints, thus triggering a chronic inflammatory response [56, 62-64]. Therefore, the serum 
panel of cytokines selected for testing in VERA patients aimed at encompassing all the 
major known RA pathogenesis players. Of interest, it was observed that in addition to a B 
cell activation pattern, VERA patients have also a cytokine profile that supports neutrophil 
recruitment (IL-8) and Th17 cells polarization (IL-1β and IL-6) and activation (IL-17A and 
IL-22), that are ultimately able to assist the autoreactive B cells in RA progression. 
Furthermore, the analysis of SF samples from established RA patients, illustrating the 
inflammatory process that occurs locally in the joints, also revealed a similar pattern of 
cytokines, thus supporting the pathogenic role not only of the B cells, but also of the 
neutrophils and Th17 cells in RA development and chronicity.  
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Neutrophils are the most abundant leukocytes in the SF of patients with active RA and it 
has been observed that these cells can heavily infiltrate the synovial tissue in the first days 
of RA onset [61]. Moreover, previous results from our group demonstrated that there is a 
delay in the apoptosis of circulating neutrophils in VERA patients [65]. The elevated serum 
IL-8 levels in VERA patients when compared with both VEA and healthy controls, could 
explain the preactivated state of circulating neutrophils and their recruitment towards the 
SF in the very first weeks of RA onset [66]. Interestingly, once activated, neutrophils are 
able to produce high levels of BAFF [67], also found to be increased in VERA patients’ 
serum and established RA SF.  
BAFF is a fundamental B-cell survival factor essential for B cell proliferation and 
activation [68]. In fact, increased serum BAFF levels have been associated with several 
autoimmune diseases such as SLE [69-72], SS [73, 74] and ITP [75]. In RA patients, 
several studies have demonstrated that BAFF is elevated in serum [69, 76-78], although 
there are findings that also show no differences in comparison to healthy controls [79, 80]. 
Nevertheless, similarly to what was observed in the established RA cohort included in this 
study, BAFF levels in RA SF are higher than their corresponding serum levels [81], which 
is consistent with local production of BAFF in inflamed joints [82].  
In VERA patients, activated neutrophils could release high quantities of BAFF that 
stimulate autoreactive B cells, while in established RA this effect is more localized to the 
joints. Once stimulated with an activation and survival factor like BAFF, the B cells that 
are prone to be autoreactive can produce higher amounts of autoantibodies, such as RF or 
ACPAs, and function as more efficient APCs to activate T cells [76, 83, 84]. The immune 
complexes that further deposit in the joints activate Fcγ-receptors, such as FcγRIIIa, 
expressed by macrophages [63, 85, 86], which are consequently triggered and further 
increase the inflammatory process with the production of proinflammatory cytokines [62, 
63, 87], such as TNF or IL-1β, that were also found to be increased not only in VERA, but 
also in established RA SF.  
APRIL was also increased in VERA patients’ serum as compared with VEA and 
established RA, and its levels were even higher in RA SF, suggesting a local upregulation 
in the rheumatoid synovium. APRIL is expressed by macrophages [88, 89], dendritic cells 
[90] and fibroblast-like synoviocytes [91] and, like BAFF, is an important cytokine 
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involved in B cell survival. APRIL affects not only the class-switch recombination process 
[92-94], but also plasma cell differentiation and survival [95, 96], which could explain the 
maintenance of autoreactive B cells in  RA joints [97]. Importantly, a highly positive 
association between the infiltration of plasma cells and SF levels of APRIL has been 
demonstrated in RA patients [97, 98]. Therefore, in VERA patients, the activated 
macrophages and possibly fibroblasts infiltrating the synovial membrane can be responsible 
for APRIL production, which induces the differentiation of plasma cells and stimulates 
isotype-switching. Furthermore, the increased concentrations of APRIL detected locally in 
RA joints can be associated with the observed accumulation of both pre-switch memory 
IgD+CD27+ and post-switch memory IgD-CD27+ B cells in the synovial tissue as 
previously observed [43, 44]. It is possible that both APRIL and BAFF help to maintain the 
survival of autoreactive memory B cells in the joints. Moreover, APRIL could induce the 
occurrence of SHM process within joints, namely in areas of ectopic lymphoid neogenesis, 
and increase affinity maturation.  
Additionally, the observed increased IL-21 levels in SF from the established RA cohort 
also support local plasma cell differentiation and autoantibody production [99], that is 
consistent with the infiltration of plasma cells in the synovial membrane [97, 100].  
In VERA patients, the detection of elevated concentrations of Th17-derived cytokines, 
namely IL-17A and IL-22, suggests that these cells might also have a role to play in RA 
pathogenesis since the first weeks of RA onset [101, 102]. Indeed, Th17 cells have been 
implicated in RA pathogenesis through the production of IL-17 [103-105] and increased 
levels of this cytokine are correlated with more severe joint damage [106]. Of note, IL-1β 
and IL-6, both found to be increased in VERA patients, are known to promote the 
differentiation of Th17 cells [107, 108], which in turn secrete IL-17A and IL-22 [109, 110]. 
Interestingly, IL-17A is a cytokine that promotes the recruitment and survival of 
neutrophils [111, 112], induces the secretion of proinflammatory cytokines (such as IL-1β, 
IL-6, IL-8 and TNF) [62, 113], upregulation of RANKL [104] and stimulates the activity of 
matrix metalloproteases, thus leading to cartilage catabolism and bone resorption [114-
117]. 
Considering the cytokine pattern observed in VERA patients, it is therefore tempting to 
consider that a pathogenic relationship exists between B cells, neutrophils, macrophages 
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and Th17 cells since the first weeks of RA onset. After an initial unknown triggering event 
that induces RA development, neutrophils are attracted to the joints, mediated by an IL-8 
chemotactic gradient [66] and, once activated, can release high amounts of BAFF [67], 
which consequently stimulate autoreactive B cells function and survival [68, 69, 76]. The 
activated macrophages and fibroblasts are also able to produce APRIL, that induces plasma 
cell differentiation and CSR [92-96]. Simultaneoulsy, proinflammatory cytokines such as 
IL-1β and IL-6 are released and drive Th17 cells polarization. Activated Th17 cells produce 
high levels of IL-17A and IL-22, and are able to extend neutrophil survival [111, 112], help 
B cells in autoantibody production [118-120] and stimulate osteoclastogenesis, thus leading 
to cartilage and bone destruction [104, 116, 117]. Importantly, the increased IL-6 levels 
generated not only in VERA patients, but also in established RA serum and SF samples, 
support a continuous recruitment of autoreactive B cells toward the synovium [121, 122] 
during RA progression, thus contributing to an exacerbation of the inflammatory process 
due to the production of autoantibodies and immune complexes. Furthermore, in 
established RA patients, the increased levels of IL-21, mainly produced by CD4+ T cells, 
including Th17 cells [123-125], not only induce plasma cell differentiation, but also 
potently enhance Th17 proliferation in RA [126].  
Interestingly, cytokines associated with the function of Th1 (IL-2, IL-12 (p70), and INF-
γ) and Th2 (IL-4 and IL-10) cells were not significantly elevated in VERA patients. 
Therefore, Th17-cell polarization and activation seems to be the most relevant T-cell 
related occurence in very early RA patients.  
The establishment of a pathogenic interaction between Th17 and B cells since early RA 
onset is also reinforced by the fact that B cell chemoattractant CXCL13 is preferentially 
expressed by Th17 cells [127]. CXCL13 is essential for B cell migration towards RA joints 
and B cell follicular organization [64] and recent findings have correlated CXCL13 
expression with RA synovitis [128] and identified this chemokine as a novel serological 
marker predictive of RA severity [129]. Importantly, these observations suggest that B cell 
and Th17-related cytokine targeted therapies could be beneficial to RA patients since the 
first weeks of RA onset. Indeed, therapies such as atacicept or belimumab, that target B-cell 
related survival cytokines APRIL and BAFF, are being evaluated for RA treatment [130-
135]. Additionally, tocilizumab, an IL-6 receptor inhibiting agent, was recently approved 
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for RA treatment and is highly effective in established RA [136, 137]. Similarly, 
neutralizing antibodies to IL-17 are being tested for treating established RA patients [138].  
 
B-cell related gene expression analysis 
 
Some studies have highlighted the association between RA gene expression profile and 
disease severity, thus providing valuable insights into RA pathogenesis [139-142]. 
Importantly, it has been documented that genes regulating and affecting cellular processes 
such as proliferation, apoptosis, cytokine networks and autoimmunity were differently 
expressed in RA B cells [143-145]. Interestingly, previous studies have shown that among 
the highest induced genes in human established RA were several B-cell associated genes, 
including immunoglobulins, B-cell markers such as CD20, and cytokines and chemokines 
that directly act on B cells, such as BAFF and CXCL13 [145]. These observations, together 
with our previous results, prompt us to hypothesize that B-cell biology is already 
dysregulated in RA onset, setting the grounds for the induction and perpetuation of a 
pathogenic humoral immune response. Therefore, the expression of a group of genes 
related to B cell homeostasis, maturation and survival was evaluated in VERA patients and 
compared to different stages of RA progression: untreated early RA patients with less than 
one year of disease duration (ERA) and established RA patients. Furthermore, other 
untreated early arthritis patients (EA) that did not evolve to RA and had less than one year 
of disease duration were also included in this study.  
It was found that BAFF gene expression, similarly to BAFF serum levels, was highest in 
VERA patients. The expression of BAFF-R significantly increased with disease 
progression, while TACI was elevated since the first weeks of RA onset; Pax5 gene 
expression was also increased in all RA stages; CXCR5 was only elevated in established 
RA and no differences were observed in BCMA, AID, Blimp-1 and Bcl-2 expression. 
Importantly, these alterations can potentiate the development of autoreactive B cells since 
the first weeks of RA onset.  
The disturbances that were found in BAFF/ BAFF-receptors system in VERA patients 
were extremely interesting and appealing for a B cell intervention treatment in early RA. 
BAFF binds to three receptors expressed by B cells: BAFF-R, BCMA and TACI, with 
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BAFF-R being the only one that exclusively binds BAFF and to which BAFF has higher 
affinity [146]. Although the precise mechanisms that control expression of all three BAFF 
receptors are currently unclear, studies indicate that the developmental stage, cytokine 
milieu and the microenvironment play a key role in regulating the receptor expression 
[147].  
Studies with knockout mice have demonstrated that B-cell proliferation depends on 
either BAFF-R or TACI signaling [96]. Excess BAFF may lower the threshold for BCR 
signaling and maintain survival of pathogenic autoreactive B cells, thus breaking B cell 
tolerance. Signaling through BAFF-R can result not only in survival enhancement [148, 
149], but also in B cell maturation [150], while TACI triggering can stimulate isotype 
switching and plasma cells differentiation [151]. Nevertheless, TACI functional activity is 
ambiguous. In fact, it has been demonstrated that TACI not only provides positive signals 
driving T-independent B cell response [152] and survival of activated B cells and 
plasmablasts [151, 153], but also delivers negative signals suppressing B cell activation 
[154]. Moreover, while TACI-/- mice predominantly develop autoimmunity and 
lymphoproliferation [155], TACI deficiency in humans primarily manifests itself as an 
antibody deficiency syndrome. Mutations in TACI were associated with common variable 
immunodeficiency (CVID) [156] and it has been shown that antibody responses after 
vaccination with pneumovax were selectively impaired in TACI-deficient humans [157]. 
Furthermore, it has been demonstrated that TLR7 and TLR9 triggering strongly upregulated 
TACI expression, which suggests that autoimmunity might also be correlated with 
reciprocal induction and activation of TACI and TLRs [158-160]. Of note, it has been 
shown that TLR9 can directly affect activation and proliferation of bone marrow B cells 
from RA patients and, thus, influence the pathogenesis of RA [161].  
Considering the gene expression pattern observed in VERA patients, it is possible to 
hypothesize that the elevated BAFF serum levels negatively regulate BAFF-R expression 
on B cells and, simultaneously, upregulate TACI. The induction of TACI expression on 
activated B cells could serve as a danger signal, reflecting the need to avoid the potential 
harmful effects of prolonged activation of B cells through BAFF-BAFF-R interaction [148, 
162]. With disease progression, signaling through BAFF-R eventually surpasses TACI, 
thus allowing autoreactive B cells to persist. Interestingly, an increase in both BAFF and 
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BAFF-R mRNA expression was found in RA synovial tissue [145, 163]. The higher 
affinity of serum BAFF, present at lower concentrations at later RA stages, towards BAFF-
R instead of TACI expressed by B cells which are more prone to be autoreactive supports 
this notion. Importantly, TACI binds APRIL and BAFF equally with high affinity [164] 
and serves as the only receptor for BAFF/ APRIL heterotrimers [165]. Thus, since CSR 
depends on APRIL signaling via TACI [92], the high levels of TACI expression and 
increased APRIL serum concentrations observed in VERA patients could contribute to the 
development of CSR and autoantibody formation by autoreactive B cells since the first 
weeks of RA onset. Moreover, the maintenance of elevated levels of TACI expression in 
ERA and established RA patients and the increased concentrations of APRIL found in RA 
SF support the notion of an activation of CSR during RA progression.  
Previous studies have also demonstrated that BAFF increases CXCL13-dependent 
chemotaxis of memory B cells through BAFF-R triggering [166]. Therefore, increased 
BAFF serum and mRNA levels since the first weeks of RA onset could support the 
migration of pre-switch memory IgD+CD27+ B cells towards the synovial membrane, thus 
justifying the decrease of this B-cell subpopulation in circulation not only in VERA 
patients, but also in established RA [43]. In established RA patients, this effect is probably 
higher in joints than in peripheral blood, since BAFF levels are increased in RA SF. 
The observation that Pax5 gene expression was elevated in all RA stages also reinforces 
the role of B cells in RA pathogenesis. Indeed, Pax5 has been referred to as the guardian of 
B cell identity and function [167, 168]. Pax5 gene codifies a transcription factor, also 
known as B-cell-specific activation protein (BSAP), which is essential for B cell 
commitment as well as for B cell development, and continuous expression of Pax5 is 
required throughout the B cell lineage to maintain the functional identity of B cells [169]. 
Pax5 is essential for many aspects of B lymphopoiesis including the initial commitment to 
the lineage, immunoglobulin rearrangement, pre-BCR signaling and maintaining cell 
identity in mature B cells [168, 170]. Importantly, Pax5 not only regulates B cell fate by 
concurrently activating the expression of B cell-specific genes, such as CD19, but also 
represses non-B cell lineages [167, 171-174]. In fact, dysregulated or reduced Pax5 activity 
has also been implicated in human disease, such as in CVID patients [172] and B-cell 
neoplasms [175].  
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Pax5 gene expression was significantly higher in RA patients in comparison with other 
early forms of arthritis. Importantly, this observation, together with the absence of 
differences in BAFF, BAFF-R and TACI expression in these patients in comparison to 
controls reinforces the specific role of B cells in RA progression when compared to other 
inflammatory joint diseases.  
Silencing of Pax5 gene by upregulation of B-lymphocyte-induced maturation protein-1 
(Blimp-1) is essential for terminal differentiation of B cells to plasma cells [176, 177]. In an 
animal model of SLE, a reduction in Pax5 gene expression with a simultaneous 
upregulation of Blimp-1 mRNA and IL-21 serum levels was shown [178], which is in 
accordance with previous observations of increased plasma cell frequencies in blood from 
SLE patients [25, 179, 180]. Nevertheless, the absence of differences in IL-21 serum levels 
in VERA patients in comparison to healthy controls supports the findings of normal 
absolute numbers and frequencies of circulating plasma cells in VERA patients. Indeed, 
since the concentration of IL-21 was only significantly elevated in RA SF and plasma cells 
are known to infiltrate RA synovial membrane [181], this cytokine should be inducing 
Blimp-1 upregulation and decreasing Pax5 gene expression locally in the joints, thus 
allowing the differentiation of plasma cells [99, 182].  
CXCR5, a receptor involved in B cell chemotaxis, is upregulated in RA synovium [183], 
suggesting a local role in B cell chemotaxis towards synovial membrane. The increased 
CXCR5 levels observed in established RA patients in comparison to controls and VERA 
patients reveals that this effect is stronger in later RA stages. Nevertheless, the expression 
of CXCR5 is not restricted to B cells. CD4+ T cells present in B cell follicles, named 
follicular helper T (TFH) cells, which have been established as a T cell subset specialized 
for providing help to B cells in GCs [184, 185] also express CXCR5 and migrate towards B 
cell follicles in response to a CXCL13 gradient [186-189]. Therefore, the hypothesis that 
the increased CXCR5 gene expression in established RA patients is due not only to B cells, 
but also to circulating TFH cells cannot be excluded.  
Interestingly, CD4+CXCR5+ T cells can be subdivided in Th1, Th2 and Th17 subsets in 
human blood and it has been recently demonstrated that both CXCR5+ Th2 and CXCR5+ 
Th17 cells, but not CXCR5+ Th1 cells, are able to help B cells in plasma cell differentiation 
and isotype-switching through the production of IL-10 and IL-21 [188-190]. These 
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observations also reinforce the proposed interaction between Th17 and B cells in RA 
pathogenesis.  
The expression of β2-microglobulin (β2m), a component of MHC class I molecules 
[191, 192], was also found to be significantly increased in VERA, ERA and EA patients. 
This observation indicates early immune system activation not only at RA onset, but also in 
other forms of arthritis. The immune system triggering since the first weeks of RA onset is 
supported by the increased serum and synovial fluid β2m levels that have been found in RA 
[78, 193].  
 
B cell depletion therapy and characterization of the 
newly emergent circulating B cell subpopulations during 
B cell reconstitution 
 
In the present work there was also the opportunity to study an established cohort of RA 
patients under B cell depletion therapy with RTX. The main advantages of analyzing 
patients that initiate RTX therapy rely on the concept that B cell depletion may restore the 
immune system, eliminate autoreactive B cell clones and reestablish tolerance. Therefore, it 
is extremely important to study and characterize the newly emergent circulating B cell 
subpopulations during B cell reconstitution, in order to better understand the pathogenic 
mechanisms that might be associated with B cells and thus explain their involvement in RA 
progression. Indeed, the relapse of disease activity following B cell depletion therapy is 
based on altered mechanisms that are quiescent during the absence of circulating B cells 
and, therefore, provides a unique opportunity to study the re-emergence of the disease 
process.  
A phenotypic characterization of peripheral blood B cell subpopulations was performed 
in established active RA patients before initiating RTX treatment (pre-RTX), in clinically 
relapsing RA patients either concordant for B cell repopulation (C-R), or discordant, with 
relapse more than three months after repopulation (D-R) and in RA patients who were in 
remission over three months after B cell repopulation (discordant non-relapsing (D-NR)). 
Similarly to previous studies [47, 48], during B cell repopulation and irrespective of clinical 
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relapse, the majority of circulating B cells had a naïve CD19+IgD+CD27- phenotype and, as 
expected, there was a lower frequency of memory CD27+ memory B cells in circulation. In 
particular, the frequencies of pre-switch memory CD19+IgD+CD27+ were decreased after 
RTX therapy in comparison to pre-RTX patients, which is consistent with a favourable 
clinical response to RTX treatment [30, 49].  
Interestingly, patients in remission (D-NR) had lower frequencies of post-switch 
memory IgD-CD27+ B cells in comparison with relapsing patients, thus suggesting that an 
activation of class-switch recombination process is related to the re-establishment of an 
active disease. Importantly, these results support previous studies that documented an 
association between lower circulating numbers of post-switch memory IgD-CD27+ B cells 
with a longer clinical response [47, 48]. These observations also reinforce the intervention 
of memory B cells in the development and pathogenesis of RA, thus supporting the need to 
achieve efficient memory B cell depletion during RTX treatment.  
Furthermore, considering the importance of BAFF for B cell survival and the previously 
discussed results observed in VERA patients, it was hypothesized that the balance between 
BAFF-R expression and soluble BAFF could influence the relationship between returning 
B-cell subpopulations and clinical relapse. Therefore, the mean fluorescence intensity 
(MFI) and surface BAFF-R expression were analyzed in circulating B cell subsets and 
serum BAFF levels were quantified in RA patients before and after RTX treatment.  
BAFF-R gene expression analysis in VERA, ERA and established RA patients revealed 
that the expression of this receptor significantly increased with disease progression in 
comparison to healthy controls. However, no differences could be observed in BAFF-R 
expression in the cohort of RA patients before RTX treatment when comparing with 
controls. The reasons that may account for these differences in the two independent 
established RA cohorts could rely on the different therapeutic agents that were administered 
to the patients. In fact, while the established RA patients enrolled in the BAFF-R gene 
expression study were under MTX therapy, the majority of the RA patients before initiating 
RTX treatment had failed anti-TNF therapies. Importantly, previous studies have 
demonstrated that a good clinical response to TNF antagonist therapy in patients with RA is 
associated with a significant decline in serum BAFF protein levels [77], although no 
correlation has been established with the expression of BAFF-receptors. Moreover, 
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treatment with TNF inhibitors induces phenotypical and functional alterations in peripheral 
B cells, such as an increase in CD20 expression [194]. Thus, the possibility that anti-TNF 
therapy alters surface expression of BAFF-receptors, namely BAFF-R, on B cells cannot be 
excluded.  
After RTX treatment, a decrease in BAFF-R expression (MFI and frequencies) in both 
naïve and memory B cells of relapsing patients (C-R and D-R) was found in comparison to 
healthy controls and pre-RTX patients, while no differences were detected in patients in 
remission (D-NR). Particularly, it was observed that memory B cells from relapsing 
patients tended to express lower levels of BAFF-R than naïve B cells. Indeed, it is known 
that BAFF-R is expressed on human B cells from the transitional stage onwards and is lost 
from memory B cells as they differentiate into Ig-secreting plasma cells [195]. 
Nevertheless, the reduction in BAFF-R expression after RTX treatment particularly on 
memory B cells was not due to an increase in circulating plasmablasts (data not shown), 
which are known to be associated with clinical relapse [29].  
BAFF serum levels were within normal range in pre-RTX patients and significantly 
increased after RTX treatment in all patients groups, as previously described [79], thus 
reflecting the loss of the majority of circulating B cells. Of note, chronically raised BAFF 
levels have been suggested to exert a negative feedback on BAFF-R expression [196]. 
However, no correlation was found between BAFF-R expression and BAFF serum levels 
within each group of patients. Therefore, the reduced BAFF-R expression must be related 
with disease re-establishment. Indeed, since BAFF-R expression in patients in remission 
(D-NR) was similar to those before starting RTX (pre-RTX), the signals required for 
BAFF-R downregulation must be closely linked to clinical relapse.  
It has been suggested that BAFF levels form a more accurate indicator of total B-cell 
mass [197]. This notion implies that serum BAFF levels are raised when there is a 
diminution in peripheral blood B cell subpopulations and return to normal values during B 
cell reconstitution. In fact, a decline in serum BAFF levels has been associated with the 
reemergence of B cells in peripheral blood [79]. It was demonstrated that BAFF levels fell 
more sharply in patients in whom clinical relapse was associated with B-cell return, than in 
those who relapsed months after B cell reconstitution [79]. It is interesting to speculate that, 
similarly to RTX treated RA patients who experience a transient B cell depletion, the 
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reduction observed in the circulating levels of pre-switch memory IgD+CD27+ B cell 
subpopulation in VERA patients could also support the increased BAFF serum levels 
observed in these patients.   
After B cell depletion therapy, newly generated B cells expand into an environment that 
has retained a variable number of resistant B cells, a mature T-cell compartment and long-
lived plasma cells. It has been demonstrated that transitional B cells exit the bone marrow 
already expressing BAFF-R, but their BAFF-R expression levels are lower than mature B 
cells [198], thus suggesting that further B cell maturation yields an increase in BAFF-R 
expression. Furthermore, evidence supporting the existence of a pre-activated state of 
immature B cells before they exit the bone marrow in RA patients [161] are consistent with 
the early impairment in B cell tolerance observed in RA patients [199].  
Altered thresholds for BCR signaling have also been described in RA and other 
autoimmune diseases that can contribute to the generation of autoreactive B cells [200-
202]. Interestingly, it has been previously demonstrated that BCR and BAFF signaling 
occur through independent mechanisms that can directly affect the development of 
autoimmunity [203]. In fact, in vitro studies have shown that the engagement of each 
BAFF-receptor (BAFF-R, TACI, or BCMA) blocked BCR-induced cell death in B cell 
lines [203]. Moreover, the relevance of IgM BCR-mediated signals for the induction of 
arthritis in CIA mouse models is supported not only by the high numbers of IgM-
expressing B cells and IgM-producing plasma cells that are present in arthritic joints, but 
also for the deficiency in RF production observed in IgM-/- mice [200]. Importantly, these 
observations reinforce the notion that most of the B cells that migrate into joints have not 
undergone class switching and, consequently, predominant CSR should be occuring locally 
in the joints during the inflammatory response, which is also consistent with the data 
observed in VERA patients.  
B cell stimulation through TLRs can also be a mechanism directly related with 
autoimmunity and eventually involved in clinical relapse. TLR9, which is constitutively 
expressed by B cells, recognizes unmethylated microbial CpG DNA, which, in turn, is 
similar to certain CpG DNA motifs within the mammalian genome [204-206]. 
Interestingly, hypomethylated genomic CpG DNA has been found in RA and SLE patients, 
supporting the involvement of TLR9 signaling and the development of autoimmunity [207-
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210]. Previous studies support that dual engagement of BCR and TLR9 may activate 
autoreactive B cells that recognize endogenous CpG DNA released from apoptotic cells and 
CpG DNA-IgG immune complexes in RA joints, and induce their development into RF-
producing B cells [38, 211-213]. Importantly, stimulation through TLRs, namely TLR9, is 
more efficient than T-dependent pathways at downregulating BAFF-R expression on 
memory B-cell populations [195, 214]. CpG DNA motifs have also been shown to amplify 
autoreactive IgG production by upregulating BAFF [215]. Therefore, it is possible that in 
relapsing patients B cells are stimulated by CpG DNA-immune complexes, released during 
B cell apoptosis that occurs due to B cell depletion therapy with RTX. This could affect the 
expression and triggering of other B cell receptors, such as BAFF-receptors or BCR.  
Future studies regarding the analysis of TLRs, the remaining BAFF-receptors (TACI 
and BCMA) and in vitro studies with BAFF/APRIL heterotrimers are interesting proposals 
to be addressed in patients undergoing B cell depletion therapy with RTX and their possible 
relationship with clinical relapse. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 167 
 
 
References 
1. Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells 
expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a 
general marker for somatically mutated (memory) B cells. J Exp Med 1998;188:1679-89. 
2. Agematsu K, Hokibara S, Nagumo H, Komiyama A. CD27: a memory B-cell marker. Immunol Today 
2000;21:204-6. 
3. McHeyzer-Williams LJ, Malherbe LP, McHeyzer-Williams MG. Checkpoints in memory B-cell 
evolution. Immunol Rev 2006;211:255-68. 
4. Bauer K, Zemlin M, Hummel M, Pfeiffer S, Karstaedt J, Steinhauser G, et al. Diversification of Ig 
heavy chain genes in human preterm neonates prematurely exposed to environmental antigens. J 
Immunol 2002;169:1349-56. 
5. Weller S, Braun MC, Tan BK, Rosenwald A, Cordier C, Conley ME, et al. Human blood IgM 
"memory" B cells are circulating splenic marginal zone B cells harboring a prediversified 
immunoglobulin repertoire. Blood 2004;104:3647-54. 
6. Weller S, Mamani-Matsuda M, Picard C, Cordier C, Lecoeuche D, Gauthier F, et al. Somatic 
diversification in the absence of antigen-driven responses is the hallmark of the IgM+ IgD+ CD27+ B 
cell repertoire in infants. J Exp Med 2008;205:1331-42. 
7. Tangye SG, Good KL. Human IgM+CD27+ B cells: memory B cells or "memory" B cells? J Immunol 
2007;179:13-9. 
8. Weller S, Faili A, Garcia C, Braun MC, Le Deist FF, de Saint Basile GG, et al. CD40-CD40L 
independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc 
Natl Acad Sci U S A 2001;98:1166-70. 
9. Lucas AH, Moulton KD, Tang VR, Reason DC. Combinatorial library cloning of human antibodies to 
Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence 
for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F. Infect Immun 
2001;69:853-64. 
10. Martin F, Kearney JF. Marginal-zone B cells. Nat Rev Immunol 2002;2:323-35. 
11. Shi Y, Agematsu K, Ochs HD, Sugane K. Functional analysis of human memory B-cell subpopulations: 
IgD+CD27+ B cells are crucial in secondary immune response by producing high affinity IgM. Clin 
Immunol 2003;108:128-37. 
12. Kruetzmann S, Rosado MM, Weber H, Germing U, Tournilhac O, Peter HH, et al. Human 
immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in 
the spleen. J Exp Med 2003;197:939-45. 
13. Di Sabatino A, Rosado MM, Ciccocioppo R, Cazzola P, Morera R, Corazza GR, et al. Depletion of 
immunoglobulin M memory B cells is associated with splenic hypofunction in inflammatory bowel 
disease. Am J Gastroenterol 2005;100:1788-95. 
14. Klein U, Kuppers R, Rajewsky K. Variable region gene analysis of B cell subsets derived from a 4-year-
old child: somatically mutated memory B cells accumulate in the peripheral blood already at young age. 
J Exp Med 1994;180:1383-93. 
15. Klein U, Kuppers R, Rajewsky K. Evidence for a large compartment of IgM-expressing memory B cells 
in humans. Blood 1997;89:1288-98. 
16. Liu YJ, de Bouteiller O, Arpin C, Briere F, Galibert L, Ho S, et al. Normal human IgD+IgM- germinal 
center B cells can express up to 80 mutations in the variable region of their IgD transcripts. Immunity 
1996;4:603-13. 
17. Arpin C, de Bouteiller O, Razanajaona D, Fugier-Vivier I, Briere F, Banchereau J, et al. The normal 
counterpart of IgD myeloma cells in germinal center displays extensively mutated IgVH gene, Cmu-
Cdelta switch, and lambda light chain expression. J Exp Med 1998;187:1169-78. 
18. Song H, Cerny J. Functional heterogeneity of marginal zone B cells revealed by their ability to generate 
both early antibody-forming cells and germinal centers with hypermutation and memory in response to a 
T-dependent antigen. J Exp Med 2003;198:1923-35. 
19. Liu YJ, Malisan F, de Bouteiller O, Guret C, Lebecque S, Banchereau J, et al. Within germinal centers, 
isotype switching of immunoglobulin genes occurs after the onset of somatic mutation. Immunity 
1996;4:241-50. 
 168 
 
 
20. White H, Gray D. Analysis of immunoglobulin (Ig) isotype diversity and IgM/D memory in the 
response to phenyl-oxazolone. J Exp Med 2000;191:2209-20. 
21. Tian C, Luskin GK, Dischert KM, Higginbotham JN, Shepherd BE, Crowe JE, Jr. Evidence for 
preferential Ig gene usage and differential TdT and exonuclease activities in human naive and memory 
B cells. Mol Immunol 2007;44:2173-83. 
22. Agematsu K, Nagumo H, Shinozaki K, Hokibara S, Yasui K, Terada K, et al. Absence of IgD-CD27(+) 
memory B cell population in X-linked hyper-IgM syndrome. J Clin Invest 1998;102:853-60. 
23. Attanavanich K, Kearney JF. Marginal zone, but not follicular B cells, are potent activators of naive 
CD4 T cells. J Immunol 2004;172:803-11. 
24. Mandik-Nayak L, Racz J, Sleckman BP, Allen PM. Autoreactive marginal zone B cells are 
spontaneously activated but lymph node B cells require T cell help. J Exp Med 2006;203:1985-98. 
25. Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, et al. Disturbed peripheral B 
lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000;165:5970-9. 
26. Bohnhorst JO, Thoen JE, Natvig JB, Thompson KM. Significantly depressed percentage of CD27+ 
(memory) B cells among peripheral blood B cells in patients with primary Sjogren's syndrome. Scand J 
Immunol 2001;54:421-7. 
27. Bohnhorst JO, Bjorgan MB, Thoen JE, Jonsson R, Natvig JB, Thompson KM. Abnormal B cell 
differentiation in primary Sjogren's syndrome results in a depressed percentage of circulating memory B 
cells and elevated levels of soluble CD27 that correlate with Serum IgG concentration. Clin Immunol 
2002;103:79-88. 
28. Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic 
sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 
2004;50:1918-27. 
29. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B 
cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006;54:2377-86. 
30. Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of 
response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008;58:1566-75. 
31. Agematsu K, Nagumo H, Yang FC, Nakazawa T, Fukushima K, Ito S, et al. B cell subpopulations 
separated by CD27 and crucial collaboration of CD27+ B cells and helper T cells in immunoglobulin 
production. Eur J Immunol 1997;27:2073-9. 
32. Jacquot S, Kobata T, Iwata S, Morimoto C, Schlossman SF. CD154/CD40 and CD70/CD27 interactions 
have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma 
cell differentiation by CD27 signaling. J Immunol 1997;159:2652-7. 
33. Agematsu K, Nagumo H, Oguchi Y, Nakazawa T, Fukushima K, Yasui K, et al. Generation of plasma 
cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27/CD70 
interaction. Blood 1998;91:173-80. 
34. Agematsu K, Hokibara S, Nagumo H, Shinozaki K, Yamada S, Komiyama A. Plasma cell generation 
from B-lymphocytes via CD27/CD70 interaction. Leuk Lymphoma 1999;35:219-25. 
35. Sze DM, Toellner KM, Garcia de Vinuesa C, Taylor DR, MacLennan IC. Intrinsic constraint on 
plasmablast growth and extrinsic limits of plasma cell survival. J Exp Med 2000;192:813-21. 
36. William J, Euler C, Christensen S, Shlomchik MJ. Evolution of autoantibody responses via somatic 
hypermutation outside of germinal centers. Science 2002;297:2066-70. 
37. Herlands RA, William J, Hershberg U, Shlomchik MJ. Anti-chromatin antibodies drive in vivo antigen-
specific activation and somatic hypermutation of rheumatoid factor B cells at extrafollicular sites. Eur J 
Immunol 2007;37:3339-51. 
38. Herlands RA, Christensen SR, Sweet RA, Hershberg U, Shlomchik MJ. T cell-independent and toll-like 
receptor-dependent antigen-driven activation of autoreactive B cells. Immunity 2008;29:249-60. 
39. Berek C, Berger A, Apel M. Maturation of the immune response in germinal centers. Cell 
1991;67:1121-9. 
40. Weisel F, Wellmann U, Winkler TH. Autoreactive B cells get activated in extrafollicular sites. Eur J 
Immunol 2007;37:3330-3. 
41. Kim HJ, Krenn V, Steinhauser G, Berek C. Plasma cell development in synovial germinal centers in 
patients with rheumatoid and reactive arthritis. J Immunol 1999;162:3053-62. 
42. Krenn V, Souto-Carneiro MM, Kim HJ, Berek C, Starostik P, Konig A, et al. Histopathology and 
molecular pathology of synovial B-lymphocytes in rheumatoid arthritis. Histol Histopathol 
2000;15:791-8. 
 169 
 
 
43. Souto-Carneiro MM, Mahadevan V, Takada K, Fritsch-Stork R, Nanki T, Brown M, et al. Alterations in 
peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action 
of tumour necrosis factor. Arthritis Res Ther 2009;11:R84. 
44. Gause A, Gundlach K, Carbon G, Daus H, Trumper L, Pfreundschuh M. Analysis of VH gene 
rearrangements from synovial B cells of patients with rheumatoid arthritis reveals infiltration of the 
synovial membrane by memory B cells. Rheumatol Int 1997;17:145-50. 
45. Bohm I. Decrease of B-cells and autoantibodies after low-dose methotrexate. Biomed Pharmacother 
2003;57:278-81. 
46. Fedor ME, Rubinstein A. Effects of long-term low-dose corticosteroid therapy on humoral immunity. 
Ann Allergy Asthma Immunol 2006;97:113-6. 
47. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells 
after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:613-20. 
48. Moller B, Aeberli D, Eggli S, Fuhrer M, Vajtai I, Vogelin E, et al. Class-switched B cells display 
response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis Res Ther 2009;11:R62. 
49. Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, et al. Rituximab 
therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with 
rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther 
2009;11:R131. 
50. Bleesing JJ, Souto-Carneiro MM, Savage WJ, Brown MR, Martinez C, Yavuz S, et al. Patients with 
chronic granulomatous disease have a reduced peripheral blood memory B cell compartment. J Immunol 
2006;176:7096-103. 
51. Nagase H, Agematsu K, Kitano K, Takamoto M, Okubo Y, Komiyama A, et al. Mechanism of 
hypergammaglobulinemia by HIV infection: circulating memory B-cell reduction with plasmacytosis. 
Clin Immunol 2001;100:250-9. 
52. Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, et al. Genome-
wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in 
ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008;40:204-10. 
53. Ding B, Padyukov L, Lundstrom E, Seielstad M, Plenge RM, Oksenberg JR, et al. Different patterns of 
associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-
negative rheumatoid arthritis in the extended major histocompatibility complex region. Arthritis Rheum 
2009;60:30-8. 
54. Gestermann N, Mekinian A, Comets E, Loiseau P, Puechal X, Hachulla E, et al. STAT4 is a confirmed 
genetic risk factor for Sjogren's syndrome and could be involved in type 1 interferon pathway signaling. 
Genes Immun 2010;11:432-8. 
55. Padyukov L, Seielstad M, Ong RT, Ding B, Ronnelid J, Seddighzadeh M, et al. A genome-wide 
association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid 
arthritis. Ann Rheum Dis 2011;70:259-65. 
56. Edwards JC, Leigh RD, Cambridge G. Expression of molecules involved in B lymphocyte survival and 
differentiation by synovial fibroblasts. Clin Exp Immunol 1997;108:407-14. 
57. Berek C, Kim HJ. B-cell activation and development within chronically inflamed synovium in 
rheumatoid and reactive arthritis. Semin Immunol 1997;9:261-8. 
58. Edwards JC, Cambridge G. Rheumatoid arthritis: the predictable effect of small immune complexes in 
which antibody is also antigen. Br J Rheumatol 1998;37:126-30. 
59. Fonseca JE, Edwards JC, Blades S, Goulding NJ. Macrophage subpopulations in rheumatoid synovium: 
reduced CD163 expression in CD4+ T lymphocyte-rich microenvironments. Arthritis Rheum 
2002;46:1210-6. 
60. Fonseca JE, Cortez-Dias N, Francisco A, Sobral M, Canhao H, Resende C, et al. Inflammatory cell 
infiltrate and RANKL/OPG expression in rheumatoid synovium: comparison with other inflammatory 
arthropathies and correlation with outcome. Clin Exp Rheumatol 2005;23:185-92. 
61. Mourao AF, Canhao H, Sousa E, Cascao R, da Costa JB, de Almeida LS, et al. From a neutrophilic 
synovial tissue infiltrate to a challenging case of rheumatoid arthritis. Acta Reumatol Port 2010;35:228-
31. 
62. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, et al. IL-17 stimulates 
the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human 
macrophages. J Immunol 1998;160:3513-21. 
 170 
 
 
63. Clavel C, Nogueira L, Laurent L, Iobagiu C, Vincent C, Sebbag M, et al. Induction of macrophage 
secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid 
arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum 
2008;58:678-88. 
64. Manzo A, Vitolo B, Humby F, Caporali R, Jarrossay D, Dell'accio F, et al. Mature antigen-experienced 
T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory 
environment of the rheumatoid joint. Arthritis Rheum 2008;58:3377-87. 
65. Weinmann P, Moura RA, Caetano-Lopes JR, Pereira PA, Canhao H, Queiroz MV, et al. Delayed 
neutrophil apoptosis in very early rheumatoid arthritis patients is abrogated by methotrexate therapy. 
Clin Exp Rheumatol 2007;25:885-7. 
66. Dominical VM, Bertolo MB, Almeida CB, Garrido VT, Miguel LI, Costa FF, et al. Neutrophils of 
Rheumatoid Arthritis Patients on Anti-TNF-alpha Therapy and in Disease Remission Present Reduced 
Adhesive Functions in Association with Decreased Circulating Neutrophil-Attractant Chemokine 
Levels. Scand J Immunol 2011;73:309-18. 
67. Scapini P, Carletto A, Nardelli B, Calzetti F, Roschke V, Merigo F, et al. Proinflammatory mediators 
elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated 
neutrophils: implications for inflammatory diseases. Blood 2005;105:830-7. 
68. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, et al. BAFF, a novel ligand of 
the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189:1747-56. 
69. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in 
patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44:1313-9. 
70. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, et al. B lymphocyte stimulator 
overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis 
Rheum 2003;48:3475-86. 
71. Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus 
erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. 
Lupus 2006;15:570-6. 
72. Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, et al. B cell 
depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator 
levels, autoantibody profile and clinical response. Ann Rheum Dis 2008;67:1011-6. 
73. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, et al. The level of BLyS (BAFF) correlates 
with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003;62:168-71. 
74. Gottenberg JE, Busson M, Cohen-Solal J, Lavie F, Abbed K, Kimberly RP, et al. Correlation of serum B 
lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement 
in primary Sjogren's syndrome. Ann Rheum Dis 2005;64:1050-5. 
75. Zhu XJ, Shi Y, Peng J, Guo CS, Shan NN, Qin P, et al. The effects of BAFF and BAFF-R-Fc fusion 
protein in immune thrombocytopenia. Blood 2009;114:5362-7. 
76. Bosello S, Youinou P, Daridon C, Tolusso B, Bendaoud B, Pietrapertosa D, et al. Concentrations of 
BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early 
rheumatoid arthritis. J Rheumatol 2008;35:1256-64. 
77. La DT, Collins CE, Yang HT, Migone TS, Stohl W. B lymphocyte stimulator expression in patients 
with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects 
between good and poor clinical responders. Ann Rheum Dis 2008;67:1132-8. 
78. Gottenberg JE, Miceli-Richard C, Ducot B, Goupille P, Combe B, Mariette X. Markers of B-
lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease 
activity in the ESPOIR cohort. Arthritis Res Ther 2009;11:R114. 
79. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B 
lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships 
with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006;54:723-32. 
80. Collins CE, Gavin AL, Migone TS, Hilbert DM, Nemazee D, Stohl W. B lymphocyte stimulator (BLyS) 
isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS 
mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 2006;8:R6. 
81. Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, et al. Local production of B 
lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. 
Arthritis Rheum 2003;48:982-92. 
 171 
 
 
82. Seyler TM, Park YW, Takemura S, Bram RJ, Kurtin PJ, Goronzy JJ, et al. BLyS and APRIL in 
rheumatoid arthritis. J Clin Invest 2005;115:3083-92. 
83. Holmdahl M, Vestberg M, Holmdahl R. Primed B cells present type-II collagen to T cells. Scand J 
Immunol 2002;55:382-9. 
84. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, Anderson KS, Butler MO, et al. 
Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of 
CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 
2002;99:3319-25. 
85. Blom AB, Radstake TR, Holthuysen AE, Sloetjes AW, Pesman GJ, Sweep FG, et al. Increased 
expression of Fcgamma receptors II and III on macrophages of rheumatoid arthritis patients results in 
higher production of tumor necrosis factor alpha and matrix metalloproteinase. Arthritis Rheum 
2003;48:1002-14. 
86. Iwahashi M, Yamamura M, Aita T, Okamoto A, Ueno A, Ogawa N, et al. Expression of Toll-like 
receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis. 
Arthritis Rheum 2004;50:1457-67. 
87. Sokolove J, Zhao X, Chandra PE, Robinson WH. Immune complexes containing citrullinated fibrinogen 
costimulate macrophages via Toll-like receptor 4 and Fcgamma receptor. Arthritis Rheum 2011;63:53-
62. 
88. Lee SM, Jeon ST, Suk K, Lee WH. Macrophages express membrane bound form of APRIL that can 
generate immunomodulatory signals. Immunology 2010;131:350-6. 
89. Lee SM, Kim WJ, Suk K, Lee WH. Cell to Cell Interaction Can Activate Membrane-bound APRIL 
Which Are Expressed on Inflammatory Macrophages. Immune Netw 2010;10:173-80. 
90. Mohr E, Serre K, Manz RA, Cunningham AF, Khan M, Hardie DL, et al. Dendritic cells and 
monocyte/macrophages that create the IL-6/APRIL-rich lymph node microenvironments where 
plasmablasts mature. J Immunol 2009;182:2113-23. 
91. Nagatani K, Itoh K, Nakajima K, Kuroki H, Katsuragawa Y, Mochizuki M, et al. Rheumatoid arthritis 
fibroblast-like synoviocytes express BCMA and are stimulated by APRIL. Arthritis Rheum 
2007;56:3554-63. 
92. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, et al. DCs induce CD40-independent 
immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002;3:822-9. 
93. Castigli E, Scott S, Dedeoglu F, Bryce P, Jabara H, Bhan AK, et al. Impaired IgA class switching in 
APRIL-deficient mice. Proc Natl Acad Sci U S A 2004;101:3903-8. 
94. Castigli E, Wilson SA, Scott S, Dedeoglu F, Xu S, Lam KP, et al. TACI and BAFF-R mediate isotype 
switching in B cells. J Exp Med 2005;201:35-9. 
95. Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C, et al. APRIL is critical for 
plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. 
Blood 2008;111:2755-64. 
96. Bossen C, Cachero TG, Tardivel A, Ingold K, Willen L, Dobles M, et al. TACI, unlike BAFF-R, is 
solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and 
plasmablasts. Blood 2008;111:1004-12. 
97. Dong W, Li X, Liu H, Zhu P. Infiltrations of plasma cells in synovium are highly associated with 
synovial fluid levels of APRIL in inflamed peripheral joints of rheumatoid arthritis. Rheumatol Int 
2009;29:801-6. 
98. Gabay C, Krenn V, Bosshard C, Seemayer CA, Chizzolini C, Huard B. Synovial tissues concentrate 
secreted APRIL. Arthritis Res Ther 2009;11:R144. 
99. Ettinger R, Sims GP, Fairhurst AM, Robbins R, da Silva YS, Spolski R, et al. IL-21 induces 
differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol 
2005;175:7867-79. 
100. Dong W, Li X, Feng Y, Fan C, Chen Z, Zhu P. The differential expressions of 78-kDa glucose-regulated 
protein of infiltrating plasma cells in peripheral joints with the histopathological variants of rheumatoid 
synovitis. Arthritis Res Ther 2009;11:R4. 
101. Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops H, et al. Role of Th17 cells in 
human autoimmune arthritis. Arthritis Rheum 2010;62:2876-85. 
102. van Hamburg JP, Asmawidjaja PS, Davelaar N, Mus AM, Colin EM, Hazes JM, et al. Th17 cells, but 
not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix 
 172 
 
 
metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including 
autocrine interleukin-17A production. Arthritis Rheum 2011;63:73-83. 
103. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, et al. Human interleukin-17: A T cell-
derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999;42:963-
70. 
104. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids 
from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 
1999;103:1345-52. 
105. Shahrara S, Huang Q, Mandelin AM, 2nd, Pope RM. TH-17 cells in rheumatoid arthritis. Arthritis Res 
Ther 2008;10:R93. 
106. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, et al. Synovial membrane 
cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year 
prospective study (the DAMAGE study cohort). Arthritis Rheum 2006;54:1122-31. 
107. Zhou L, Ivanov, II, Spolski R, Min R, Shenderov K, Egawa T, et al. IL-6 programs T(H)-17 cell 
differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 
2007;8:967-74. 
108. Koenders MI, Devesa I, Marijnissen RJ, Abdollahi-Roodsaz S, Boots AM, Walgreen B, et al. 
Interleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin-1 receptor 
antagonist-deficient mice. Arthritis Rheum 2008;58:3461-70. 
109. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, et al. Interleukin 
(IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial 
peptides. J Exp Med 2006;203:2271-9. 
110. Pene J, Chevalier S, Preisser L, Venereau E, Guilleux MH, Ghannam S, et al. Chronically inflamed 
human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 2008;180:7423-30. 
111. Pelletier M, Maggi L, Micheletti A, Lazzeri E, Tamassia N, Costantini C, et al. Evidence for a cross-talk 
between human neutrophils and Th17 cells. Blood 2010;115:335-43. 
112. Parsonage G, Filer A, Bik M, Hardie D, Lax S, Howlett K, et al. Prolonged, granulocyte-macrophage 
colony-stimulating factor-dependent, neutrophil survival following rheumatoid synovial fibroblast 
activation by IL-17 and TNFalpha. Arthritis Res Ther 2008;10:R47. 
113. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, et al. T cell interleukin-17 
induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 
1996;183:2593-603. 
114. Chabaud M, Lubberts E, Joosten L, van Den Berg W, Miossec P. IL-17 derived from juxta-articular 
bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001;3:168-77. 
115. Cai L, Yin JP, Starovasnik MA, Hogue DA, Hillan KJ, Mort JS, et al. Pathways by which interleukin 17 
induces articular cartilage breakdown in vitro and in vivo. Cytokine 2001;16:10-21. 
116. Yago T, Nanke Y, Ichikawa N, Kobashigawa T, Mogi M, Kamatani N, et al. IL-17 induces 
osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently 
inhibited by anti-TNF-alpha antibody: a novel mechanism of osteoclastogenesis by IL-17. J Cell 
Biochem 2009;108:947-55. 
117. Pollinger B, Junt T, Metzler B, Walker UA, Tyndall A, Allard C, et al. Th17 cells, not IL-
17+(gamma)(delta) T cells, drive arthritic bone destruction in mice and humans. J Immunol 
2011;186:2602-12. 
118. Vinuesa CG, Tangye SG, Moser B, Mackay CR. Follicular B helper T cells in antibody responses and 
autoimmunity. Nat Rev Immunol 2005;5:853-65. 
119. Salzer U, Grimbacher B. Common variable immunodeficiency: The power of co-stimulation. Semin 
Immunol 2006;18:337-46. 
120. Hickman-Brecks CL, Racz JL, Meyer DM, Labranche TP, Allen PM. Th17 cells can provide B cell help 
in autoantibody induced arthritis. J Autoimmun 2010. 
121. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in 
synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. 
Arthritis Rheum 1988;31:784-8. 
122. Fonseca JE, Santos MJ, Canhao H, Choy E. Interleukin-6 as a key player in systemic inflammation and 
joint destruction. Autoimmun Rev 2009;8:538-42. 
123. Leonard WJ, Spolski R. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and 
differentiation. Nat Rev Immunol 2005;5:688-98. 
 173 
 
 
124. Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, et al. IL-21 initiates an alternative pathway 
to induce proinflammatory T(H)17 cells. Nature 2007;448:484-7. 
125. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, et al. Essential autocrine regulation 
by IL-21 in the generation of inflammatory T cells. Nature 2007;448:480-3. 
126. Niu X, He D, Zhang X, Yue T, Li N, Zhang JZ, et al. IL-21 regulates Th17 cells in rheumatoid arthritis. 
Hum Immunol 2010;71:334-41. 
127. Takagi R, Higashi T, Hashimoto K, Nakano K, Mizuno Y, Okazaki Y, et al. B cell chemoattractant 
CXCL13 is preferentially expressed by human Th17 cell clones. J Immunol 2008;181:186-9. 
128. Rosengren S, Wei N, Kalunian KC, Kavanaugh A, Boyle DL. CXCL13: a novel biomarker of B-cell 
return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology 
(Oxford) 2011;50:603-10. 
129. Meeuwisse CM, van der Linden MP, Rullmann TA, Allaart CF, Nelissen R, Huizinga TW, et al. 
Identification of CXCL13 as marker for outcome of rheumatoid arthritis using an in silico model of the 
rheumatic joint. Arthritis Rheum 2011. 
130. Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, Mircetic V, et al. Atacicept in patients with 
rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-
escalating, single- and repeated-dose study. Arthritis Rheum 2008;58:61-72. 
131. Nestorov I, Munafo A, Papasouliotis O, Visich J. Pharmacokinetics and biological activity of atacicept 
in patients with rheumatoid arthritis. J Clin Pharmacol 2008;48:406-17. 
132. Ding C. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory 
autoimmune diseases. Expert Opin Biol Ther 2008;8:1805-14. 
133. Bracewell C, Isaacs JD, Emery P, Ng WF. Atacicept, a novel B cell-targeting biological therapy for the 
treatment of rheumatoid arthritis. Expert Opin Biol Ther 2009;9:909-19. 
134. Daridon C, Burmester GR, Dorner T. Anticytokine therapy impacting on B cells in autoimmune 
diseases. Curr Opin Rheumatol 2009;21:205-10. 
135. Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, et al. B-lymphocyte stimulator/a 
proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease 
and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther 
2010;12:R48. 
136. Roll P, Muhammad K, Schumann M, Kleinert S, Einsele H, Dorner T, et al. In vivo effect of the anti 
interleukin-6 receptor inhibitor tocilizumab on the B-cell compartment. Arthritis Rheum 2011. 
137. Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, et al. In rheumatoid 
arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 
24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline. Mod Rheumatol 
2011. 
138. Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, et al. LY2439821, a 
humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid 
arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis 
Rheum 2010;62:929-39. 
139. Bovin LF, Rieneck K, Workman C, Nielsen H, Sorensen SF, Skjodt H, et al. Blood cell gene expression 
profiling in rheumatoid arthritis. Discriminative genes and effect of rheumatoid factor. Immunol Lett 
2004;93:217-26. 
140. Batliwalla FM, Baechler EC, Xiao X, Li W, Balasubramanian S, Khalili H, et al. Peripheral blood gene 
expression profiling in rheumatoid arthritis. Genes Immun 2005;6:388-97. 
141. Edwards CJ, Feldman JL, Beech J, Shields KM, Stover JA, Trepicchio WL, et al. Molecular profile of 
peripheral blood mononuclear cells from patients with rheumatoid arthritis. Mol Med 2007;13:40-58. 
142. Toonen EJ, Barrera P, Radstake TR, van Riel PL, Scheffer H, Franke B, et al. Gene expression profiling 
in rheumatoid arthritis: current concepts and future directions. Ann Rheum Dis 2008;67:1663-9. 
143. Olsen N, Sokka T, Seehorn CL, Kraft B, Maas K, Moore J, et al. A gene expression signature for recent 
onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann Rheum Dis 2004;63:1387-92. 
144. Szodoray P, Alex P, Frank MB, Turner M, Turner S, Knowlton N, et al. A genome-scale assessment of 
peripheral blood B-cell molecular homeostasis in patients with rheumatoid arthritis. Rheumatology 
(Oxford) 2006;45:1466-76. 
145. Soto H, Hevezi P, Roth RB, Pahuja A, Alleva D, Acosta HM, et al. Gene array analysis comparison 
between rat collagen-induced arthritis and human rheumatoid arthritis. Scand J Immunol 2008;68:43-57. 
 174 
 
 
146. Shulga-Morskaya S, Dobles M, Walsh ME, Ng LG, MacKay F, Rao SP, et al. B cell-activating factor 
belonging to the TNF family acts through separate receptors to support B cell survival and T cell-
independent antibody formation. J Immunol 2004;173:2331-41. 
147. Avery DT, Kalled SL, Ellyard JI, Ambrose C, Bixler SA, Thien M, et al. BAFF selectively enhances the 
survival of plasmablasts generated from human memory B cells. J Clin Invest 2003;112:286-97. 
148. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, et al. Mice transgenic for 
BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 
1999;190:1697-710. 
149. Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, et al. BAFF mediates survival of 
peripheral immature B lymphocytes. J Exp Med 2000;192:1453-66. 
150. Rolink AG, Tschopp J, Schneider P, Melchers F. BAFF is a survival and maturation factor for mouse B 
cells. Eur J Immunol 2002;32:2004-10. 
151. Castigli E, Wilson SA, Elkhal A, Ozcan E, Garibyan L, Geha RS. Transmembrane activator and calcium 
modulator and cyclophilin ligand interactor enhances CD40-driven plasma cell differentiation. J Allergy 
Clin Immunol 2007;120:885-91. 
152. von Bulow GU, van Deursen JM, Bram RJ. Regulation of the T-independent humoral response by 
TACI. Immunity 2001;14:573-82. 
153. Ozcan E, Garibyan L, Lee JJ, Bram RJ, Lam KP, Geha RS. Transmembrane activator, calcium 
modulator, and cyclophilin ligand interactor drives plasma cell differentiation in LPS-activated B cells. J 
Allergy Clin Immunol 2009;123:1277-86 e5. 
154. Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, Grewal IS. Loss of TACI causes fatal 
lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 
2003;18:279-88. 
155. Yan M, Wang H, Chan B, Roose-Girma M, Erickson S, Baker T, et al. Activation and accumulation of 
B cells in TACI-deficient mice. Nat Immunol 2001;2:638-43. 
156. Salzer U, Chapel HM, Webster AD, Pan-Hammarstrom Q, Schmitt-Graeff A, Schlesier M, et al. 
Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in 
humans. Nat Genet 2005;37:820-8. 
157. Castigli E, Wilson SA, Garibyan L, Rachid R, Bonilla F, Schneider L, et al. TACI is mutant in common 
variable immunodeficiency and IgA deficiency. Nat Genet 2005;37:829-34. 
158. Groom JR, Fletcher CA, Walters SN, Grey ST, Watt SV, Sweet MJ, et al. BAFF and MyD88 signals 
promote a lupuslike disease independent of T cells. J Exp Med 2007;204:1959-71. 
159. Katsenelson N, Kanswal S, Puig M, Mostowski H, Verthelyi D, Akkoyunlu M. Synthetic CpG 
oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion. Eur J Immunol 
2007;37:1785-95. 
160. Treml LS, Carlesso G, Hoek KL, Stadanlick JE, Kambayashi T, Bram RJ, et al. TLR stimulation 
modifies BLyS receptor expression in follicular and marginal zone B cells. J Immunol 2007;178:7531-9. 
161. Rudnicka W, Burakowski T, Warnawin E, Jastrzebska M, Bik M, Kontny E, et al. Functional TLR9 
modulates bone marrow B cells from rheumatoid arthritis patients. Eur J Immunol 2009;39:1211-20. 
162. Batten M, Fletcher C, Ng LG, Groom J, Wheway J, Laabi Y, et al. TNF deficiency fails to protect BAFF 
transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 
2004;172:812-22. 
163. Nakajima K, Itoh K, Nagatani K, Okawa-Takatsuji M, Fujii T, Kuroki H, et al. Expression of BAFF and 
BAFF-R in the synovial tissue of patients with rheumatoid arthritis. Scand J Rheumatol 2007;36:365-72. 
164. Hymowitz SG, Patel DR, Wallweber HJ, Runyon S, Yan M, Yin J, et al. Structures of APRIL-receptor 
complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand 
binding. J Biol Chem 2005;280:7218-27. 
165. Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, et al. BLyS and APRIL form 
biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic 
diseases. J Immunol 2002;169:4314-21. 
166. Badr G, Borhis G, Lefevre EA, Chaoul N, Deshayes F, Dessirier V, et al. BAFF enhances chemotaxis of 
primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells. Blood 
2008;111:2744-54. 
167. Nutt SL, Heavey B, Rolink AG, Busslinger M. Commitment to the B-lymphoid lineage depends on the 
transcription factor Pax5. Nature 1999;401:556-62. 
 175 
 
 
168. Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and function. 
Nat Immunol 2007;8:463-70. 
169. Wakatsuki Y, Neurath MF, Max EE, Strober W. The B cell-specific transcription factor BSAP regulates 
B cell proliferation. J Exp Med 1994;179:1099-108. 
170. Holmes ML, Pridans C, Nutt SL. The regulation of the B-cell gene expression programme by Pax5. 
Immunol Cell Biol 2008;86:47-53. 
171. Kozmik Z, Wang S, Dorfler P, Adams B, Busslinger M. The promoter of the CD19 gene is a target for 
the B-cell-specific transcription factor BSAP. Mol Cell Biol 1992;12:2662-72. 
172. Kaneko H, Ariyasu T, Inoue R, Fukao T, Kasahara K, Teramoto T, et al. Expression of Pax5 gene in 
human haematopoietic cells and tissues: comparison with immunodeficient donors. Clin Exp Immunol 
1998;111:339-44. 
173. Souabni A, Cobaleda C, Schebesta M, Busslinger M. Pax5 promotes B lymphopoiesis and blocks T cell 
development by repressing Notch1. Immunity 2002;17:781-93. 
174. Cotta CV, Zhang Z, Kim HG, Klug CA. Pax5 determines B- versus T-cell fate and does not block early 
myeloid-lineage development. Blood 2003;101:4342-6. 
175. Desouki MM, Post GR, Cherry D, Lazarchick J. PAX-5: a valuable immunohistochemical marker in the 
differential diagnosis of lymphoid neoplasms. Clin Med Res 2010;8:84-8. 
176. Lin KI, Angelin-Duclos C, Kuo TC, Calame K. Blimp-1-dependent repression of Pax-5 is required for 
differentiation of B cells to immunoglobulin M-secreting plasma cells. Mol Cell Biol 2002;22:4771-80. 
177. Shapiro-Shelef M, Lin KI, McHeyzer-Williams LJ, Liao J, McHeyzer-Williams MG, Calame K. Blimp-
1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B 
cells. Immunity 2003;19:607-20. 
178. Ozaki K, Spolski R, Ettinger R, Kim HP, Wang G, Qi CF, et al. Regulation of B cell differentiation and 
plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol 2004;173:5361-71. 
179. Jacobi AM, Odendahl M, Reiter K, Bruns A, Burmester GR, Radbruch A, et al. Correlation between 
circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. 
Arthritis Rheum 2003;48:1332-42. 
180. Jacobi AM, Mei H, Hoyer BF, Mumtaz IM, Thiele K, Radbruch A, et al. HLA-DRhigh/CD27high 
plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann Rheum Dis 
2010;69:305-8. 
181. Scheel T, Gursche A, Zacher J, Haupl T, Berek C. V-region gene analysis of locally defined synovial B 
and plasma cells reveals selected B cell expansion and accumulation of plasma cell clones in rheumatoid 
arthritis. Arthritis Rheum 2011;63:63-72. 
182. Kwon H, Thierry-Mieg D, Thierry-Mieg J, Kim HP, Oh J, Tunyaplin C, et al. Analysis of interleukin-
21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription 
factors. Immunity 2009;31:941-52. 
183. Schmutz C, Hulme A, Burman A, Salmon M, Ashton B, Buckley C, et al. Chemokine receptors in the 
rheumatoid synovium: upregulation of CXCR5. Arthritis Res Ther 2005;7:R217-29. 
184. King C, Tangye SG, Mackay CR. T follicular helper (TFH) cells in normal and dysregulated immune 
responses. Annu Rev Immunol 2008;26:741-66. 
185. Fazilleau N, Mark L, McHeyzer-Williams LJ, McHeyzer-Williams MG. Follicular helper T cells: 
lineage and location. Immunity 2009;30:324-35. 
186. Breitfeld D, Ohl L, Kremmer E, Ellwart J, Sallusto F, Lipp M, et al. Follicular B helper T cells express 
CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp 
Med 2000;192:1545-52. 
187. Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B. CXC chemokine receptor 5 
expression defines follicular homing T cells with B cell helper function. J Exp Med 2000;192:1553-62. 
188. Kim CH, Rott LS, Clark-Lewis I, Campbell DJ, Wu L, Butcher EC. Subspecialization of CXCR5+ T 
cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells. J Exp Med 
2001;193:1373-81. 
189. Morita R, Schmitt N, Bentebibel SE, Ranganathan R, Bourdery L, Zurawski G, et al. Human blood 
CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that 
differentially support antibody secretion. Immunity 2011;34:108-21. 
190. Good KL, Bryant VL, Tangye SG. Kinetics of human B cell behavior and amplification of proliferative 
responses following stimulation with IL-21. J Immunol 2006;177:5236-47. 
191. Bernier GM. beta 2-Microglobulin: structure, function and significance. Vox Sang 1980;38:323-7. 
 176 
 
 
192. Cresswell P, Ackerman AL, Giodini A, Peaper DR, Wearsch PA. Mechanisms of MHC class I-restricted 
antigen processing and cross-presentation. Immunol Rev 2005;207:145-57. 
193. Duquesnoy B, Asfour M, Santoro F, Vandemeulebroucke B, Hochart JP, Delcambre B. Beta2 
microglobulin, antibeta2 microglobulin activity and circulating immune complexes in rheumatoid 
arthritis. Serum and synovial study. Rev Rhum Mal Osteoartic 1980;47:481-7. 
194. Karampetsou MP, Andonopoulos AP, Liossis SN. Treatment with TNFalpha blockers induces 
phenotypical and functional aberrations in peripheral B cells. Clin Immunol 2011. 
195. Darce JR, Arendt BK, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during 
human B cell differentiation. J Immunol 2007;179:7276-86. 
196. Sellam J, Miceli-Richard C, Gottenberg JE, Ittah M, Lavie F, Lacabaratz C, et al. Decreased B cell 
activating factor receptor expression on peripheral lymphocytes associated with increased disease 
activity in primary Sjogren's syndrome and systemic lupus erythematosus. Ann Rheum Dis 2007;66:790-
7. 
197. Leandro MJ, de la Torre I. Translational Mini-Review Series on B Cell-Directed Therapies: The 
pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-
depletion therapy. Clin Exp Immunol 2009;157:191-7. 
198. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of 
circulating human transitional B cells. Blood 2005;105:4390-8. 
199. Samuels J, Ng YS, Coupillaud C, Paget D, Meffre E. Impaired early B cell tolerance in patients with 
rheumatoid arthritis. J Exp Med 2005;201:1659-67. 
200. Zheng B, Zhang X, Guo L, Han S. IgM plays an important role in induction of collagen-induced 
arthritis. Clin Exp Immunol 2007;149:579-85. 
201. Kubo T, Uchida Y, Watanabe Y, Abe M, Nakamura A, Ono M, et al. Augmented TLR9-induced Btk 
activation in PIR-B-deficient B-1 cells provokes excessive autoantibody production and autoimmunity. 
J Exp Med 2009;206:1971-82. 
202. Guo L, Tian J, Guo Z, Zheng B, Han S. The absence of immunoglobulin D B cell receptor-mediated 
signals promotes the production of autoantibodies and exacerbates glomerulonephritis in murine lupus. 
Clin Exp Immunol 2011. 
203. Craxton A, Draves KE, Gruppi A, Clark EA. BAFF regulates B cell survival by downregulating the 
BH3-only family member Bim via the ERK pathway. J Exp Med 2005;202:1363-74. 
204. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709-60. 
205. Krieg AM. A role for Toll in autoimmunity. Nat Immunol 2002;3:423-4. 
206. Vinuesa CG, Goodnow CC. Immunology: DNA drives autoimmunity. Nature 2002;416:595-8. 
207. Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M. Evidence for impaired T cell 
DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 
1990;33:1665-73. 
208. Nile CJ, Read RC, Akil M, Duff GW, Wilson AG. Methylation status of a single CpG site in the IL6 
promoter is related to IL6 messenger RNA levels and rheumatoid arthritis. Arthritis Rheum 
2008;58:2686-93. 
209. Liu CC, Fang TJ, Ou TT, Wu CC, Li RN, Lin YC, et al. Global DNA methylation, DNMT1, and MBD2 
in patients with rheumatoid arthritis. Immunol Lett 2011;135:96-9. 
210. Liu CC, Ou TT, Wu CC, Li RN, Lin YC, Lin CH, et al. Global DNA methylation, DNMT1, and MBD2 
in patients with systemic lupus erythematosus. Lupus 2011;20:131-6. 
211. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. 
Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 
2002;416:603-7. 
212. Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of 
autoreactive B cells by CpG dsDNA. Immunity 2003;19:837-47. 
213. He B, Qiao X, Cerutti A. CpG DNA induces IgG class switch DNA recombination by activating human 
B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol 
2004;173:4479-91. 
214. Darce JR, Arendt BK, Chang SK, Jelinek DF. Divergent effects of BAFF on human memory B cell 
differentiation into Ig-secreting cells. J Immunol 2007;178:5612-22. 
215. Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-
dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp 
Med 2004;199:1631-40. 
  
 
 
 
 
HAPTER V 
Conclusions 
 
 
 
 
 
 
 
 
 178 
 
 
 179 
 
 
ONCLUSIONS 
 
The study of B cells since the first weeks of RA onset supports an early intervention of 
these cells in RA progression and has revealed that: 1) disturbances occur in peripheral B 
cell subpopulations consistent with the migration of memory B cells towards synovial 
membrane, where the main inflammatory process develops; 2) cytokines related with B cell 
recruitment, activation and survival are increased in circulation in VERA patients and 
reinforce the important interaction of B cells with other cellular components of the immune 
system, such as Th17 cells; 3) early short-term treatment with corticosteroids or MTX leads 
to clinical improvement, but does not seem to have an impact on either circulating B cell 
subpopulations, or in the cytokine pattern of VERA patients; 4) a gene expression profile 
supporting B cell maturation, activation and survival is displayed in the first weeks of RA 
onset, particularly in comparison with other forms of arthritis.  
 
In conclusion, the results of this study suggest that an earlier introduction of B-cell 
directed therapies, such as B cell depletion (anti-CD19, anti-CD22) or indirect B-cell 
targeted therapies affecting B cell receptors or its ligands (such as atacicept or belimumab), 
might be of beneficial clinical use to induce early remission. Furthermore, studies 
concerning chronic RA patients under B cell depletion therapy with RTX suggest that 
class-switch recombination process and alterations in the expression of BAFF-receptors are 
associated with clinical relapse. These observations are extremely important and need to be 
addressed in further investigations to better understand the exact role of B cells in RA 
development and disease re-establishment, particularly during relapse. 
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Alterations on peripheral blood B-cell
subpopulations in very early arthritis patients
Rita A. Moura1, Pamela Weinmann1, Patrı´cia A. Pereira1, Joana Caetano-Lopes1,
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Ma´rio V. Queiroz1,2, Maria M. Souto-Carneiro4, Luı´s Grac¸a5,6 and
Joa˜o E. Fonseca1,2
Abstract
Objective. To characterize circulating B-cell subpopulations of arthritis patients with <6 weeks of disease
duration.
Methods. Peripheral blood samples were collected from very early untreated polyarthritis patients, with
<6 weeks of disease duration, for flow cytometric evaluation of B-cell subpopulations. Samples from
patients who were later diagnosed as RA [very early RA (VERA)] were also collected 4–6 weeks after
starting a low dose of prednisone (5–10 mg) and 4 months after reaching the minimum effective dose of
MTX. A matched healthy group was used as a control.
Results. VERA patients have a lower percentage of total peripheral blood memory B cells (CD19+CD27+)
and a significant decrease in the frequency of circulating pre-switch memory B cells (CD19+IgD+CD27+) as
compared with controls. Therapy with corticosteroids or MTX was unable to restore the normal frequen-
cies of these B-cell subpopulations. A significant decrease in peripheral pre-switch memory B cells is
equally observed in other early arthritis patients. Furthermore, no significant differences are found in the
frequencies of CD4+ and CD8+ T cells in all patient groups.
Conclusions. In very early polyarthritis patients, there is a reduction in circulating pre-switch memory
B cells. The reasons that may account for this effect are still unknown. Short-term corticosteroids and
MTX do not seem to have a direct effect on circulating B-cell subpopulations in VERA patients.
Key words: Rheumatoid arthritis, B cells, Corticosteroids, Methotrexate, Autoimmunity.
Introduction
RA is a chronic, systemic autoimmune disease of
unknown aetiology affecting 1% of the world population.
RA is characterized by symmetric polyarthritis associated
with pain and swelling in multiple joints that, if left
untreated, ultimately leads to joint destruction [1].
The very early inflammatory reaction that occurs in the
rheumatoid synovium is mainly constituted by neutrophils
[2, 3]. However, this first inflammatory infiltrate quickly
leads to increased expression of inflammatory cytokines,
chemokines and adhesion molecules, inducing the recruit-
ment of B cells, T cells and macrophages [4–6]. In fact, it is
this secondary cell infiltrate that supports the persistence
of the inflammatory response and mediates cartilage and
bone destruction. Although RA has long been considered
as a T-cell-centred disorder, recent evidence suggests
that B cells do play an important role in the onset and
perpetuation of this disease [7]. B cells function both as
IL-producing cells and antigen presenting cells that acti-
vate T cells [8, 9] and are also responsible for the
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production of autoantibodies [10–12], such as RF. RF can
interact with FcgRIIIa (CD16) receptors on monocytes and
macrophages inducing the production of TNF [13].
Moreover, B-cell depletion therapy with rituximab, a mAb
directed to CD20, have confirmed the importance of these
cells in established RA [14]. Several studies have shown
that following B-cell depletion in patients with RA, there is
clinical and serological improvement that parallels with a
decrease in RF levels [15]. Despite the evidence for a crit-
ical role of B cells in established RA, the knowledge on the
participation of these cells in the early phase of the disease
is still scarce. In addition, the effect of commonly used
DMARDs, such as MTX, on B cells is also largely unknown.
The major goal of this study is to characterize circulat-
ing B-cell subpopulations in very early RA (VERA) and in
other very early arthritis (VEA) patients when compared
with healthy donors, and also to evaluate whether corti-
costeroids and MTX therapies have an impact on the
frequencies of these cell subsets.
Materials and methods
Patients
Blood samples were obtained from 46 untreated polyar-
thritis patients (Rheumatology Department, Hospital
de Santa Maria, Lisbon) with <6 weeks of disease dura-
tion. Twenty-two of these patients later on fulfilled the
ACR criteria for RA [16]. These patients were classified
as VERA patients and further samples were collected at
4–6 weeks after starting a low dose of oral prednisone (5–
10 mg) (Time 1) and 4 months after reaching the minimum
effective dose of MTX, up to a maximum of 20 mg/week,
which was needed to reduce the 28-joint disease activity
score (DAS28) to <3.2 (Time 2) [17]. The baseline blood
samples from VERA patients were compared with 24 VEA
patients and 29 healthy donors who were used as con-
trols. The HAQ [18] was applied to all patients and the
DAS28 was calculated in all patients who fulfilled the
ACR criteria for RA. The local ethics committee
(Comissa˜o de E´tica do Hospital de Santa Maria) approved
the study and all patients signed an informed consent.
Patient’s management was done in accordance with the
standard practice and the study was conducted in accor-
dance with the Declaration of Helsinki as amended in
Edinburgh (2000).
Antibodies
Immunophenotyping of B and T cells in peripheral blood
and peripheral blood mononuclear cells (PBMC) samples
was performed using matched combinations of
anti-human murine mAbs conjugated to FITC, phycoery-
thrin (PE), peridinin chlorophyll protein (PerCP) or allophy-
cocyanin (APC). Isotype control antibodies were used for
each fluorophore. For B-cell analysis, combinations of
anti-CD19 conjugated to PerCP (clone 4G7, BD
Biosciences, San Jose, CA, USA) or APC (HIB19,
eBioscience, San Jose, CA, USA), anti-IgD conjugated
to FITC or PE (IA6-2, BD Biosciences) and anti-CD27 con-
jugated to PE or APC (O323, eBioscience) were used.
T cells were identified with anti-CD3 PerCP (SK7, BD
Biosciences), anti-CD4 FITC (MEM-241, Immunotools,
Friesoythe, Germany) and anti-CD8 APC (MEM-31,
Immunotools).
Whole-blood staining
Approximately 5 ml of whole blood was collected by
venipuncture into tubes containing ethylenediamine tetra-
acetic acid. Erythrocytes were lysed with FACS Lysing
Solution (BD Biosciences) and cells were stained, incu-
bated for 20 min at 4C, washed and stored in the dark
at 4C until analysed by flow cytometry. Frozen PBMC
samples of patients were also used for staining protocol
in order to establish the reproducibility of flow cytometry
data from fresh and frozen samples. A total of 200 000
cells/sample were acquired with a FACSCalibur (BD
Biosciences). Data were analysed with FlowJo (TreeStar,
Stanford University, CA, USA). Absolute cell counts were
calculated from differential leucocyte count determined at
each time point for all patients.
PBMC isolation
PBMCs were isolated from 20 ml of heparinized whole
blood following density gradient centrifugation with
Percoll (Amersham, Stockholm, Sweden). Cellular viability
was estimated with Trypan Blue (Sigma, St. Louis, USA).
Cells were frozen in 1 ml/107 cells RPMI-1640 (Invitrogen,
Paisley, UK), 40% fetal calf serum (Invitrogen), 10%
dimethyl-sulphoxide (Sigma) and stored at 80C until
further use.
Measurement of autoantibodies
RFs (IgM, IgG and IgA) and anti-cyclic citrullinated peptide
(anti-CCP) were determined at baseline in all patients and
also at Times 1 and 2 for VERA patients. IgM-RF, IgG-RF
and IgA-RF were measured in the serum by IMTEC
Autoimmune Diagnostics ELISA test system kits (Human
GmbH, Wiesbaden, Germany) according to the manufac-
turer’s instructions and samples were processed using a
ChemWell 2910 automated analyser. Serum levels of
anti-CCP were measured by ELIA CCP test system
(Phadia GmbH, Freiburg, Germany) and samples were
analysed using an ImmunoCAP 100 instrument.
Statistical analysis
Statistical differences were determined using one-way
analysis of variance and Bonferroni’s multiple comparison
tests using GraphPad Prism (GraphPad, San Diego, CA,
USA). For populations that did not follow Gaussian distri-
bution, the Kruskal–Wallis non-parametric test was used.
Differences were considered statistically significant for
P< 0.05.
Results
Disease assessment and autoantibody production
A total of 46 polyarthritis patients with <6 weeks of dis-
ease duration were evaluated. Twenty-two patients,
www.rheumatology.oxfordjournals.org 1083
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18 females and 4 males, with a mean age of 46.9 (16.3)
years (range 23–77 years) fulfilled the ACR criteria for
RA later on and were classified as VERA patients. At base-
line, 10 of the VERA patients were RF positive, 6 of whom
had anti-CCP antibodies (analysis performed up to
6 weeks after onset). All the RF-negative patients simulta-
neously lacked anti-CCP antibodies. A quantitative analy-
sis of the production of RF and anti-CCP was also
performed (Table 1). Patients with detectable levels for
RF were positive for both IgM- and IgG-RF. Only two of
the patients were positive for IgA-RF (data not shown).
Interestingly, although not statistically significant, the
mean levels of IgG-RF and anti-CCP decreased with ther-
apy (Table 1). After therapy with corticosteroids and MTX,
a clinical response associated with the decrease in DAS28
score (P= 0.0019 and P= 0.0068, respectively) could be
observed. In the remaining group of 24 other VEA sub-
jects, 16 females and 8 males, with a mean age of 44.8
(18.5) years (range 19–87 years), patients were later clas-
sified as having SLE (4), crystal-induced arthritis (3), PsA
(2), colon adenocarcinoma (1), multiple myeloma (1), PMR
(1), arthritis associated with HIV infection (1), arthritis
associated with Crohn’s disease (1), unremitting undiffer-
entiated arthritis (2), unremitting ReA (2) and 6 patients
entered spontaneously into remission before 3 months
of follow-up, remaining without a specific diagnosis and
were thus classified as a self-limited form of arthritis. For
this study, 29 healthy controls, 22 females and 7 males,
with a mean age of 39.8 (13.6) years (range 22–63 years)
were also analysed.
VERA patients have a reduced memory B-cell
subpopulation irrespective of therapy
The main B-cell memory subsets were analysed, depend-
ing on their IgD and CD27 expression, being classified
as pre-switch memory B cells (IgD+CD27+) and post-
switch memory B cells (IgDCD27+). The frequencies
of total peripheral blood B cells (CD19+), naı¨ve B
cells (CD19+IgD+CD27), pre-switch memory B cells
(CD19+IgD+CD27+), post-switch memory B cells
(CD19+IgDCD27+), total memory B cells (CD19+CD27+)
and plasma cells (CD19+CD27high) from VERA patients
were compared with the same populations of healthy
donors (Fig. 1). The frequency of total B cells at baseline
was similar between VERA patients and healthy controls,
being the average of circulating B cells gated in total lym-
phocytes of 11.69% (6.85) and 11.37% (5.69), respec-
tively (Fig. 2A). Furthermore, corticosteroids and MTX
did not affect the frequency of total B cells. Also, the
analysis of absolute cell numbers of total B cells con-
firmed this result (Fig. 2A). Naı¨ve B cells were significantly
higher in VERA patients without treatment when com-
pared with controls (Fig. 2B) and their percentages
tended to return to normal values after corticosteroid
and MTX treatment, although this effect was not statisti-
cally significant. In addition, the analysis of absolute cell
counts of this B-cell subpopulation did not show any sta-
tistically significant difference between groups (Fig. 2B).
Both controls and VERA patients had comparably very
low levels (<3%) of circulating plasma cells (Fig. 2C).
VERA patients had significantly lower frequencies of
pre-switch memory B cells when compared with controls
(Fig. 3A), irrespective of therapy. Importantly, this obser-
vation was also confirmed by a decrease in the absolute
numbers of this B-cell subpopulation (Fig. 3B). In contrast,
no statistically significant differences were observed in
post-switch memory B cells between VERA patients and
controls (Fig. 3C). A lower percentage of total memory B
cells was observed in untreated VERA patients as com-
pared with controls (Fig. 3D) and no effect after MTX treat-
ment was observed. Furthermore, no correlation was
found between the age of the patients and the percent-
ages or absolute cell numbers of pre-switch and total
memory B cells (data not shown). No correlation was
found between DAS28 and the percentages or absolute
cell numbers of pre-switch and total memory B cells at all
time points (data not shown). Moreover, in order to verify
whether an association existed between peripheral B-cell
abnormalities, particularly in the memory B-cell pool, with
the presence or absence of autoantibodies in the serum,
circulating B-cell subsets were analysed at baseline com-
paring seronegative and seropositive VERA patients both
for RF (IgM and IgG) and anti-CCP, but no statistically
significant differences were observed (data not shown).
We also investigated differences between VERA
patients and controls in circulating T cells, namely total
TABLE 1 Characteristics of VERA patients and other VEA patients
VERA (n=22)
Clinical parameter Baseline Visit 1 Visit 2 VEA (n=24)
DAS28 6.083 (1.629) 4.268 (1.568)* 3.079 (1.659)* NA
HAQ 1.335 (0.730) 0.900 (0.687) 0.808 (0.746) 0.908 (0.651)
IgM-RF, U/ml 26.8 (9.2) 28.3 (13.8) 19.6 (4.5) 0
IgG-RF, U/ml 356.3 (375.9) 333.1 (240.9) 175.7 (207.9) 0
Anti-CCP, U/ml 111.9 (115.6) 101.1 (60.7) 51.4 (20.6) 0
Leucocyte counts (109/l) 7.452 (2.432) 7.727 (2.531) 6.789 (2.226) 6.955 (2.155)
Baseline: before any treatment; Visit 1: after 4–6 weeks with 5–10 mg prednisone; Visit 2: 4 months after reaching the minimum
effective dose of MTX. *Differences are considered statistically significant for P< 0.05. All values indicated represent the mean
(S.D.). NA: not applicable.
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(CD3+), CD4+ and CD8+ T cells, and whether corticoster-
oids and MTX could have some effect on these popula-
tions. In VERA patients, no significant differences were
found in the frequencies of CD4+ and CD8+ T cells as
compared with controls, or after treatment (data not
shown).
Although 22 VERA patients were selected for this study,
5 patients were lost to follow-up, technical problems
occurred with the processing of the samples in 4 patients
and 3 patients missed one of the appointments. Thus, the
number of patients considered at each time point (n) is
indicated together with the appropriate data in all the
figures.
VEA patients have a diminished pre-switch memory
B-cell subset at baseline
Other very early polyarthritis patients evaluated with
<6 weeks of disease duration, who later were diagnosed
as having types of arthritis other than RA, were followed in
this study for comparison with VERA patients. VEA
patients did not show any statistically significant differ-
ence in both frequencies and absolute numbers of total
B cells (Fig. 4A), naı¨ve B cells (Fig. 4B) or plasma cells
(Fig. 4C) when compared with controls. However, similar
to what was observed in VERA patients, VEA patients had
a significantly (P< 0.05) lower frequency of pre-switch
and total memory B cells as compared with controls
(Fig. 5). Interestingly, the frequency of pre-switch
memory B cells was similar in both VEA and VERA
patients without treatment, being the average of 6.94%
(4.64) and 5.33% (3.82), respectively (Fig. 5A). The analy-
sis of absolute numbers of pre-switch memory B cells in
the peripheral blood of VEA patients confirmed a statisti-
cally significant reduction in this B-cell subpopulation (Fig.
5B). No other statistically significant results were obtained
with post-switch memory B cells (Fig. 5C), or with CD4+
and CD8+ T cells (data not shown). The subanalysis of the
six patients who entered spontaneously into remission
depicted the same pattern. As noted for VERA patients,
no correlation was found between the age of VEA patients
and the percentages or absolute cell numbers of
pre-switch and total memory B cells (data not shown).
Discussion
Several studies have documented the presence of B cells
in the rheumatoid synovium [5, 19–23] and reinforced the
importance of these cells in RA progression. However,
little is known about peripheral blood B-cell subpopula-
tions and their functions in the very early phase of the
disease.
Our results demonstrate, for the first time, that VERA
patients have a lower pre-switch memory
(CD19+IgD+CD27+) B-cell subset as compared with con-
trols and that treatment with corticosteroids and MTX
does not affect this B-cell subpopulation. However, this
difference does not appear to be specific of VERA
patients, since other early arthritis patients with the
same disease duration show a similar pattern. As a con-
sequence, the reduction of pre-switch memory B cells
seems to be an early manifestation of polyarthritis.
It has been demonstrated that adult circulating B cells
can be separated into three subpopulations on the basis
of CD27 and IgD expression: IgD+CD27 naı¨ve B cells,
IgD+CD27+ and IgDCD27+ memory B cells [24–26].
Klein et al. [27] have also described that IgM+IgD+CD27+
B cells carried somatically hypermutated antibodies,
which indicates that this population is in fact a memory
B-cell subset. However, the functional differences and
characteristics between the two memory B-cell subpopu-
lations remain to be clearly elucidated. In a study per-
formed by Shi et al. [28], data were obtained that helped
to clarify the differences between memory B-cell subsets.
FIG. 1 B-cell analysis by flow cytometry. A region (gate) was defined around total lymphocytes in peripheral blood,
depending upon cell size (forward scatter) and granularity (side scatter). Total B cells were identified based on the
expression of the cell surface marker CD19, and its subpopulations were classified according to IgD and CD27
expression in healthy controls (A) and patients (B). Thus, naı¨ve B cells (I) were classified as CD19+IgD+CD27; pre-switch
memory B cells (II) as CD19+IgD+CD27+; post-switch memory B cells (III) as CD19+IgDCD27+; and plasma cells (IV) as
CD19+IgDCD27high.
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FIG. 2 Therapy with corticosteroids and MTX does not affect circulating total B cells, naı¨ve B cells or plasma cells of
VERA patients. Data from flow cytometry analysis of peripheral blood B cells from VERA patients without treatment and
after therapy with corticosteroids and MTX. Total B cells (CD19+) (A) were gated on total lymphocytes and represented
are the frequencies and absolute cell numbers. Naı¨ve B cells (CD19+IgD+CD27) (B) and plasma cells (CD19+CD27high)
(C) were gated in CD19+ B cells. Differences are considered statistically significant for P< 0.05.
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In fact, it was demonstrated that IgD+CD27+ are
unclass-switched memory B cells that play a crucial role
in secondary immune response by producing high-affinity
IgM in the early phase of infections and IgDCD27+ are
class-switched memory B cells that mainly express sur-
face IgG and IgA isotypes. These findings were reinforced
by the discovery that activation-induced cytidine
deaminase, which is essential for class-switch recombi-
nation process [29, 30], was spontaneously expressed in
IgDCD27+ B cells, but was not found in IgD+CD27+
memory B cells [28].
CD27 is now an important marker for analysis of B-cell
differentiation in diseases characterized by disturbances
in B-cell development. In fact, distinct types of abnormal
FIG. 3 VERA patients have reduced frequencies and absolute numbers of pre-switch memory B cells. Data from flow
cytometry analysis of memory B cells from VERA patients without treatment and after therapy with corticosteroids and
MTX. All subpopulations were gated in CD19+ B cells. Representation of pre-switch memory B cells (CD19+IgD+CD27+)
frequencies (A) and absolute numbers (B). Post-switch memory B cells (CD19+IgDCD27+) (C) and total memory B cells
(CD19+CD27+) (D) frequencies are represented. Differences are considered statistically significant for P< 0.05.
www.rheumatology.oxfordjournals.org 1087
B-cell subpopulations in very early arthritis patients
B-cell homeostasis have been documented in some auto-
immune diseases and other immunodeficiency disorders.
Of interest, previous reports had already mentioned a
decrease in IgD+CD27+ memory B-cell subset in patients
with SLE [31], primary SS [32–34] or SSc [35]. Also, a
reduction in circulating memory B cells was demonstrated
in patients with X-linked Hyper-IgM syndrome [36],
chronic granulomatous disease [37] and HIV infection
[38]. Hence, lower levels of circulating memory B cells
seem to be hallmark linked with chronic inflammation
rather than an exclusive feature of autoimmune condi-
tions. Furthermore, in a study performed by Hansen et
al. [39], it was shown that the generation of the peripheral
B-cell memory subset in SS patients seems to be partic-
ularly affected by abnormalities in post-recombination
events. Our observations suggest that changes in the
B-cell memory subset also occur in very early stages of
RA and other polyarthritis. In VERA patients, despite the
FIG. 4 Early arthritis patients do not have any significant difference in circulating total B cells, naı¨ve B cells or plasma
cells when compared with healthy controls. Data from flow cytometry analysis of peripheral blood B cells from other early
arthritis patients at baseline. Total B cells (CD19+) (A) were gated on total lymphocytes and represented are the fre-
quencies and absolute cell numbers. Naı¨ve B cells (CD19+IgD+CD27) (B) and plasma cells (CD19+CD27high) (C) were
gated in CD19+ B cells. Differences are considered statistically significant for P< 0.05.
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clinical response induced by corticosteroids and MTX, no
effect of these treatments was reflected in changes of
IgD+CD27+ memory B-cell levels.
Since B cells differentiate into memory or plasma cells
[26], the reduced frequency of circulating memory B cells
in both VERA patients and other early arthritis patients
could be explained by a skewing towards plasma cell dif-
ferentiation, or by an increase in naı¨ve B-cell population,
thus resulting in less memory B cells. However, in our
study, we did not find any statistically significant differ-
ence in the frequencies of circulating plasma cells when
comparing both VERA and VEA patients with controls,
although we might not exclude the possibility of this
B-cell subpopulation being increased in the bone
marrow, where it mainly resides [40], or in the rheumatoid
synovium. Disturbances in the naı¨ve B-cell subpopulation
have been observed in other autoimmune conditions
associated simultaneously with a decrease in circulating
memory B cells. In fact, SS [34, 41] and SSc [35] patients
have a predominance of CD27 naı¨ve B cells and a
reduced frequency of CD27+ memory B cells in
circulation. In our study, VERA patients had an increased
naı¨ve B-cell subpopulation observed at baseline as com-
pared with controls, returning this B-cell subset to normal
values upon corticosteroids and MTX therapy.
Nevertheless, this effect was not statistically significant.
Moreover, there was not a statistically significant differ-
ence between absolute cell counts of this B-cell subpopu-
lation in VERA patients as compared with controls.
Also, similar results were observed in VEA patients when
analysing naı¨ve B cells. Considering our results, we
hypothesize that during the initial phase of arthritis, circu-
lating pre-switch memory B cells are recruited to the
synovial membrane, where the production of high-affinity
IgM is induced, which can react with antigens (self and
non-self, depending if it is an autoimmune condition or
not) and lead to inflammation. Importantly, it has been
demonstrated that in established RA patients there is an
accumulation of both pre-switch IgD+CD27+ and
post-switch IgDCD27+ memory B cells in the synovial
membrane, which supports our hypothesis [42].
Furthermore, there is also the possibility that in the initial
FIG. 5 Early arthritis patients have reduced frequencies and absolute numbers of pre-switch memory B cells. Data from
flow cytometry analysis of memory B cells from other early arthritis patients at baseline. All subpopulations were gated in
CD19+ B cells. Representation of pre-switch memory B cells (CD19+IgD+CD27+) frequencies (A) and absolute numbers
(B). Post-switch memory B cells (CD19+IgDCD27+) (C) and total memory B cells (CD19+CD27+) (D) frequencies are
represented. Differences are considered statistically significant for P< 0.05.
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phase of arthritis, pre-switch memory B cells are recruited
towards secondary lymphoid organs, where they conse-
quently become activated, thus leading to a decrease in
the circulating pool.
In addition, corticosteroids and MTX did not affect the
levels of the other B-cell subpopulations in circulation, or
CD4+ or CD8+ T-cell frequencies. Corticosteroids are fre-
quently administered to RA patients and their use can
cause redistribution of lymphocyte populations [43],
since long-term, low-dose corticosteroid therapy induces
a decrease in B-cell counts [44]. However, our results indi-
cate that short-term low doses of corticosteroids do not
appear to affect B-cell counts. On the other hand, the
effect of MTX on circulating blood cells in autoimmune
conditions is controversial [45–47]. In a study performed
by Bohm [48], it was observed that SLE patients treated
with short-term MTX had slightly increased levels of total
CD3+, CD4+ and CD8+ T cells, whereas monocytes and
B cells remained stable. However, long-term MTX treat-
ment decreased absolute numbers of both B and T cells.
Moreover, a decrease in autoantibody levels accom-
panied the B-cell response to long-term MTX.
Nevertheless, several studies by Lacki and co-workers
[49–52] state that there are no significant differences in
the percentage of CD3+, CD4+ and CD8+ T cells in RA
patients treated with long-term MTX, although a decrease
in B-cell levels is observed. Our results seem to indicate
that T- and B-cell subsets are not affected by short-term
treatment with MTX in the VERA patients.
Conclusions
In summary, in the first few weeks of arthritis onset there
seems to be an alteration in the frequency of circulating
memory B cells, particularly pre-switch memory B cells,
as compared with controls. In addition, the short-term use
of corticosteroids and MTX does not seem to affect cir-
culating B-cell subpopulations in the VERA patients.
However, since other early arthritis patients, who did not
fulfil the ACR criteria for RA, also had a decrease in
pre-switch memory B cells before any treatment was
started, it seems that this effect is not unique and specific
to the initial phase of RA. Further studies are required for a
better understanding of the biological meaning of the
reduction in the memory B-cell pool in an early arthritis
condition.
Rheumatology key messages
. In very early polyarthritis patients, there is a reduc-
tion in pre-switch memory B cells.
. Short-term therapy with corticosteroids and MTX
does not affect circulating B-cell subpopulations.
Acknowledgements
The authors would like to acknowledge Joa˜o Cavaleiro
and Ana Margarida Nery for technical assistance and
Peter Lipsky for helpful discussions.
Funding: This work was supported by a grant from
Sociedade Portuguesa de Reumatologia/Schering-
Plough 2005. R.A.M. was funded by Fundac¸a˜o para a
Cieˆncia e Tecnologia (FCT) SFRH/BD/30247/2006, and
M.M.S.-C. by Marie Curie Intra-European Fellowship
LIF-025885 and a EULAR Young Investigator Award.
Disclosure statement: The authors have declared no con-
flicts of interest.
References
1 Sweeney SE, Firestein GS. Rheumatoid arthritis: regula-
tion of synovial inflammation. Int J Biochem Cell Biol 2004;
36:372–8.
2 Assi LK, Wong SH, Ludwig A et al. Tumor necrosis factor
alpha activates release of B lymphocyte stimulator by
neutrophils infiltrating the rheumatoid joint. Arthritis
Rheum 2007;56:1776–86.
3 Laragione T, Brenner M, Yarlett NC et al. The arthritis
severity quantitative trait locus Cia7 regulates neutrophil
migration into inflammatory sites. Genes Immun 2007;8:
147–53.
4 Fonseca JE, Edwards JC, Blades S, Goulding NJ.
Macrophage subpopulations in rheumatoid synovium:
reduced CD163 expression in CD4+ T lymphocyte-rich
microenvironments. Arthritis Rheum 2002;46:1210–6.
5 Fonseca JE, Cortez-Dias N, Francisco A et al.
Inflammatory cell infiltrate and RANKL/OPG expression in
rheumatoid synovium: comparison with other inflamma-
tory arthropathies and correlation with outcome. Clin Exp
Rheumatol 2005;23:185–92.
6 Szekanecz Z, Koch AE. Macrophages and their products
in rheumatoid arthritis. Curr Opin Rheumatol 2007;19:
289–95.
7 Chaiamnuay S, Bridges SL Jr. The role of B cells and
autoantibodies in rheumatoid arthritis. Pathophysiology
2005;12:203–16.
8 Takemura S, Klimiuk PA, Braun A, Goronzy JJ,
Weyand CM. T cell activation in rheumatoid synovium is
B cell dependent. J Immunol 2001;167:4710–8.
9 Silverman GJ, Carson DA. Roles of B cells in rheumatoid
arthritis. Arthritis Res Ther 2003;5(Suppl. 4):S1–6.
10 Reparon-Schuijt CC, van Esch WJ, van Kooten C et al.
Secretion of anti-citrulline-containing peptide antibody by
B lymphocytes in rheumatoid arthritis. Arthritis Rheum
2001;44:41–7.
11 van Esch WJ, Reparon-Schuijt CC, Hamstra HJ et al.
Polyreactivity of human IgG Fc-binding phage antibodies
constructed from synovial fluid CD38+ B cells of patients
with rheumatoid arthritis. J Autoimmun 2002;19:241–50.
12 Bridges SL. Update on autoantibodies in rheumatoid
arthritis. Curr Rheumatol Rep 2004;6:343–50.
13 Mathsson L, Lampa J, Mullazehi M, Ronnelid J. Immune
complexes from rheumatoid arthritis synovial fluid induce
FcgammaRIIa dependent and rheumatoid factor corre-
lated production of tumour necrosis factor-alpha by
peripheral blood mononuclear cells. Arthritis Res Ther
2006;8:R64.
14 Edwards JC, Cambridge G. B-cell targeting in rheumatoid
arthritis and other autoimmune diseases. Nat Rev
Immunol 2006;6:394–403.
1090 www.rheumatology.oxfordjournals.org
Rita A. Moura et al.
15 Cambridge G, Leandro MJ, Edwards JC et al.
Serologic changes following B lymphocyte depletion
therapy for rheumatoid arthritis. Arthritis Rheum 2003;48:
2146–54.
16 Arnett FC, Edworthy SM, Bloch DA et al. The American
Rheumatism Association 1987 revised criteria for the
classification of rheumatoid arthritis. Arthritis Rheum 1988;
31:315–24.
17 Fries JF, Spitz P, Kraines RG, Holman HR. Measurement
of patient outcome in arthritis. Arthritis Rheum 1980;23:
137–45.
18 Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA,
van de Putte LB, van Riel PL. Modified disease activity
scores that include twenty-eight-joint counts.
Development and validation in a prospective longitudinal
study of patients with rheumatoid arthritis. Arthritis Rheum
1995;38:44–8.
19 Gause A, Gundlach K, Zdichavsky M et al. The B lym-
phocyte in rheumatoid arthritis: analysis of rearranged V
kappa genes from B cells infiltrating the synovial mem-
brane. Eur J Immunol 1995;25:2775–82.
20 Schroder AE, Greiner A, Seyfert C, Berek C. Differentiation
of B cells in the nonlymphoid tissue of the synovial
membrane of patients with rheumatoid arthritis. Proc Natl
Acad Sci USA 1996;93:221–5.
21 Berek C, Kim HJ. B-cell activation and development within
chronically inflamed synovium in rheumatoid and reactive
arthritis. Semin Immunol 1997;9:261–8.
22 Takemura S, Braun A, Crowson C et al. Lymphoid neo-
genesis in rheumatoid synovitis. J Immunol 2001;167:
1072–80.
23 Mauri C, Ehrenstein MR. Cells of the synovium in rheu-
matoid arthritis. B cells. Arthritis Res Ther 2007;9:205.
24 Maurer D, Holter W, Majdic O, Fischer GF, Knapp W.
CD27 expression by a distinct subpopulation of human
B lymphocytes. Eur J Immunol 1990;20:2679–84.
25 Agematsu K, Nagumo H, Yang FC et al. B cell subpopu-
lations separated by CD27 and crucial collaboration of
CD27+ B cells and helper T cells in immunoglobulin
production. Eur J Immunol 1997;27:2073–9.
26 Agematsu K, Hokibara S, Nagumo H, Komiyama A.
CD27: a memory B-cell marker. Immunol Today 2000;21:
204–6.
27 Klein U, Rajewsky K, Kuppers R. Human immunoglobulin
(Ig)M+IgD+ peripheral blood B cells expressing the
CD27 cell surface antigen carry somatically mutated vari-
able region genes: CD27 as a general marker for somati-
cally mutated (memory) B cells. J Exp Med 1998;188:
1679–89.
28 Shi Y, Agematsu K, Ochs HD, Sugane K. Functional ana-
lysis of human memory B-cell subpopulations:
IgD+CD27+ B cells are crucial in secondary immune
response by producing high affinity IgM. Clin Immunol
2003;108:128–37.
29 Muramatsu M, Kinoshita K, Fagarasan S, Yamada S,
Shinkai Y, Honjo T. Class switch recombination and
hypermutation require activation-induced cytidine deami-
nase (AID), a potential RNA editing enzyme. Cell 2000;102:
553–63.
30 Okazaki IM, Kinoshita K, Muramatsu M, Yoshikawa K,
Honjo T. The AID enzyme induces class switch recombi-
nation in fibroblasts. Nature 2002;416:340–5.
31 Odendahl M, Jacobi A, Hansen A et al. Disturbed periph-
eral B lymphocyte homeostasis in systemic lupus erythe-
matosus. J Immunol 2000;165:5970–9.
32 Bohnhorst JO, Thoen JE, Natvig JB, Thompson KM.
Significantly depressed percentage of CD27+ (memory)
B cells among peripheral blood B cells in patients with
primary Sjogren’s syndrome. Scand J Immunol 2001;54:
421–7.
33 Bohnhorst JO, Bjorgan MB, Thoen JE, Jonsson R,
Natvig JB, Thompson KM. Abnormal B cell differentiation
in primary Sjogren’s syndrome results in a depressed
percentage of circulating memory B cells and elevated
levels of soluble CD27 that correlate with Serum IgG
concentration. Clin Immunol 2002;103:79–88.
34 Hansen A, Odendahl M, Reiter K et al. Diminished
peripheral blood memory B cells and accumulation of
memory B cells in the salivary glands of patients with
Sjogren’s syndrome. Arthritis Rheum 2002;46:2160–71.
35 Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered
blood B lymphocyte homeostasis in systemic sclerosis:
expanded naive B cells and diminished but activated
memory B cells. Arthritis Rheum 2004;50:1918–27.
36 Agematsu K, Nagumo H, Shinozaki K et al. Absence of
IgD-CD27(+) memory B cell population in X-linked
hyper-IgM syndrome. J Clin Invest 1998;102:853–60.
37 Bleesing JJ, Souto-Carneiro MM, Savage WJ et al.
Patients with chronic granulomatous disease have a
reduced peripheral blood memory B cell compartment.
J Immunol 2006;176:7096–103.
38 Nagase H, Agematsu K, Kitano K et al. Mechanism of
hypergammaglobulinemia by HIV infection: circulating
memory B-cell reduction with plasmacytosis. Clin
Immunol 2001;100:250–9.
39 Hansen A, Gosemann M, Pruss A et al. Abnormalities in
peripheral B cell memory of patients with primary
Sjogren’s syndrome. Arthritis Rheum 2004;50:1897–908.
40 Arce S, Luger E, Muehlinghaus G et al. CD38 low
IgG-secreting cells are precursors of various CD38
high-expressing plasma cell populations. J Leukoc Biol
2004;75:1022–8.
41 Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB,
Thompson KM. Bm1-Bm5 classification of peripheral
blood B cells reveals circulating germinal center founder
cells in healthy individuals and disturbance in the B cell
subpopulations in patients with primary Sjogren’s syn-
drome. J Immunol 2001;167:3610–8.
42 Souto-Carneiro MM, Mahadevan V, Takada K et al.
Alterations in peripheral blood memory B cells in patients
with active rheumatoid arthritis are dependent on the
action of tumour necrosis factor. Arthritis Res Ther 2009;
11:R84.
43 Laan RF, Jansen TL, van Riel PL. Glucocorticosteroids in
the management of rheumatoid arthritis. Rheumatology
1999;38:6–12.
44 Fedor ME, Rubinstein A. Effects of long-term low-dose
corticosteroid therapy on humoral immunity. Ann Allergy
Asthma Immunol 2006;97:113–6.
45 Olsen NJ, Callahan LF, Pincus T. Immunologic studies of
rheumatoid arthritis patients treated with methotrexate.
Arthritis Rheum 1987;30:481–8.
46 Olsen NJ, Murray LM. Antiproliferative effects of metho-
trexate on peripheral blood mononuclear cells. Arthritis
Rheum 1989;32:378–85.
www.rheumatology.oxfordjournals.org 1091
B-cell subpopulations in very early arthritis patients
47 Cronstein BN. Molecular therapeutics. Methotrexate and
its mechanism of action. Arthritis Rheum 1996;39:
1951–60.
48 Bohm I. Decrease of B-cells and autoantibodies after low-
dose methotrexate. Biomed Pharmacother 2003;57:278–81.
49 Lacki JK, Mackiewicz SH, Wiktorowicz KE. Lymphocyte
phenotype studies of rheumatoid arthritis patients treated
with methotrexate. Arch Immunol Ther Exp 1994;42:
287–90.
50 Lacki JK, Schochat T, Sobieska M et al. Immunological
studies in patients with rheumatoid arthritis treated with
methotrexate or cyclophosphamide. Z Rheumatol 1994;
53:76–82.
51 Lacki JK, Mackiewicz SH. [The effect of immunosup-
pressive drugs on expression of surface antigens of
lymphocytes in patients with rheumatoid arthritis]. Pol
Arch Med Wewn 1997;97:134–43.
52 Lacki JK, Korczowska I, Mackiewicz SH. Quantitative
changes in peripheral blood lymphocytes in erosive RA
patients treated with methotrexate. Correlation with
disease activity. J Investig Allergol Clin Immunol 1999;9:
96–100.
1092 www.rheumatology.oxfordjournals.org
Rita A. Moura et al.
 
Concise report
Cytokine pattern in very early rheumatoid arthritis
favours B-cell activation and survival
Rita A. Moura1,*, Rita Casca˜o1,*, Ineˆs Perpe´tuo1, Helena Canha˜o1,2,
Elsa Vieira-Sousa1,2, Ana F. Moura˜o1,3, Ana M. Rodrigues1,2,
Joaquim Polido-Pereira1,2, Ma´rio V. Queiroz2, Henrique S. Rosa´rio4,
Maria M. Souto-Carneiro5, Luis Graca6,7 and Joa˜o E. Fonseca1,2
Abstract
Objectives. B cells play an important role in the perpetuation of RA, particularly as autoantibody-
producing cells. The ICs that further develop deposit in the joints and aggravate the inflammatory process.
However, B-cell contribution in the very early stage of the disease remains unknown. The main goal of this
work was to determine the concentration of cytokines potentially relevant for B-cell activation in serum
from very early polyarthritis patients, with <6 weeks of disease duration, who latter on evolved into very
early RA (VERA).
Methods. A proliferation-inducing ligand (APRIL), B-cell activating factor (BAFF) and IL-21 levels were
measured by ELISA in the serum of VERA, other very early arthritis (VEA), established RA patients and
controls. SF samples of established RA were also analysed.
Results. VERA patients have higher levels of APRIL and BAFF as compared with VEA, established RA and
controls. Furthermore, APRIL and BAFF levels are also significantly elevated in RA-SF when compared
with serum.
Conclusions. The increased levels of APRIL and BAFF in VERA patients suggests that B-cell activation
and the development of autoreactive B-cell responses might be crucial in early phases of RA. Therefore,
APRIL and BAFF could be promising targets for therapy in the early phase of RA.
Key words: B cells, VERA, Synovial fluid, APRIL, BAFF.
Introduction
B cells play critical roles in RA pathogenesis. They are the
source of RFs and anti-CCP autoantibodies, which
contribute to IC formation in the joints. These cells are
also efficient antigen-presenting cells and contribute to
T-cell activation through expression of co-stimulatory
molecules. B cells simultaneously respond and produce
chemokines and cytokines that promote leucocyte infiltra-
tion into the joints, formation of ectopic lymphoid struc-
tures, angiogenesis and synovial hyperplasia. Moreover,
B-cell depletion therapy with rituximab, as well as the
promising results obtained with atacicept in a Phase Ib
trial [1], confirmed the importance of these cells in estab-
lished RA [2, 3]. However, B-cell participation in the early
phase of the disease is not yet completely understood.
Interestingly, our previous studies showed a significant
decrease of pre-switch memory B cells (IgD+CD27+) in
peripheral blood of very early RA (VERA) patients, with
<6 weeks of disease duration, when compared with
controls [4]. In accordance with the results of another
group, it is highly likely that this B-cell subset migrates
towards the SM, contributing to the onset of the synovitis
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process [5]. Our hypothesis is that the cytokine environ-
ment in early RA favours the recruitment, activation and
survival of B cells, and herein we tested this concept in a
cohort of very early polyarthritis patients.
Materials and methods
Patients
Blood samples were collected from 19 untreated very
early polyarthritis patients with <6 weeks of disease
duration, who after a minimum follow-up of 3–4 months
fulfilled the 1987 ACR criteria for RA [6]. These patients
were classified as VERA patients. Further samples were
collected 4–6 weeks after starting a low dose of oral
CSs (5–10 mg of prednisone) (Time 1) and 4 months
after reaching the minimum effective dose of MTX (Time
2) up to a maximum of 20 mg/week required to reduce
the 28-joint DAS (DAS-28) to <3.2 [7]. Also, baseline
blood samples from VERA patients were compared
with 19 other very early arthritis (VEA) patients who, after
the same follow-up, did not evolve into RA and with
24 controls. Additionally, 12 blood and 15 SF samples
were obtained from MTX-treated established RA patients.
Of note, SF samples were only collected from established
RA, since most VERA patients did not have joint effusions
in easily accessible joints (Table 1). The HAQ [8] and
the DAS-28 were applied to all patients. The study was
approved by the local ethics committee (Comissa˜o de
E´tica do Hospital de Santa Maria, Lisbon, Portugal)
and all patients gave informed consent. Patient care
was conducted in accordance with the standard clinical
practice in the Rheumatology Department, Hospital de
Santa Maria, Lisbon, Portugal and the study was
performed in accordance with the Declaration of Helsinki
as amended in Edinburgh (2000).
Cytokine quantification
A proliferation-inducing ligand (APRIL), B-cell activating
factor (BAFF) and IL-21 levels were determined by
ELISA (Bender MedSystems GmbH, Vienna, Austria)
according to the manufacturer’s instructions. Samples
were analysed using plate reader Infinite M200 (Tecan,
Ma¨nnedorf, Switzerland).
Measurement of autoantibodies
RF-immunoglobulin M (RF-IgM) was determined in all pa-
tients by IMTEC Autoimmune Diagnostics ELISA kit
(Human GmbH, Wiesbaden, Germany) according to the
manufacturer’s instructions and samples were processed
using a ChemWell 2910 automated analyser. Serum levels
of anti-CCP were measured by the ELIA CCP test system
(Phadia GmbH, Freiburg, Germany) and samples were
analysed using an ImmunoCAP 100 instrument.
Statistical analysis
Statistical differences were determined with non-
parametric Kruskal–Wallis and Mann–Whitney tests using
GraphPad Prism (GraphPad, San Diego, CA, USA).
Correlation analysis was performed using Spearman’s T
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test. Differences were considered to be statistically
significant for P< 0.05.
Results
Characterization of patients and disease evaluation
A total of 38 polyarthritis patients with <6 weeks of
disease duration were consecutively included. VERA
patients had a mean (S.D.) age of 59 (17) years; 84.2%
were female, 42% were RF positive and 32% anti-CCP
positive. The baseline DAS-28 and HAQ were 6.1 (1.8) and
1.4 (0.8), respectively. After treatment with CSs and MTX
there was a significant reduction of both DAS-28 and HAQ
values (Table 1). VEA patients were classified as having
SpA (five cases), SLE (four cases), crystal-induced arthritis
(two cases), SS (one case), paraneoplastic polyarthritis
related to multiple myeloma (one case) and arthritis asso-
ciated with HIV infection (one case), and five patients
entered spontaneous remission before 3 months of
follow-up, remaining without a specific diagnosis and
were thus classified as presenting a self-limited polyarthri-
tis. These early polyarthritis patients represent a subset of
a larger cohort previously described by our group [4].
Furthermore, unpaired blood and SF samples were col-
lected from established RA patients who had similar
DAS-28 and HAQ values to those of VERA patients at
baseline (Table 1).
APRIL and BAFF levels are increased in VERA
patients at baseline
At baseline, APRIL and BAFF levels were significantly
higher in VERA patients as compared with both VEA and
controls (Fig. 1A). No differences were observed between
treated or untreated VERA patients, or between VEA and
controls (Table 1). Moreover, no significant differences in
IL-21 levels could be observed in VERA when compared
with either VEA patients and controls, or after therapy with
CSs and MTX (data not shown). Furthermore, there was
no correlation between DAS-28, anti-CCP or RF autoanti-
bodies and APRIL and BAFF serum concentrations (data
not shown).
VERA patients have higher APRIL and BAFF levels
in comparison with established RA patients
In order to compare early RA with the chronic phase,
we also analysed established RA serum samples.
Importantly, VERA patients, in baseline and even after
MTX treatment, had higher circulating levels of both
APRIL (P< 0.05) and BAFF (P< 0.001) in comparison
with established RA. However, regarding IL-21, no differ-
ences could be found in VERA when compared with
established RA (data not shown). Furthermore, no signifi-
cant differences could be observed in established RA in
comparison with controls (data not shown).
Established RA-SF has increased levels of APRIL,
BAFF and IL-21
To verify whether in established RA patients a B-cell
activation environment could be present in the joint fluid
despite lower APRIL and BAFF serum levels, we tested
the same cytokine panel in established RA-SF. APRIL,
BAFF and IL-21 levels were in fact increased locally in
the joints of established RA patients in comparison with
RA serum (Fig. 1B).
Discussion
In the present work, a cytokine pattern favouring B-cell
activation is observed in RA patients with <6 weeks of
disease duration, when compared with other causes of
VEA and established RA. Our previous results demon-
strated a significant decrease of pre-switch memory
B cells (IgD+CD27+) in peripheral blood of VERA patients
[4]. This is in agreement with the report from another
group referring to a migration of this B-cell subset towards
the SM [5]. In fact, in established RA, ectopic germinal
centre-like structures develop in the inflamed synovial
tissue that support survival of B cells and autoantibody
production [9]. Therefore, we also analysed established
RA-SF samples and depicted the presence of a
cytokine-based B-cell survival environment that could
explain the maintenance of potentially autoreactive B
cells in the synovium. Our results demonstrated that
VERA patients have increased APRIL and BAFF levels
when compared with VEA and controls. Interestingly,
APRIL was also increased in VERA patients’ serum as
compared with established RA and its levels were even
higher in RA-SF suggesting a local up-regulation in the
synovium. APRIL affects not only the class-switch recom-
bination process [10–12], but also plasma cell differenti-
ation and survival [13, 14], which could thus explain the
maintenance of autoreactive B cells in the joints [15].
Actually, a highly positive association between the infiltra-
tion of plasma cells and SF levels of APRIL has been
demonstrated in RA patients [15, 16]. BAFF, similar to
APRIL, is a fundamental B-cell survival factor and we
have also detected increased serum levels in VERA
patients when compared with established RA. Moreover,
BAFF was also significantly elevated in RA-SF in compari-
son with RA serum. Previous studies have demonstrated
that BAFF increases the chemokine (C-X-C motif) ligand
13 (CXCL13)-dependent chemotaxis of memory B cells
through BAFF receptor (BAFF-R) triggering [17].
Therefore, increased BAFF levels in RA could support
the migration of pre-switch memory B cells towards RA
synovium, thus justifying the decrease of this B-cell sub-
population in circulation. Furthermore, increased IL-21
levels in RA-SF support local plasma cell differentiation
and autoantibody production [18]. Additionally, therapy
with neither CSs nor MTX affected cytokine production
in VERA patients. However, the patients with established
RA that we have studied were on chronic treatment with
MTX and low-dose CSs and this might have influenced the
serum levels of APRIL and BAFF. The effect of low-dose
CSs and MTX on cytokine production in RA patients is
still controversial [19, 20]. So, an absence of effect of
short-term therapy with CSs and MTX on the cytokines
analysed was not entirely unexpected in VERA, but an
effect on chronic-treated patients might in fact occur.
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Conclusions
In conclusion, we have shown increased APRIL and BAFF
levels in VERA and in RA-SF, which could hypothetically
support the maintenance, expansion, activation and
survival of autoreactive B cells from the first weeks of
disease onset. Therefore, we suggest that APRIL and
BAFF may be potential promising treatment targets in
the very early phase of RA.
Rheumatology key messages
. APRIL and BAFF levels are increased from the first
weeks of RA onset.
. APRIL and BAFF may be potential promising
treatment targets in VERA.
FIG. 1 VERA patients have higher APRIL and BAFF levels than controls and those with VEA at baseline (A). Serum
samples from VEA patients with no therapy and healthy controls were analysed by ELISA technique. Differences were
considered to be statistically significant at P< 0.05. Established RA patients have increased levels of APRIL, BAFF and
IL-21 locally in the joints (B). Serum and SF samples from established RA patients were analysed by ELISA technique.
Dotted lines represent the limit of detection for the assay. Differences were considered to be statistically significant at
P< 0.05.
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Identification of a cytokine network sustaining
neutrophil and Th17 activation in untreated
early rheumatoid arthritis
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Abstract
Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by sustained
synovitis. Recently, several studies have proposed neutrophils and Th17 cells as key players in the onset and
perpetuation of this disease. The main goal of this work was to determine whether cytokines driving neutrophil
and Th17 activation are dysregulated in very early rheumatoid arthritis patients with less than 6 weeks of disease
duration and before treatment (VERA).
Methods: Cytokines related to neutrophil and Th17 activation were quantified in the serum of VERA and
established RA patients and compared with other very early arthritis (VEA) and healthy controls. Synovial fluid (SF)
from RA and osteoarthritis (OA) patients was also analyzed.
Results: VERA patients had increased serum levels of cytokines promoting Th17 polarization (IL-1b and IL-6), as
well as IL-8 and Th17-derived cytokines (IL-17A and IL-22) known to induce neutrophil-mediated inflammation. In
established RA this pattern is more evident within the SF. Early treatment with methotrexate or corticosteroids led
to clinical improvement but without an impact on the cytokine pattern.
Conclusions: VERA patients already display increased levels of cytokines related with Th17 polarization and
neutrophil recruitment and activation, a dysregulation also found in SF of established RA. 0 Thus, our data suggest
that a cytokine-milieu favoring Th17 and neutrophil activity is an early event in RA pathogenesis.
Introduction
Rheumatoid arthritis (RA), the most common chronic
autoimmune disease, affects approximately 1% of the
population worldwide. This disease comprises a syn-
drome of pain, stiffness, and symmetrical synovitis
which leads to joint destruction, functional disability,
and substantial comorbidity due to the involvement of
multiple organs and systems. The migration of leuko-
cytes toward the synovium is crucial for the establish-
ment of a chronic inflammatory process in RA [1-3].
This multi-regulated mechanism involves interactions
with endothelial cells through cell adhesion molecules
and complex cytokine and chemokine pathways.
Neutrophils specifically play an important role in the
onset and perpetuation of RA, not only as interleukin
(IL)-producing cells but also as cells responsible for the
release of high amounts of reactive oxygen species and
destructive enzymes, such as metalloproteases, contri-
buting to joint erosions [4]. Neutrophils are among the
first leukocytes to arrive at sites of inflammation. In
fact, these cells are the most abundant in the synovial
fluid (SF) of patients with active RA, and previous
results from our group showed that the synovial tissue
is heavily infiltrated by neutrophils in the first weeks of
RA onset [5]. Interestingly, in animal models of arthritis,
neutrophil depletion prevented joint inflammation if
neutrophil-depleting antibodies were given before the
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induction of arthritis. Moreover, when the depleting
antibody was given very early after the induction of
arthritis, complete abrogation of the inflammatory
symptoms was achieved [6].
T helper 17 (Th17) cells have also been proposed to
have a relevant role in the early phase of RA through
the production of IL-17 [7,8]. This cytokine promotes
the recruitment and survival of neutrophils, induces the
secretion of proinflammatory cytokines and the upregu-
lation of RANKL (receptor activator of nuclear factor-
kappa B ligand), and stimulates the activity of matrix
metalloproteases, leading to cartilage catabolism and
bone resorption [9,10]. The recruitment, activation, and
effector function of Th17 cells and neutrophils are dri-
ven by a network of cytokines and chemokines secreted
by multiple cellular sources. In established RA, it has
been reported that IL-1b, IL-6, IL-8, IL-17, and tumor
necrosis factor are elevated in the serum and this corre-
lates with a higher disease activity [11-13]. Nevertheless,
our knowledge of the influence of the cytokine network
on RA onset remains limited. The characterization of
the cytokine profile at this stage, where the transition
from an acute to a chronic inflammatory phase occurs,
may lead to the identification of early key players, with
potential implications for early treatment strategies.
Thus, the main goal of our work was to determine
whether cytokines driving neutrophil and Th17 cell acti-
vation and proinflammatory function were already pre-
sent in very early RA (with less than 6 weeks of disease
duration) and how this early cytokine environment dif-
fers from established RA. We also evaluated whether the
introduction of low-dose corticosteroids and methotrex-
ate (MTX) therapy had any influence on the cytokine
profile observed at that early stage of the disease. We
found that cytokines related to Th17 polarization and
neutrophil recruitment and activation were elevated in
early RA and that the conventional therapeutic options,
though able to control clinical manifestations of the dis-
ease, were ineffective in reversing this underlying proin-
flammatory drive.
Materials and methods
Patients
Blood samples were obtained from 38 consecutive
untreated polyarthritis patients with less than 6 weeks of
disease duration. Some of these patients (19), after a
minimum follow-up of 3 months, fulfilled the 1987
American College of Rheumatology (ACR) criteria for
RA [14]. These patients were classified as very early rheu-
matoid arthritis (VERA) patients, and further samples
were collected 4 to 6 weeks after starting a low dose of
oral corticosteroids (5 to 10 mg of prednisone) (time 1)
and 4 months after reaching the minimum effective dose
of MTX (time 2) (up to a maximum of 20 mg/week) that
was required to reduce the disease activity score using 28
joint counts (DAS28) to less than 3.2 [15]. The remaining
early arthritis patients (19), who did not develop RA,
were classified as very early arthritis (VEA). Baseline
blood samples from VERA and VEA patients were com-
pared with 27 healthy donors used as controls. Addition-
ally, 12 blood and 15 SF samples were obtained from
patients with established RA. SF samples were also col-
lected from 10 patients with osteoarthritis (OA) (Rheu-
matology Department, Hospital de Santa Maria, Lisbon,
Portugal) (Table 1). Owing to the clinical characteristics
of the VEA patients, SF in easily accessible joints was not
available in VERA and VEA patients and thus SF was not
analyzed in these groups of patients. The health assess-
ment questionnaire (HAQ) [16] and DAS28 were applied
to all patients. The study was approved by the local ethics
committee, and all patients signed an informed consent
form. Patient care was conducted in accordance with
standard clinical practice, and the study was performed
in accordance with the Declaration of Helsinki as
amended in Edinburgh (2000).
Cytokine quantification
IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12(p70), IL-17A,
IL-22, IL-23, and interferon-gamma levels were mea-
sured in the serum and SF by FlowCytomix assay kit
(Bender MedSystems, Vienna, Austria) in accordance
with the instructions of the manufacturer. Standard
curves for each cytokine were generated by using refer-
ence cytokine concentrations supplied by the manufac-
turer. Samples were acquired with a FACS Calibur flow
cytometer (BD Biosciences, San Jose, CA, USA). Raw
data of the flow cytometry bead assay were analyzed by
FlowCytomix Pro 2.2 software (Bender MedSystems).
Measurement of autoantibodies
Rheumatoid factor (RF)-IgM was determined in all
patients by means of an IMTEC Autoimmune Diagnos-
tics ELISA [enzyme-linked immunosorbent assay] kit
(Human GmbH, Wiesbaden, Germany) in accordance
with instructions of the manufacturer, and samples were
processed using a ChemWell 2910 automated analyzer
(GMI, Ramsey, Minnesota, USA). Serum levels of anti-
cyclic citrullinated peptide (anti-CCP) were measured by
ELIA™ CCP test system (Phadia GmbH, Freiburg, Ger-
many), and samples were analyzed with an ImmunoCAP
100 instrument (Phadia GmbH).
Statistical analysis
Statistical differences were determined with non-
parametric Kruskal-Wallis, Mann-Whitney, and
Wilcoxon signed-rank tests and GraphPad Prism (Graph-
Pad Software, Inc., San Diego, CA, USA). Correlation
analysis was performed with the Spearman test.
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Differences were considered statistically significant for
P values of less than 0.05.
Results
Characterization of patients and disease evaluation
A total of 38 polyarthritis patients with less than 6
weeks of disease duration were evaluated. Nineteen
patients fulfilled the 1987 ACR criteria for RA after a
minimum follow-up of 3 months and were classified as
VERA patients. The mean age of the VERA patients was
59 ± 17 years, 84% were female, 42% were RF-positive
and 32% anti-CCP-positive, the initial DAS28 was 6.1 ±
1.8, and the initial HAQ was 1.4 ± 0.8. After treatment
with low doses of prednisone and MTX, there was a sig-
nificant reduction of both DAS28 and HAQ values
(Table 1). The group of VEA patients included 19
patients, and 14 of them later had one of the following
diagnoses: spondylarthritis (5 cases), systemic lupus
erythematosus (4 cases), crystal induced arthritis (2
cases), Sjögren syndrome (1 case), paraneoplastic polyar-
thritis related to multiple myeloma (1 case), and arthritis
associated with HIV infection (1 case). Five patients
entered spontaneously into remission before 3 months
of follow-up, remaining without a specific diagnosis and
were thus classified as presenting a self-limited form of
polyarthritis. The mean age of the VEA patients was 40
± 13 years, 79% were female, all patients were RF-nega-
tive and anti-CCP-negative, the initial DAS28 was 4.5 ±
1.6, and the initial HAQ was 0.8 ± 0.6. Both DAS28 and
HAQ values were significantly lower than those of
VERA patients at baseline (Table 1). These early polyar-
thritis patients represent a subset of a larger cohort pre-
viously described by our group [17].
Furthermore, blood samples were collected from 12
patients with established RA; mean age was 60 ± 10
years, 92% were female, and 67% were RF-positive and
45% anti-CCP-positive (Table 1). Additionally, SF sam-
ples were collected from 12 patients with established
RA; mean age was 57 ± 10 years, and 73% were female
(Table 1). The established RA group of patients had a
DAS28 and a HAQ mean scores similar to VERA base-
line values.
IL-8 is increased in VERA patients and locally in the joints
of patients with established RA
Given the proposed role of neutrophils in the pathogen-
esis of RA [18,19], we quantified the major neutrophil
chemoattractant, IL-8, in the serum of VERA patients.
At baseline, VERA patients had significantly higher
levels of IL-8 when compared with both VEA and
healthy controls (Figure 1a). After 2 to 4 weeks of low-
dose corticosteroids and after 4 months of MTX ther-
apy, there were no significant changes in the levels of
circulating IL-8 (data not shown). Interestingly, VERA
patients also had significantly higher circulating levels of
IL-8 in comparison with serum from established RA
(Figure 1a). Neutrophils accumulate locally in the joints
of patients with RA [20]. Thus, we quantified the con-
centration of IL-8 in the SF of patients with RA and
compared the concentration with that of SF from
patients with OA. We found significantly higher levels
of IL-8 in the SF of patients with RA in comparison
with OA SF (Figure 1b).
IL-17 levels are dysregulated in both VERA patients and
patients with established RA
Previous studies from our group showed that there is a
delay in the apoptosis of circulating neutrophils in
VERA patients [21]. Therefore, we analyzed IL-17A
levels in these patients since it has already been
described that this cytokine is important for the survival
of neutrophils [22]. Moreover, IL-17A is a signature
cytokine of Th17 cells, a subset proposed to have a key
role in RA pathogenesis [9,23]. We found that VERA
patients had significantly higher levels of IL-17A when
compared with healthy controls, but not with VEA
patients (Figure 2a). Furthermore, in our previous work,
we found no difference in the frequency and absolute
Table 1 Clinical information about healthy controls and patients with VERA, VEA, RA, or OA
Controls
(n = 24)
VERA (n = 19) VEA
(n = 19)
RA
(n = 12)
RA SF
(n = 15)
OA SF
(n = 10)
Baseline Time 1 Time 2
Age in years, mean ± SD 40 ± 13 50 ± 17 40 ± 13 63 ± 10 57 ± 10 67 ± 13
Sex, female/male 17/7 16/3 15/4 11/1 11/4 5/5
DAS28, mean ± SD NA 6.1 ± 1.8 4.1 ± 1.6a 3.1 ± 1.6a 4.5 ± 1.6a 5.2 ± 1.0 4.6 ± 1.4 NA
HAQ, mean ± SD NA 1.4 ± 0.8 0.8 ± 0.7a 0.8 ± 0.7 0.8 ± 0.6a 1.5 ± 1.0 1.4 ± 0.8 NA
RF-positive, % ND 42 ND ND 0 67 ND ND
Anti-CCP-positive, % ND 32 ND ND 0 45 ND ND
aDisease activity score using 28 joint counts (DAS28) and health assessment questionnaire (HAQ) values were compared between very early rheumatoid arthritis
(VERA) and very early arthritis (VEA) patients with reference to VERA baseline values. Differences were considered statistically significant for P values of less than
0.05. anti-CCP, anti-cyclic citrullinated peptide; IL, interleukin; MTX, methotrexate; NA, not applicable; ND, not determined; OA, osteoarthritis; RA, rheumatoid
arthritis; RF, rheumatoid factor; SD, standard deviation; SF, synovial fluid.
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numbers of CD4+ and CD8+ T-cell subpopulations in
the peripheral blood of these patients when analyzed by
flow cytometry [17].
Regarding the effects of early therapy, we found that
neither corticosteroids nor MTX affected the level of
IL-17A (data not shown). Moreover, IL-17A was signifi-
cantly increased locally within the joints of patients with
established RA in comparison with control SF from
patients with OA (Figure 2b).
RA has a Th17-cytokine pattern since the very first weeks
of onset
Having found that IL-17A was elevated in VERA
patients, we decided to quantify a panel of cytokines
known to be associated with Th17 polarization. At base-
line, VERA patients had significantly higher levels of IL-
1b and IL-22 in comparison with both VEA and healthy
controls. In addition, we found that VERA patients have
significantly higher IL-6 levels than healthy controls
(Figure 3). Furthermore, the significantly higher circulat-
ing levels of IL-6 and IL-22 were maintained in estab-
lished RA (Figure 3).
Locally, within the joints of patients with RA, the SF
displayed elevated levels of IL-1b and IL-6 in compari-
son with OA SF (Figure 4 and Table 2). Moreover, no
significant differences could be observed for IL-23 in
circulation or locally in the joints (data not shown). We
have also studied cytokines associated with the function
of Th2 (IL-4 and IL-10) and Th1 (IL-2, IL-12 (p70), and
INFg) cells. However, no statistically significant differ-
ences could be observed for any of these cytokines (data
not shown).
Discussion
Several studies have previously demonstrated that neu-
trophils play an important role in the onset of RA [21].
Figure 1 Interleukin-8 (IL-8) is increased in the serum of very early rheumatoid arthritis (VERA) patients and in synovial fluid (SF) of
established rheumatoid arthritis (RA). (a) The serum concentration of IL-8 was measured in VERA and very early arthritis (VEA) patients as well
as healthy controls and patients with established RA. The serum concentration of IL-8 was increased in VERA patients compared with any other
group. Dotted line represents the limit of detection for the assay. (b) The concentration of IL-8 was measured in the SF collected from patients
with established RA and from a control group with osteoarthritis (OA). We found a significant increase of IL-8 in RA-SF. Differences were
considered statistically significant for P values of less than 0.05 according to the Mann-Whitney test.
Figure 2 Very early rheumatoid arthritis (VERA) patients and synovial fluid (SF) of established rheumatoid arthritis (RA) display
increased levels of interleukin-17A (IL-17A). (a) The serum concentration of IL-17A was measured in VERA and very early arthritis (VEA)
patients as well as healthy controls and patients with established RA. The serum concentration of IL-17A was increased in VERA patients
compared with healthy controls. (b) The concentration of IL-17A was measured in the SF collected from patients with established RA and from
a control group with osteoarthritis (OA). In the SF of patients with RA, we observed a significant increase of IL-17A. Dotted lines represent the
limit of detection for the assay. Differences were considered statistically significant for P values of less than 0.05 according to the Mann-Whitney
test.
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This hypothesis is supported by data from animal mod-
els [24]. In fact, neutrophils are the most abundant leu-
kocytes in the SF of patients with active RA, and in
early RA, these cells show significantly lower levels of
apoptosis when compared with patients with other per-
sistent forms of arthritis or with arthritis that has a self-
limited disease course [25]. Additionally, previous results
from our group demonstrated that there is a delay in
the apoptosis of circulating neutrophils in VERA
patients [21] and that these cells heavily infiltrate the
synovial tissue during RA onset [5].
In the present study, we demonstrate that a neutro-
phil- and Th17-driving cytokine pattern is present in
untreated VERA patients with less than 6 weeks of
Figure 3 Cytokines related to T helper 17 (Th17) polarization are increased in the serum of very early rheumatoid arthritis (VERA)
patients and synovial fluid of established rheumatoid arthritis (RA). The serum concentrations of interleukin (IL)-1b, IL-6, and IL-22 were
measured in VERA and very early arthritis (VEA) patients as well as healthy controls and patients with established RA. All three cytokines were
increased in VERA patients compared with healthy controls. IL-6 was equally elevated in all groups of patients with an inflammatory disease,
whereas the other two cytokines were increased only in VERA (IL-1b) or in VERA and RA patients (IL-22). Dotted lines represent the limit of
detection for the assays. Differences were considered statistically significant for P values of less than 0.05 according to the Mann-Whitney test.
Figure 4 Cytokines related to T helper 17 (Th17) polarization are increased in the synovial fluid (SF) of established rheumatoid
arthritis (RA). The concentrations of interleukin (IL)-1b and IL-6 were markedly increased in the SF collected from patients with established RA
when compared with osteoarthritis (OA). Dotted lines represent the limit of detection for the assays. Differences were considered statistically
significant for P values of less than 0.05 according to the Mann-Whitney test.
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disease duration. We consider this observation of inter-
est because the knowledge concerning the immune
mechanisms associated with the onset of RA is still elu-
sive. In fact, the majority of early RA studies include
patients with 3 to 12 months of disease duration or
even more. In accordance with an early participation of
neutrophils in RA, our results revealed that VERA
patients have increased levels of IL-8 when compared
with both VEA and healthy controls, and this could
explain the preactivated state of circulating neutrophils
[18] and their recruitment toward the SF from the very
first weeks of RA onset.
In addition, Th17 cells are known to be important for
the promotion of neutrophil-mediated inflammation by
producing IL-17A, a cytokine known to indirectly acti-
vate neutrophil chemotaxis and extend their survival
[10,22]. We found a high serum concentration of IL-17A
in VERA patients as well as locally within the joints of
patients with established RA. This might indicate that an
activation of Th17 cells from a very early phase of the
disease can promote neutrophil participation in RA
pathogenesis [22]. However, we found no evidence for
changes in the frequency of T-cell subsets in the periph-
eral blood of VERA patients [17]. This observation is not
unexpected; the relatively small representation of anti-
gen-specific T cells in the circulating pool are the acti-
vated T cells that drive the pathology more likely found
within the tissues [26]. In a study performed by Kokko-
nen and colleagues [27], the levels of several cytokines
and chemokines were analyzed in blood samples from a
group of individuals 3.3 years before RA onset (’pre-
patients’) and compared with healthy donors and RA
patients with 7.7 ± 3.6 months of disease duration. An
interesting finding was that IL-17 was present at its high-
est concentration in pre-patients and the level of this
cytokine was lower in patients with RA. This is in accor-
dance with our own results; we observed an increased
level of IL-17 in RA patients with less than 6 weeks of
disease duration, whereas in patients with established
RA, the levels were not significantly different from those
of healthy controls. Remarkably, the IL-17 median con-
centration observed in our established RA cohort (2.6 pg/
mL) was even lower than that of RA patients from the
work of Kokkonen and colleagues [27] (6.0 pg/mL).
Thus, this observation reinforces the role of IL-17 in the
initial phase of RA, and as the pathogenesis progresses to
a chronic stage, other factors are subsequently brought
into action in the peripheral blood. Unlike Kokkonen and
colleagues, we have not detected differences in Th1- and
Th2-related cytokines between both VERA and patients
with established RA in comparison with controls. These
discrepancies might be related to the different methodol-
ogies used.
Additionally, the elevated levels of IL-1b observed in
VERA patients can stimulate endothelial cells, T and B
cells, and fibroblasts in the joints to produce IL-6 and
IL-8. But importantly, IL-1b and IL-6, both found to be
increased in VERA patients, are known to promote the
differentiation of Th17 cells, which in turn secrete
IL-17A and IL-22 [28,29], two cytokines that were ele-
vated in VERA patients and have an essential function
in the pathogenesis of autoimmune diseases [29].
Currently, the treatment of choice for RA at the time
of presentation is MTX. Interestingly, in spite of clinical
improvement (DAS28 reduced from 6.1 ± 1.8 to 3.1 ±
1.6), neither therapy with low-dose corticosteroids nor
combined therapy with low-dose corticosteroids and
MTX corrected the dysregulated cytokine pattern
observed in VERA patients. In fact, low-dose corticos-
teroids and MTX have unclear effects on the RA cyto-
kine network. For instance, corticosteroids fail to reduce
serum levels of IL-1b and IL-8 [30] and MTX does not
alter serum IL-1b concentration when compared with
pre-treatment levels [31,32]. Our results suggest that the
conditions contributing to Th17 cells and neutrophil-
mediated inflammation, thus driving early pathogenesis,
are not modified with early treatment with low-dose
corticosteroids and MTX.
The elevated IL-1b, IL-6, IL-8, and IL-17A levels
observed in the SF of patients with RA confirm a local
Table 2 Cytokine levels in healthy controls and patients with VERA, VEA, established RA, or OA
Cytokine, pg/mL Controls VERA VEA RA RA SF OA SF
IL-1b 4.2
(4.2-116.8)
17.7
(4.2-99.7)
4.2
(4.2-272.7)
4.2
(4.2-360.3)
6.5
(4.2-322.1)
4.2
(4.2-15.5)
IL-6 1.2
(1.2-7.2)
5.2
(1.2-153.2)
1.2
(1.2-84.7)
8.2
(1.2-19.7)
6361.0
(272.7-24,135.0)
177.6
(46.6-4,881.0)
IL-8 9.9
(0.5-407.7)
57.6
(12.5-1,546.0)
8.9
(0.5-665.2)
15.2
(0.8-67.5)
735.7
(28.3-3,717.0)
48.2
(22.0-680.0)
IL-17A 2.5
(2.5-333.7)
62.0
(2.5-1,714.0)
2.5
(2.5-1,477.0)
2.6
(2.5-375.6)
21.1
(2.5-369.1)
2.5
(2.5-9.5)
IL-22 43.3
(43.3-153.4)
165.3
(43.3-380.6)
43.3
(43.3-270.5)
131.7
(75.8-250.7)
153.4
(75.8-336.0)
151.7
(92.4-235.3)
Values are presented as median (range). IL, interleukin; OA, osteoarthritis; RA, rheumatoid arthritis; SF, synovial fluid; VEA, very early arthritis; VERA, very early
rheumatoid arthritis.
Cascão et al. Arthritis Research & Therapy 2010, 12:R196
http://arthritis-research.com/content/12/5/R196
Page 6 of 8
role for these cytokines in the maintenance of synovitis.
Moreover, IL-6 can support a continuous recruitment of
autoreactive B cells toward the synovium [33,34], contri-
buting to an exacerbation of the inflammatory process
because of the production of autoantibodies and
immune complexes.
Conclusions
Taken together, our data reinforce the potential rele-
vance of therapies targeting IL-1b [35,36] and IL-6
[37,38] in early RA. In addition, the data establish IL-8
and IL-17A as other potential therapeutic targets at an
early stage of the disease. Finally, we found that MTX
and corticosteroids, though effective in reducing disease
activity in VERA patients, do not appear to correct
underlying cytokine dysregulation driving the Th17/neu-
trophil-mediated inflammation.
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ABSTRACT
Objectives To examine the expression of B-cell-
activating factor receptor (BAFF-R) on naive CD27− and 
memory CD27+ B cells in normal individuals and patients 
with rheumatoid arthritis (RA) undergoing B-cell depletion 
therapy with rituximab.
Patients and Methods BAFF-R expression on B-cell 
subsets was determined in normal controls 
(NC; n=11), active patients with RA pre-rituximab 
(pre-RX; n=15), relapsing patients either concordant 
for B-cell repopulation (C-R, n=13) or discordant, 
with relapse more than 3 months after repopulation 
(D-R, n=11) and patients in remission over 3 months 
postrepopulation (discordant non-relapsing (D-NR), n=5). 
Serum BAFF was measured by ELISA and analysed using 
Mann–Whitney.
Results There was no signifi cant difference between 
NC, pre-RX and D-NR patients in %BAFF-R-positive B 
cells or mean fl uorescence intensity (MFI) in naive and 
memory B cells. Relapsing patients had signifi cantly 
lower MFI and %BAFF-R-positive cells in both naive and 
memory compartments from NC and pre-RX (C-R and 
D-R; p<0.01). BAFF levels in pre-RX patients were within 
the normal range and did not correlate with BAFF-R 
expression in any patient group. D-NR patients had 
relatively lower proportions of pre and postswitch CD27+ 
B cells than pre-RX patients (D-NR vs pre-RX; p<0.05 for 
both) and also lower numbers of postswitch B cells than 
D-R patients (D-NR vs D-R, p<0.05).
Conclusion BAFF-R expression was signifi cantly 
reduced on both naive and memory B cells in patients 
at relapse, regardless of the relationship with B-cell 
repopulation or serum BAFF levels. Re-establishment 
of active disease was also associated with an increase 
in class-switch recombination. Factors responsible for 
lower levels of BAFF-R may relate to altered thresholds 
for autoreactive B-cell generation at relapse in patients 
with RA.
B-cell-activating factor (BAFF), also known as B 
lymphocyte stimulator (BlyS), THANK, TALL-1, 
zTNF-4 or TNFSF13b, is a protein member of the 
tumour necrosis factor (TNF) family that plays an 
important role in B-cell maturation, homeostasis 
and  survival.1 BAFF binds to three receptors on 
B cells: TACI, BCMA and BAFF-R (or BR3), with 
BAFF-R being the only ligand that exclusively binds 
BAFF.2
Studies of BAFF-R-deﬁ cient mice demon-
strated that BAFF was essential for B-cell survival, 
B-cell-activating factor receptor expression on naive 
and memory B cells: relationship with relapse in 
patients with rheumatoid arthritis following B-cell 
depletion therapy
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primarily through the alternative nuclear factor κ 
light-chain enhancer of activated B cells pathway,3 
and for B-cell maturation and immunoglobulin (Ig) 
class switching through the classic nuclear factor 
κ B pathway.4 B cells from these animals develop 
normally up to the IgM+ transitional stage but do 
not complete their maturation in the spleen.5 The 
numbers of memory and marginal zone cells and 
of serum Ig are severely reduced (>90%) as were 
responses to both T-dependent and T-independent 
stimuli.2
Human B cells are less dependent on BAFF-R sig-
nalling for maturation than murine B cells. In the 
few reported cases of common variable immuno-
deﬁ ciency related to BAFF-R deﬁ ciency in humans, 
circulating BAFF levels were greatly elevated and 
peripheral B-cell numbers were reduced (fourfold 
lower). The condition was of late onset and was 
not associated with severe infections.6 Although 
mature but not transitional B cells were reduced 
in these individuals, class-switched memory B 
cells were detectable. Correspondingly, vaccina-
tion studies showed that T-dependent responses 
appeared to be much less dependent on BAFF-R 
signalling than T-independent responses. As in 
BAFF-R−/− mice, IgA responses in these patients 
were not compromised.
One of the suggested roles for BAFF, based 
largely on animal experiments, is that increased 
levels will lower thresholds for the survival of 
autoreactive B-cell clones, and decrease competi-
tion within germinal centre environments.7 8 In 
humans, elevated levels of serum BAFF have been 
associated with both the presence and activity of 
several autoimmune diseases (Sjogrens syndrome, 
systemic lupus erythematosus (SLE) and idiopathic 
thrombocytopaenia).9–15 In patients with rheuma-
toid arthritis (RA), the relationship is less clear, 
with conﬂ icting reports as to whether levels of cir-
culating BAFF are signiﬁ cantly elevated and if there 
is a relationship with disease activity or titres of 
autoantibodies.14 16 17
Following treatment of RA patients with ritux-
imab, serum BAFF levels have been shown to rise, 
reﬂ ecting the loss of the majority of peripheral B 
cells. The correlation of BAFF levels with periph-
eral B-cell counts is not, however, perfect and it has 
been suggested that BAFF levels form a more accu-
rate indicator of total B-cell mass.18 Chronically 
raised BAFF levels have been suggested to exert a 
negative feedback on BAFF-R expression.19
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One of the key initial ﬁ ndings of the clinical response to ritux-
imab was that B-cell return was not always associated with 
relapse, and that disease could remain in remission for months 
or even years following B-cell repopulation.20 In patients with 
RA, rises in autoantibodies, particularly rheumatoid factor (RhF), 
seem to herald relapse following regardless of whether clinical 
relapse has been concordant or discordant with B-cell return.21 
Serum BAFF levels rose rapidly after rituximab, and then fell 
with rising peripheral B-cell numbers, although the relation-
ship was not always clear. There was also some evidence for an 
increased uptake of BAFF if relapse occurred concurrently.17 21
The re-establishment of clinical disease following B-cell 
depletion therapy relies on engaging pro-inﬂ ammatory path-
ways, which are quiescent in the absence of circulating B 
cells, and therefore provides a unique opportunity to study the 
 re-emergence of the disease process. As a result of its impor-
tance in B-cell survival, particularly for new emigrant and naive 
B cells, we hypothesised that the balance between BAFF-R 
expression and soluble BAFF may inﬂ uence the relationship 
between returning B-cell populations and the resumption of 
autoimmunity. With this in mind, we measured serum BAFF 
levels and BAFF-R expression on B-cell populations to determine 
whether there was any relationship between serum BAFF levels 
and BAFF-R on naive and memory B cells at different key time 
points after rituximab therapy.
MATERIALS AND METHODS
Patients
Blood samples were obtained from 11 normal controls (NC) and 
44 consecutive patients with a diagnosis of RA who fulﬁ lled 
the American College of Rheumatology criteria for RA22 The 
patients were all attending the Department of Rheumatology at 
University College London Hospital and were treated with ritux-
imab, on the basis of clinical need. Patients received 2-weekly 
infusions of 1 g rituximab preceded by 100 mg intravenous 
methylprednisolone. The study was approved by the hospital 
ethics committee and all patients gave informed consent before 
entering the study. The normal range for cluster of differentia-
tion 19+ (CD19+) B cells used by the local pathology laboratory 
was 0.03–0.40×109/l. Levels less than 0.005×109/l were deﬁ ned 
as undetectable.
Detection of B cells
Depletion of B cells in the peripheral blood was deemed to have 
occurred when CD19+ B cells were undetectable. In all patients, 
total peripheral blood B-cell depletion was achieved for at least 
2 months. B-cell return (B-cell repopulation) was deﬁ ned as when 
B cells were again detectable in the peripheral blood (ie, when 
the CD19+ cell count was ≥0.005×109/l).
Clinical relapse
Clinical relapse after rituximab was based on any return of 
symptoms of RA plus a rise in C-reactive protein following an 
original fall of at least 50% in C-reactive during the previous 
course of B-cell depletion therapy. Patients at clinical relapse 
were classiﬁ ed as concordant (relapse ≤3 months after repopula-
tion in peripheral blood) or discordant (relapse >3 months after 
repopulation in peripheral blood).
Peripheral blood mononuclear cells isolation and staining
Peripheral blood mononuclear cells (PBMC) were freshly isolated 
from 10 ml heparinised whole blood following density gradient 
centrifugation with Ficoll-Paque Plus (GE Healthcare, Uppsala, 
Sweden) and stained on the same day of collection. Cells were 
washed and cellular viability was estimated with Trypan blue 
(Sigma, St Louis, USA). PBMC (1×106/sample) were incubated 
with appropriate conjugated antibodies for 15 min at room tem-
perature in the dark and then washed. Erythrocytes were lysed 
with BD PharmLyse (BD, Biosciences, San Diego, USA) buffer 
according to the manufacturer’s instructions and cells were then 
ﬁ xed with paraformaldehyde 2% for 5 min at room tempera-
ture. PBMC were stored in the dark at 4°C until analysed by 
ﬂ ow cytometry. A total of 300 000 cells/sample gated in total 
lymphocytes were acquired with FACSCaliBur (BD). Data were 
analysed with FlowJo (TreeStar, Stanford University, California, 
USA). Absolute cell counts were calculated from the differential 
leucocyte count determined at each time point for all patients.
Phenotypic analysis
Immunophenotyping of B and T cells in PBMC samples was 
performed using matched combinations of antihuman murine 
monoclonal antibodies conjugated to ﬂ uorescein isothiocyanate 
(FITC), phycoerythrin (PE), peridinin chlorophyll protein cyanin 
(PerCP-Cy5.5), or allophycocyanin (APC). For B-cell analysis, 
combinations of anti-CD19 conjugated to PerCP-Cy5.5 or APC 
(clone HIB19), anti-IgD FITC (clone IA6-2) and anti-CD27 PE 
(clone O323) were used to deﬁ ne naive (CD19+IgD+CD27−), 
preswitch memory (CD19+IgD+CD27+), postswitch memory 
(CD19+IgD−CD27+) and IgD−CD27− B cells.
The expression of BAFF-R was analysed using combinations 
of anti-CD19 PerCP-Cy5.5, anti-CD27 PE and anti-BAFF-R FITC 
(11C1; mouse IgG1, clone 8A7) and the mean ﬂ uorescence inten-
sity (MFI) of BAFF-R was determined for naive (CD19+CD27−) 
and memory B cells (CD19+CD27+). All antibodies used were pur-
chased from BD Biosciences and eBioscience (San Diego, USA)
Measurement of BAFF
BAFF levels were quantiﬁ ed in serum samples from healthy 
controls and from patients at the various time points, using the 
Human Quantikine BAFF/BLyS immunoassay ELISA kit. The 
mean±SD for normal sera (n=36) were given as 1.17±0.28 ng/ml 
(range 0.67–2.45 ng/ml).
Statistical analysis
Statistical differences were determined using the non- parametric 
Mann–Whitney test using GraphPad Prism (GraphPad, San 
Diego, California, USA). Differences were considered statisti-
cally signiﬁ cant for p<0.05. Linear regression was used to cor-
relate BAFF levels and BAFF-R expression.
RESULTS
Patient cohorts
The mean age was 42 years (range 33–81) and the mean disease 
duration was 15 years (range 2–20). All patients had erosive dis-
ease. Two patients were seronegative for both RhF and antic-
itrullinated protein antibodies before treatment. The cohorts of 
consecutive patients with RA included 15 patients with active 
disease who were studied pre-rituximab (pre-RX) and 29 patients 
who had already received one or more courses of rituximab. In 
consecutive patients presenting at clinic, blood for FACS analysis 
was taken from all relapsing patients. CD19 counts were subse-
quently examined and patients assigned to concordant relapsing 
(C-R) or discordant relapsing (D-R) groups. If the patients had 
already repopulated according to the laboratory notes, but had 
remained well for more than 3 months after the date of repop-
ulation, they were assigned to the discordant non-relapsing 
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expression was also observed in all naive and memory popula-
tions following rituximab compared with those of NC (panel C). 
In order to explore these initial observations, the MFI of BAFF-R 
expression on naive and memory CD19+ B cells pre-RX were 
compared with those of B cells from NC (ﬁ gure 2). Naive B 
cells from both groups of patients at relapse (C-R and D-R) 
expressed signiﬁ cantly lower levels of BAFF-R when compared 
with NC (MFI; C-R 58.8 and D-R 53.7 vs NC, 85.5). Memory B 
cells from both cohorts of relapsing patients also showed sig-
niﬁ cantly lower expression of BAFF-R than NC (MFI; C-R 56.5 
and D-R 46.7 vs NC, 78.0). Furthermore, C-R patients showed 
a tendency to lower MFI levels than pre-RX patients in both 
naive (58.8 vs 70.4, p=0.06) and memory B-cell populations (56.5 
vs 61.2; p=0.07). We also observed a tendency towards lower 
BAFF-R MFI in D-R patients when compared with pre-RX levels 
in memory B cells, although again, this did not reach statistical 
signiﬁ cance (46.7 vs 61.2; p=0.07). Of interest, no signiﬁ cant dif-
ferences were found in the MFI of BAFF-R expression on either 
naive or memory B-cell populations in the D-NR patient group 
when compared with NC or RA patients before treatment.
Relationship between BAFF levels and BAFF-R MFI in naive and 
memory B cells
Our initial observation was that BAFF-R expression was signiﬁ -
cantly lower on B cells from patients undergoing relapse than on 
B cells from patients whose B cells had returned but in whom 
disease was not yet re-established (ﬁ gure 2). We therefore exam-
ined whether there was any relationship between circulating 
BAFF levels and expression (MFI) of BAFF-R (ﬁ gure 3). Although 
no statistically signiﬁ cant correlations were found, we could dis-
tinguish different patterns between pre-RX, C-R, D-R and D-NR 
patients. When patients were relapsing (C-R and D-R), BAFF-R 
MFI was consistently lower, irrespective of serum BAFF levels. 
Nevertheless, in patients who had repopulated but remained well 
(D-NR), there was a tendency for a negative correlation between 
circulating BAFF and BAFF-R MFI more evident in memory B 
cells (r2=0.88; p=0.06) (ﬁ gure 3). However, samples from only 
four patients were available for analysis in this group.
B-cell subpopulations in peripheral blood associated with 
different patterns of response to rituximab
It has previously been suggested that patients with higher numbers 
of circulating memory/postswitch B cells, either before treatment 
induction or at relapse were more likely to have a shorter clinical 
response to rituximab.23 24 We showed here that memory B cells 
from relapsing patients in particular tended to express lower levels 
of BAFF-R (MFI), and that this was so over a wide range of circu-
lating BAFF levels. We therefore examined whether there was any 
relationship between subpopulations of B cells in patients with 
different patterns of clinical response/relapse  (ﬁ gure 4). Circulating 
B-cell (CD19+) subpopulations were deﬁ ned according to IgD and 
(D-NR) group. Five groups were therefore described for analy-
ses: (1) NC (n=11); (2) patients with active RA pre-RX (n=15); (3) 
C-R (n=13); (4) D-R (n=11); (5) D-NR (n=5), taking into account 
repopulation and relapse after rituximab as described (table 1).
Serum BAFF levels in NC and in RA patients
Median BAFF levels in the 16 patients with RA tested before 
rituximab were within the normal range (table 1). As previ-
ously described, BAFF levels rose following rituximab.22 Levels 
were found to remain raised at relapse in both patient groups 
(C-R and D-R; p<0.01, compared with both NC and patients 
pre-RX) and to a lesser extent in patients who had repopulated 
but not relapsed (D-NR; p<0.05) when compared with NC only 
(table 1), but no statistically signiﬁ cant differences in BAFF levels 
were observed between C-R, D-R and D-NR patients.
Percentage of naive and memory B cells expressing BAFF-R
The percentages of CD19+ B cells expressing BAFF-R in CD27+ 
and CD27− subpopulations in patients and NC are represented 
in table 1. Signiﬁ cant differences were seen between the per-
centage expression of BAFF-R on naive and memory B cells 
in relapsing patients (C-R and D-R groups) compared with 
NC, and for the memory B-cell population, levels in relapsing 
patients were also signiﬁ cantly reduced compared with pre-RX 
values. In the D-R group, decreased expression on naive B cells 
was also signiﬁ cant compared with pre-RX values. In patients 
whose B cells had returned but had not yet relapsed (D-NR), no 
such decreases were found between the percentages of BAFF-R 
expressing naive or memory populations compared with NC or 
with the pre-RX group. Furthermore, when the percentages of 
BAFF-R expressing naive and memory B cells in patients who 
were relapsing (both C-R and D-R) were compared with D-NR 
patients, a signiﬁ cantly lower percentage expression was found 
in both naive and memory populations (naive D-NR vs C-R and 
D-R; p<0.05 and p<0.01, respectively; memory D-NR vs C-R or 
D-R, p<0.01 for both). The low expression of BAFF-R was not 
caused by contamination of the CD19+ gate with plasmablasts 
(which express low levels of BAFF-R) as they were gated out of 
the analysis.
MFI of BAFF-R expression on naïve and memory B cells
Figure 1 shows representative dot plots and histograms of 
BAFF-R expression on CD19+ B cells (panel A), PBMC differ-
entiated into naive and memory B cells on the basis of CD27 
expression (panel B) and histograms of the MFI of BAFF-R on 
naive (dashed lines) and memory (dotted lines) B cells (panel C). 
BAFF-R expression appeared to be decreased in patients who 
were discordant for relapse after B-cell return, both when 
remaining well or relapsing, in the examples shown. These indi-
viduals also had a tendency for a higher proportion of naive to 
memory B cells (panels A and B). A left shift in MFI of BAFF-R 
Table 1 Serum BAFF levels and BAFF-R expression on CD19+ B cells
 BAFF (ng/ml) median (range)
Naive B cells CD19+ CD27− (%) 
median (range)
Memory B cells CD19+ CD27+ (%) 
median (range)
NC (n:11) 0.88 (0.68–1.03) 98.4 (95.7–99.8) 88.3 (77.3–95.8)
Pre-RX (n:15) 1.09 (0.69–1.89) 97.8 (71.7–99.7) 87.3 (69.3–97.1)
C-R (n:13) 3.03**# (1.31–7.09) 90.3** (58.6–98.6) 54.8****## (23.4–82.1)
D-R (n:11) 2.55**# (1.02–7.46) 85.4***# (57.7–97.6) 55.8****### (27.4–77.6)
D-NR (n:5) 2.25* (1.11–4.13) 98.3 (88–99.7) 79.3 (64.1–96.9)
*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 compared with normal controls (NC) (Mann–Whitney).
#p<0.01; ##p<0.001; ###p<0.0001 compared with pre-B-cell depletion therapy.
BAFF, B cell-activating factor; C-R, concordant clinically relapsing; D-NR, discordant clinically non-relapsing; D-R, discordant clinically relapsing; pre-RX, prerituximab.
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CD27 expression and classiﬁ ed as naive (IgD+CD27−), preswitch 
memory (IgD+CD27+), postswitch memory (IgD−CD27+) and 
double-negative (IgD−CD27−) B cells. The median and range of 
total numbers of CD19+ B cells in each patient group were for 
pre-RX 175 (58–472)×106/l, C-R 42 (15–192)×106/l, D-R 61 (13–
166)×106/l, D-NR71 (21–328)×106/l. The median percentage and 
interquartile range of each subpopulation are shown for NC and 
patient groups in ﬁ gure 4. The distribution of naive to memory 
B cells in humans is approximately 60:40. The B-cell subpopula-
tion distribution of B cells from patients with RA pretreatment 
was broadly similar to NC, except for a slightly increased propor-
tion of double-negative B cells (7.3% vs 3.9%; p=0.04). Following 
rituximab, repopulation of the periphery begins with naive B cells, 
which mature at a greater or lesser rate into pre and postswitch 
CD27+ B cells. Full restoration of memory cell populations may 
not be achieved for years after treatment. As expected, the relative 
ratio of naive to memory B cells was increased at repopulation, 
mirroring ontogeny, but the relative percentage of naive cells was 
only signiﬁ cantly higher in the non-relapsing patients compared 
with NC (p<0.05). The preswitch memory B-cell population was 
signiﬁ cantly decreased in all patients postrituximab (C-R 4.2%, 
p=0.0004; D-R 4.9%, p=0.002 and D-NR 4.7%, p=0.03) when 
compared with NC (12.2%). In patients who relapsed at B-cell 
return, postswitch memory B cells had already reached levels 
approximating those of NC (C-R 12.4% vs NC 19.6%, p=0.28), 
but remained reduced in the D-NR group when compared with 
NC (6.6% vs 19.6% p=0.03), pre-RX (6.6% vs 18.1%, p=0.02) and 
D-R (6.6% vs 17.9%, p=0.05).
We also used regression analysis to determine whether serum 
BAFF levels were related to the percentage of particular B-cell 
subsets. This produced mostly negative results, although higher 
BAFF levels were statistically associated with numbers of pre-
switch memory B cells in patients who were relapsing more 
than 3 months after B-cell repopulation (D-R; p=0.02; Mann–
Whitney; data not shown).
Relationship of BAFF-R expression and B-cell phenotypes with 
months between repopulation and relapse
It is also possible that differences in levels of BAFF-R and B-cell 
phenotype distribution in patients discordant for repopula-
tion and relapse (D-R and D-NR cohorts) were related at least 
partly to differences in the time of sample collection following 
repopulation. We therefore compared months between repopu-
lation and relapse in the two cohorts and found them not to 
be signiﬁ cantly different (months between repopulation and 
sample collection in the D-NR cohort range 4–46, median=13; 
D-R cohort range 5–24, median=7; Mann–Whitney rank sum 
p=0.594).
DISCUSSION
Using the 11C1 monoclonal antibody, which recognises occu-
pied and unoccupied BAFF-R on human cells,25 we found that 
BAFF-R levels on CD27+ and CD27− B-cell subpopulations in 
RA patients before rituximab were similar to those of B cells 
from NC, although there was a tendency towards lower values 
especially in memory B-cell populations (MFI; p=0.098; table 1 
and ﬁ gure 2). We also report that BAFF-R expression was sig-
niﬁ cantly reduced on B cells from patients with RA when they 
were undergoing relapse following rituximab. Low BAFF-R lev-
els were not due to an increase in circulating plasmablasts (data 
not shown), which have been associated with clinical relapse.26 
Signiﬁ cantly, reduced BAFF-R expression was found in both 
naive and memory subpopulations and on B cells from patients 
who relapsed when B cells returned, as well as in those patients 
who relapsed more than 3 months after B-cell return. In addition, 
as all patients in the pre-RX group had active RA and were stud-
ied before the induction of B-cell depletion therapy for resistant 
disease the results also imply that reduced BAFF-R expression 
was not necessarily a consequence of inﬂ ammation and active 
disease, but was more likely related to the  re-establishment of 
disease.
The bioactive trimeric form of soluble BAFF is produced by 
a variety of cell types, namely myeloid and dendritic cells, neu-
trophils and some stromal cells.27 In humans, BAFF signalling 
through BAFF-R does not appear to be directly involved in B-cell 
maturation or in most T-cell-independent responses.6 BAFF-R is 
expressed on human B cells from the transitional stage onwards, 
and is then lost from memory B cells as they differentiate into 
Ig-secreting plasma cells.28 Stimulation through Toll-like recep-
tor (CpG IL2,15) pathways is more efﬁ cient than T-dependent 
pathways (CD40L,IL2,10) at downregulating BAFF-R expression 
on memory B-cell populations.7 28 It was also found that stimu-
lation of naive cells through either pathway had no effect on 
BAFF-R expression, although positive responses of naive human 
cells to either stimulus are poor.28
Investigations of BAFF-R expression on B cells from patients 
with rheumatic diseases are limited and to some extent report 
contrasting ﬁ ndings, and none describe patients with RA or the 
effect of rituximab. Carter et al25 showed that normal levels of 
BAFF-R were present on B cells in patients with SLE but were 
of reduced availability due to occupancy by soluble BAFF. Low 
levels of BAFF-R expression and a negative correlation between 
BAFF-R expression and higher disease activity in patients with 
SLE have been described.19 In patients with Sjogrens syndrome, 
BAFF-R expression was decreased on both naive and memory B 
cells, with the lowest levels found in patients with extraglandular 
involvement.19 Analysis of BAFF-R messenger RNA from B cells 
from these patients suggested that the lower expression was due 
to a post-translational modiﬁ cation and not to any reduction in 
BAFF-R mRNA. This could be explained if decreased BAFF-R 
expression reﬂ ected the recent binding of bioactive BAFF to 
BAFF-R followed by internalisation or shedding.25 In turn, this 
could be due to the chronic exposure of B cells to constantly 
high circulating levels of BAFF, which are often found in these 
patients. Carter et al25 showed that the receptor/cytokine com-
plex was not internalised. Loss of the receptor following ligation 
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Figure 1 Peripheral blood mononuclear cells were gated on the 
CD19+ B-cell population and the mean fl uorescence intensity (MFI) 
of B-cell-activating factor receptor (BAFF-R) expression determined 
on CD27-naive (A) and CD27+ memory (B) B-cell subpopulations. 
Normal controls (NC) and patient groups were compared using the 
Mann–Whitney U test and statistical signifi cance indicated (*p<0.01; 
**p<0.001). C-R, concordant clinically relapsing; D-NR, discordant 
clinically non-relapsing; D-R, discordant clinically relapsing; pre-RX, 
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Figure 2 Characterisation of B-cell-activating factor receptor (BAFF-R) expression and B-cell phenotypes in normal controls (NC) and patients 
with rheumatoid arthritis before B-cell depletion therapy (pre-RX), relapsing patients concordant (C-R) or discordant (D-R) with B-cell return and 
patients who had repopulated in the periphery but who remained well (D-NR). The expression of BAFF-R on CD19+ B cells in the lymphocyte gate in 
peripheral blood mononuclear cells are shown in panel A. In panel B, combinations of CD27 and CD19 were used to differentiate memory (M; CD19+ 
CD27+) and naive (N; CD19+ CD27−) B cells. Numbers in each quadrant represent percentages of each subpopulation in individual experiments. 
The histograms in panel C show representative experiments in which the mean fl uorescence intensity (MFI) of BAFF-R expression for CD27+ (dotted 
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individual to enable comparison with other histograms in each example.
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by BAFF was, however, conﬁ rmed by Sellam et al,19 who showed 
that overnight, but not short-term, culture with physiologically 
encountered concentrations of BAFF reduced BAFF-R levels on B 
cells from normal donors.
Our experience here and in earlier studies17 was that BAFF 
levels were not signiﬁ cantly raised in patients with active 
RA. However, following rituximab, BAFF levels rise rapidly 
and remain raised for variable periods of time. In our serial 
studies,17 we found that in individual patients, BAFF levels fell 
more sharply in patients in whom relapse was associated with 
B-cell return, than in those patients who relapsed months after 
B-cell return. This may have reﬂ ected increased BAFF binding 
to BAFF-R or TACI following B-cell receptor (BCR) engage-
ment. We could not conﬁ rm these results here as individual 
patients were not studied serially over the course of their cycle 
of treatment. In the present study, serum BAFF remained raised 
to similar levels in sera from patient cohorts discordant or con-
cordant with respect to B-cell return and relapse. Within each 
group of patients, however, there was no correlation between 
BAFF levels and BAFF-R expression (ﬁ gure 3) suggesting that 
reduced expression was not solely due to chronically raised 
BAFF levels, although this possibility could not be excluded 
with certainty.
When levels of expression of BAFF-R on naive and memory 
populations in pre-RX patients and controls were compared, 
CD27+ memory B-cell values tended to be lower, although this 
did not reach statistical signiﬁ cance (p=0.07; data not shown). 
The main ﬁ nding of the study was that BAFF-R levels were 
signiﬁ cantly reduced on both naive and memory B cells from 
relapsing, compared with non-relapsing, patients and pre-RX 
patients. This suggested that the reduction in BAFF-R lev-
els may have been initiated in naive cells, which then carried 
the ‘low’ BAFF-R phenotype into the mature memory B-cell 
stage. In-vitro experiments by others have shown that BAFF 
could modulate BAFF-R expression in a dose-dependent man-
ner.25 As we found no correlation between raised BAFF levels 
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Figure 3 The values for the mean fl uorescence intensity (MFI) of B cell-activating factor receptor (BAFF-R) expression in individual patients were 
plotted against BAFF levels that were measured in serum stored at the same time point (upper limit of normal range 2.45 ng/ml). Regression analysis 
was performed and signifi cance values determined for each curve. C-R, concordant clinically relapsing; D-NR, discordant clinically non-relapsing; D-R, 
discordant clinically relapsing; NC, normal controls; pre-RX, prerituximab.
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patients with RA. Within the polyreactive pool exiting the bone 
marrow, BCR speciﬁ cities with promiscuous potential, such 
as those possessed by the relatively high proportion of RhF B 
cells that can obtain help from T cells with speciﬁ city for a wide 
range of processed peptides,34 may have a survival advantage 
that could override the disadvantages of low BAFF-R expres-
sion/signalling in a genetically predisposed individual. We have 
shown that BAFF levels do not appear to be limiting in relapsing 
patients, but lower levels of BAFF-R expression on newly gener-
ated B cells may reduce survival potential and favour ‘expanded’ 
cohorts of B cells able more easily to obtain productive, but not 
necessarily antigen-speciﬁ c, T-cell help.
As well as being an effective treatment for many patients with 
RA, rituximab gives us an opportunity to study elements impor-
tant for relapse through our ability to study the re-establishment 
of disease. Following clearance of rituximab from the bone mar-
row, newly generated B cells expand into an environment that 
has retained a variable number of resistant B cells, a mature T-cell 
compartment and long-lived plasma cells. First, we know that 
B-cell return to the periphery is mandatory for relapse.20 Second, 
the gap between B-cell return and relapse may reﬂ ect the rela-
tionship between the re-expansion of surviving memory B-cell 
clones under the inﬂ uence of newly generated B cells. In both 
scenarios, maturation into Ig-secreting cells is often coincident 
with relapse, as shown by rises in autoantibodies,17 35 and also 
by the reported association with circulating plasmablasts.23 Our 
ﬁ nding of a lower proportion of postswitched memory B cells 
in non-relapsing, repopulated patients compared with relapsing 
patients supports the view that B-cell class-switch recombina-
tion is associated with relapse. The depletion of CD27hi memory 
B cells has previously been associated with clinical response to 
rituximab23 36 and low circulating numbers of IgD−CD27+ MB 
cells associated with low clinical activity indices and a longer 
clinical response, as reported by our group and others.20 37 The 
parallel ﬁ nding that BAFF-R levels in the non-relapsing repopu-
lated patients were similar to those of pre-RX patients support 
our hypothesis that the signals required for BAFF-R downregula-
tion are intimately linked to the re-establishment of disease. We 
also found that a population of double-negative (IgD−CD27−) 
B cells was signiﬁ cantly raised in patients with RA compared 
with controls, but their proportions did not change following 
rituximab. These cells may be similar to a previously described 
memory B-cell population in patients with SLE by Wei et al,38 
although others have found that only approximately 50% of 
this double-negative B-cell population bore markers of mutation 
and class switch.39
Although no statistically signiﬁ cant reduction in BAFF-R 
expression was present in RA patients before treatment, the 
ranges of percentage expression and MFI were wide (table 1, 
ﬁ gure 2). It is possible that a proportion of B cells with low 
BAFF-R levels is being generated throughout the clinical course 
of RA, but that the numbers of detectable BAFF-Rlo B cells may 
vary.
B-cell survival and differentiation is the result of a complex 
interplay between survival factors, in particular the BAFF/APRIL 
system in concert with the speciﬁ city and strength of signal 
through the BCR.40 From this study, we have shown that low 
levels of BAFF-R expression are related to the re-expansion of 
possibly pathogenic species of B cells associated with relapse. 
The re-establishment of active disease in patients with RA after 
rituximab may therefore involve preferential survival properties 
of autoreactive B cells, due to the unusual properties of their 
BCR and the ability also to overcome possible consequences of 
lower levels of BAFF-R signalling.27 31
and reduced BAFF-R expression and low BAFF-R expression on 
naive populations as well as memory B cells associated with the 
re-establishment of disease, we suggest that another mechanism 
may be responsible.
Patients with RA have been shown to possess a number of 
genetic polymorphisms linked to tolerance checkpoints in the 
bone marrow or the periphery.29 Evidence of altered thresholds 
for BCR signalling30 has been described in patients with RA 
and suggested to contribute to the generation of autoreactive 
cells. There is also accumulating evidence that pre-B/immature 
B cells from patients with RA are pre-activated before they exit 
from the bone marrow.31 It was recently shown that B cells at 
the pre-B/immature naive stage in the bone marrow of patients 
with RA had evidence of increased TLR9 protein expression and 
mRNA compared with osteoarthritis patients and also expressed 
the activation marker CD86.32 Disease-induced changes, such as 
the formation of germinal centre-like structures, cytokines such 
as TNFα, or increased levels of bacterial DNA/RNA in the bone 
marrow environment in patients with RA may disrupt the envi-
ronment in which pre-B cells are developing.33 Reduced ability 
to express receptors for the pro-survival cytokine BAFF on tran-
sitional and naive B cells after exiting the bone marrow may 
result as part of the unusual cytokine environment in which the 
B cells developed.
Once in the circulation, BCR speciﬁ city becomes a crucial 
determinant of B-cell survival and function. The expression of 
BCR speciﬁ c for citrullinated proteins and increased numbers 
of RhF-speciﬁ c B cells have been described by Samuels et al31 
within early (CD10+IgM+) populations exiting the bone mar-
row and also in mature naive B cells (CD10−IgM+) in RA 
patients compared with normal individuals. The conclusion is 
therefore that alterations of tolerance checkpoints both within 
the bone marrow and in the periphery may be occurring in 
Figure 4 Peripheral blood mononuclear cells were gated on CD19 
to characterise B-cell subpopulations further on the basis of IgD and 
CD27 expression into naive, pre and postswitch memory and double-
negative B cells. Signifi cance levels, using the Mann–Whitney U test, 
for comparisons between the different groups are depicted as *p<0.05 
versus normal controls (NC), **p<0.05 versus prerituximab (pre-RX), 
***p<0.05 discordant clinically non-relapsing (D-NR) versus discordant 
clinically relapsing (D-R). C-R, concordant clinically relapsing.
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